Author: "Was, M." / Topic: medicine.medical_specialty - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Was, M."' showing total 2,366,763 results

Start Over Author "Was, M." Topic medicine.medical_specialty

2,366,763 results on '"Was, M."'

1. Sexual dimorphism in relationship of serum leptin and relative weight for the standard in normal-weight, but not in overweight, children as well as adolescents

Author: T Nakanishi, T Ohzeki, Z Liu, Ren-Shan Li, Yuichi Nakagawa, and M Yi
Subjects: Leptin, Male, medicine.medical_specialty, Adolescent, Medicine (miscellaneous), Relative weight, Clinical nutrition, Overweight, Statistical significance, Internal medicine, Humans, Medicine, Obesity, Child, Sex Characteristics, Nutrition and Dietetics, business.industry, Body Weight, Puberty, Sexual dimorphism, Cross-Sectional Studies, Endocrinology, Normal weight, Serum leptin, Body Composition, Female, medicine.symptom, business
Abstract: Objective: To demonstrate sexual dimorphism in serum leptin levels not only during puberty, but also in childhood in Japan. Design: Cross-sectional study. Setting: Hamamatsu-Hokuen study in Japan. Subjects: Body weight and height were measured in normal-weight Japanese children and adolescents (143 boys, 178 girls), and 161 boys and 129 girls whose percentage of overweight for the standard (%Wt) was more than+25%. Serum leptin levels were compared with %Wt. Subjects were divided into group 1 (6–10 y of age) and group 2 (11–15 y of age) according to their age. Results: In overweight subjects, leptin was more highly correlated with %Wt in boys of group 2 (r=0.67, P
Published: 2024

2. Thumb-Basal Joint Arthroplasty Outcomes and Metacarpal Subsidence: A Prospective Cohort Analysis of Trapeziectomy With Suture Button Suspensionplasty Versus Ligament Reconstruction With Tendon Interposition

Author: Kristen F. Nicholson, Christopher M. Jones, Owolabi Shonuga, Asif M. Ilyas, R. Robert Takei, William Kirkpatrick, Frederic E. Liss, Jack Abboudi, Mark L. Wang, and Gregory Gallant
Subjects: medicine.medical_specialty, Joint arthroplasty, Arthritis, 030230 surgery, Thumb, Arthroplasty, Tendons, 03 medical and health sciences, Basal (phylogenetics), 0302 clinical medicine, Carpometacarpal joint, Osteoarthritis, medicine, Humans, Orthopedics and Sports Medicine, Prospective Studies, Prospective cohort study, 030222 orthopedics, Ligaments, Sutures, business.industry, Metacarpal Bones, medicine.disease, Tendon, Surgery, medicine.anatomical_structure, Trapezium Bone, Ligament, business
Abstract: Background Thumb carpometacarpal (CMC) joint arthroplasty is a common procedure in the surgical management of symptomatic thumb basal joint arthritis. Following trapeziectomy, a number of suspensionplasty techniques are often used, but limited comparative evidence exists between these techniques. The central aim of this study was to prospectively compare the outcomes of 2 suspensionplasty techniques following trapeziectomy: suture button (TightRope) versus ligament reconstruction and tendon interposition (LRTI). Methods Prospective data were collected on 112 consecutive patients with Eaton stage III-IV thumb CMC arthritis who underwent open trapeziectomy and suspensionplasty. There were 53 LRTI and 59 TightRope suspensionplasty procedures. Outcomes were measured using the Quick Disabilities of the Arm, Shoulder, and Hand ( QuickDASH) questionnaire, Visual Analogue Scale (VAS) for pain, radiographic analysis, and lateral pinch strength. Patient demographic data and complications were also recorded. Results Patients undergoing TightRope suspensionplasty had significantly higher trapeziometacarpal index and thus less subsidence than the LRTI group at 2 weeks (0.22 vs 0.17 [ P < .0001]) and 3 months (0.17 vs 0.15 [ P < .05]) postoperatively. TightRope suspensionplasty also had a significantly lower QuickDASH score at 2 weeks (64.7 vs 74.6 [ P < .05]), 3 months (20.7 vs 32.5 [ P < .05]), and 1 year postoperatively (7.57 vs 21.5 [ P < .05]) compared with the LRTI group. However, there was no difference in VAS pain, lateral pinch strength, reoperation, or complications at any time point between groups. Conclusions Thumb CMC joint arthroplasty performed with a TightRope suspensionplasty versus LRTI yielded short-term improved resistance to subsidence, long-term greater improvement in clinical outcome by QuickDASH, and no difference in pain or complication rates.
Published: 2024

3. Effects of plant-based versus marine-based omega-3 fatty acids and sucrose on brain and liver fatty acids in a mouse model of chemotherapy

Author: Tonya Orchard, Tial TinKai, Rachel M. Cole, A. Courtney DeVries, Rebecca Andridge, Kate Ormiston, Maryam B. Lustberg, Julie Fitzgerald, and Monica M. Gaudier-Diaz
Subjects: medicine.medical_specialty, Sucrose, Docosahexaenoic Acids, Linoleic acid, Medicine (miscellaneous), Lipid peroxidation, chemistry.chemical_compound, Mice, Internal medicine, Fatty Acids, Omega-3, medicine, Animals, Doxorubicin, chemistry.chemical_classification, Nutrition and Dietetics, alpha-Linolenic acid, General Neuroscience, Brain-Derived Neurotrophic Factor, Fatty Acids, food and beverages, Brain, General Medicine, Eicosapentaenoic acid, Mice, Inbred C57BL, Disease Models, Animal, Endocrinology, chemistry, Eicosapentaenoic Acid, Liver, Docosahexaenoic acid, lipids (amino acids, peptides, and proteins), Biomarkers, Polyunsaturated fatty acid, medicine.drug
Abstract: Chemotherapy can result in toxic side effects in the brain. Intake of marine-based omega-3 polyunsaturated fatty acids (n-3 PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), alter brain fatty acids, potentially improving brain function. However, it is unclear if alpha-linolenic acid (ALA), the plant-based n-3, affects brain PUFAs during chemotherapy. The objective of this study was to examine the effects of dietary ALA, EPA and DHA, with high or low sucrose, on brain PUFAs in a mouse model of chemotherapy. Secondarily, the use of liver PUFAs as surrogate measures of brain PUFAs was examined. Lipid peroxidation (4-HNE) and neurotrophic markers (BDNF) were assessed. Female C57Bl/6 mice (n = 90) were randomized to 1 of 5 diets (high EPA + DHA/high or low sucrose, high ALA/high or low sucrose, or control with no EPA + DHA/low ALA/low sucrose) and injected with doxorubicin-based chemotherapy or saline. Brain EPA and DHA were greater (p < 0.0001) with high EPA + DHA diets, regardless of sucrose; there were no significant differences in brain PUFAs between high ALA diets and control. Chemotherapy-treated mice had higher brain and liver DHA (p < 0.05) and lower brain and liver linoleic acid (p < 0.0001). Brain n-3 and n-6 PUFAs were strongly correlated with liver n-3 (r = 0.8214, p < 0.0001) and n-6 PUFAs (r = 0.7568, p < 0.0001). BDNF was correlated with brain total PUFAs (r = 0.36; p < 0.05). In conclusion, dietary ALA in proportions approximately two times greater than consumed by humans did not appreciably increase brain n-3 PUFAs compared to low ALA intake. Liver PUFAs may be a useful surrogate marker of brain PUFAs in this mouse model.
Published: 2023

4. Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Zheng

Author: Annelies Boonen, Andrea M. Burden, Tjeerd van Staa, Johanna H M Driessen, Patrick C. Souverein, Shahab Abtahi, Frank de Vries, Joop P. W. van den Bergh, Driessen, Johanna/0000-0002-4503-6408, Abtahi, Shahab/0000-0003-0482-5563, de Vries, Frank/0000-0003-3837-8319, Abtahi, Shahab, Driessen, Johanna H. M., Burden, Andrea M., Souverein, Patrick C., VAN DEN BERGH, Joop, van Staa, Tjeerd P., Boonen, Annelies, de Vries, Frank, Clinical Pharmacy, Interne Geneeskunde, RS: NUTRIM - R3 - Respiratory & Age-related Health, MUMC+: MA Reumatologie (9), RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation, MUMC+: DA KFT Medische Staf (9), and RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome
Subjects: 0301 basic medicine, rheumatoid arthritis, medicine.medical_specialty, glucocorticoids, osteoporosis, epidemiology, Immunology, Osteoporosis, Population, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Population based cohort, 0302 clinical medicine, Rheumatology, Internal medicine, Epidemiology, Immunology and Allergy, Medicine, education, 030203 arthritis & rheumatology, education.field_of_study, business.industry, Hazard ratio, medicine.disease, 030104 developmental biology, Rheumatoid arthritis, Concomitant, business, Cohort study
Abstract: Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'' by Zheng We thank Dr Zheng for his comments on our recently published article in the Annals of the Rheumatic Diseases entitled 'Concom-itant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'. 1 2 Our main goal in this study was to bring more clinical insight into the simultaneous use of these two common medications in patients with rheumatoid arthritis (RA), that is, oral glucocorticoids (GCs) and proton pump inhibitors (PPIs), using data from a large primary care database and pharmacoepidemiological methodologies. Our results showed that there was an interaction in the risk of osteoporotic (OP) fractures with concomitant use of oral GCs and PPIs in patients with RA. Based on the adjusted hazard ratios and according to the formula proposed by Rothman et al, 3 the relative excess risk due to interaction (RERI) was: 1.60-1.23 − 1.22 + 1 = 0.15. We now have also calculated the CIs and the statistical significance of this index using the method proposed by Hosmer and Lemeshow. 4 5 The lower and upper limits of the 95% CI of the RERI were −0.16 and 0.45, respectively, and the p value was 0.36. This means, although we observed a 15% more risk of OP fracture with concomitant use of oral GCs and PPIs in addition to the single use of each drug versus non-use of both, this additive interaction was not statistically significant. As we discussed in our paper, there is currently no proven biological mechanism for an action of PPIs on bone or falling, 6 while the effects of GCs on bone and the musculoskeletal system are quite established. Our secondary analyses (ie, lower fracture risk with long-term or higher daily doses of PPIs compared with short-term or lower daily doses) did not support the few proposed potential mechanisms, such as hypochlorhydria and calcium malabsorption, or an increased fall risk due to malab-sorption of magnesium or vitamin B 12. This is important to consider when interpreting a potential additive interaction between oral GCs and PPIs on fracture risk. Without this basic knowledge, it would be extremely difficult to confer any conclusions on a plausible synergistic action of these two drugs, since it would sound more as a methodological reasoning rather than a clinical explanation.
Published: 2023

5. Analysis of dermatologic procedures billed independently by nonphysician practitioners in the United States

Author: Brett M. Coldiron, Qiaochu Qi, Brian P. Hibler, and Anthony M. Rossi
Subjects: Dermatologic Procedures, medicine.medical_specialty, Scope of practice, Scope (project management), Nurse practitioners, business.industry, Retrospective cohort study, Dermatology, Primary care, Durable medical equipment, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Master file, 030220 oncology & carcinogenesis, Family medicine, medicine, business, health care economics and organizations
Abstract: Background Non-physician practitioners (NPPS), including nurse practitioners (NPs) and physician assistants (PAs) are expanding their scope of practice outside of primary care and performing more procedures in dermatology. Objective To understand the scope and geographic pattern of practice by NPs and PAs in dermatology in the US. Methods Cross-sectional retrospective cohort analysis of dermatology practices in the 2014 Medicare Physician/Supplier Procedure Summary Master File, which reflects Part B carrier and durable medical equipment fee-for-service claims in the US. Results Over 4 million procedures were billed independently by NPs and PAs, which accounts for 11.51% of all. Injection, simple repair, and biopsy were the most commonly billed by non-physician practitioners, but complex procedures were also increasingly billed independently by NPs and PAs. Proportions of their claims are higher in the East Coast, Midwest, and Mountain states. Limitations Data is at the state level, limited to Medicare beneficiaries, and doesn’t include billing incident-to physicians. Conclusions This study demonstrated the increasing scope of practice of NPs and PAs in dermatology, despite limited training and lack of uniform regulations. To ensure quality and safety of care, it is prudent to set benchmarks for proper supervision and utilization of procedures in dermatology.
Published: 2023

6. Más allá de la hiperglucemia: la variabilidad glucémica como factor pronóstico en el infarto cerebral agudo

Author: J C Portilla, J. Díez Sebastián, M. Freijo, Arturo Lisbona, M. Alonso de Leciñana, Exuperio Díez-Tejedor, Blanca Fuentes, Manuel Rodríguez-Yáñez, J. Gállego-Cullere, Antonio Gil-Núñez, Raquel Delgado-Mederos, Maite Martínez-Zabaleta, and Raquel Gutiérrez-Zúñiga
Subjects: Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, Ischemic stroke, Medicine, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract: Resumen Introduccion La variabilidad glucemica (VG) hace referencia a las oscilaciones en los niveles de glucosa en sangre y podria influir en el pronostico del ictus. Objetivo: Analizar el efecto de la VG en la evolucion del infarto cerebral agudo (IC). Metodos Analisis exploratorio del estudio GLIAS-II (multicentrico, prospectivo y observacional). Se midieron los niveles de glucemia capilar cada cuatro horas durante las primeras 48 horas y la VG se definio como la desviacion estandar de los valores medios. Variables principales: mortalidad y muerte o dependencia a los tres meses. Variables secundarias: porcentaje de complicaciones intrahospitalarias y de recurrencia de ictus, e influencia de la via de administracion de insulina sobre la VG. Resultados Se incluyeron 213 pacientes. Los pacientes que fallecieron (N = 16;7,8%) presentaron mayores valores de VG (30,9 mg/dL vs. 23,3 mg/dL; p = 0,05). En el analisis de regresion logistica ajustado por edad y comorbilidad, tanto la VG (OR = 1,03; IC del 95%: 1,003-1,06: p = 0,03) como la gravedad del IC (OR = 1,12; IC del 95%: 1,04-1,2; p = 0,004) se asociaron de forma independiente con la mortalidad a los tres meses. No se encontro asociacion entre la VG y las demas variables de estudio. Los pacientes que recibieron tratamiento con insulina subcutanea mostraron una mayor VG que los tratados con insulina intravenosa (38,9 mg/dL vs. 21,3 mg/dL; p Conclusiones Valores elevados de VG durante las primeras 48 horas tras el IC se asociaron de forma independiente con la mortalidad. La administracion subcutanea de insulina podria condicionar una mayor VG que la via intravenosa.
Published: 2023

7. Trends in Distal Esophageal and Gastroesophageal Junction Cancer Care

Author: Misha D. P. Luyer, Guusje Vugts, Renu R. Bahadoer, Marc J. van Det, Willem J. Koemans, Meindert N. Sosef, B. Görgec, Fatih Polat, Rene Scheer, Baukje Brattinga, Philip P. van der Linden, Cettela A. M. Slootmans, Richard van Hillegersberg, Marianne C Kalff, Erwin van der Harst, Marinus J. Wiezer, Frederik Lecot, Camiel Rosman, Jean-Pierre E. N. Pierie, Jan Willem Haveman, Pim B. Olthof, Peter C. Baas, Suzanne S. Gisbertz, Wendy Kelder, Víola B. Weeda, Annette D. van Dalsen, E. G. J. M. Robert Pierik, Marcia P. Gaspersz, Joos Heisterkamp, Eric J. T. Belt, Sjoerd M. Lagarde, Daan M. Voeten, Jelle P. Ruurda, Fanny J. Stoop, Peter van Duijvendijk, Linda Claassen, Victor D. Plat, Mark I. van Berge Henegouwen, Grard A. P. Nieuwenhuijzen, Jan Willem T. Dekker, Admira Ćosović, David Crull, Hein B. A. C. Stockmann, Richard P. R. Groenendijk, Guy H. E. J. Vijgen, Odin V. Sosef, Wietse J. Eshuis, Manon Drost, Martijn G. H. van Oijen, Ewout A. Kouwenhoven, Freek Daams, Wobbe O. de Steur, Johanna W. van Sandick, Henk H. Hartgrink, Donald L. van der Peet, Stijn van Esser, B. Feike Kingma, and Surgery
Subjects: medicine.medical_specialty, complications, business.industry, General surgery, neo-adjuvant treatment, Cancer, medicine.disease, Gastroesophageal Junction, survival, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, medicine, esophagectomy, Surgery, esophageal cancer, business, minimally invasive surgery
Abstract: Objective: This study evaluated the nationwide trends in care and accompanied postoperative outcomes for patients with distal esophageal and gastro-esophageal junction cancer.Summary of Background Data: The introduction of transthoracic esophagectomy, minimally invasive surgery, and neo-adjuvant chemo(radio)therapy changed care for patients with esophageal cancer.Methods: Patients after elective transthoracic and transhiatal esophagectomy for distal esophageal or gastroesophageal junction carcinoma in the Netherlands between 2007-2016 were included. The primary aim was to evaluate trends in both care and postoperative outcomes for the included patients. Additionally, postoperative outcomes after transthoracic and tran-shiatal esophagectomy were compared, stratified by time periods.Results: Among 4712 patients included, 74% had distal esophageal tumors and 87% had adenocarcinomas. Between 2007 and 2016, the proportion of transthoracic esophagectomy increased from 41% to 81%, and neo-adjuvant treatment and minimally invasive esophagectomy increased from 31% to 96%, and from 7% to 80%, respectively. Over this 10-year period, postoperative outcomes improved: postoperative morbidity decreased from 66.6% to 61.8% (P = 0.001), R0 resection rate increased from 90.0% to 96.5% (P Conclusion: In this nationwide cohort, a transition towards more neo-adju-vant treatment, transthoracic esophagectomy and minimally invasive surgery was observed over a 10-year period, accompanied by decreased postoperative morbidity, improved surgical radicality and lymph node harvest, and improved survival.
Published: 2023

8. Embolización de arterias bronquiales y arterias sistémicas no bronquiales con n-butil-cianoacrilato en pacientes con hemoptisis: un estudio monocéntrico y retrospectivo

Author: M. S. Lombardo Galera, J. J. Espejo Herrero, M. E. Perez Montilla, J. García-Revillo, P.B. García Jurado, and M. Entrenas Castillo
Subjects: Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, N-butyl-cyanoacrylate, Transcatheter embolization, medicine, Radiology, Nuclear Medicine and imaging, business, 030217 neurology & neurosurgery, 030218 nuclear medicine & medical imaging
Abstract: Resumen Objetivos Evaluar la seguridad y la eficacia de la embolizacion de arterias bronquiales y arterias sistemicas no bronquiales con n-butil-cianoacrilato en pacientes con hemoptisis. Metodos Se han analizado un total de 55 pacientes consecutivos con hemoptisis (14 leves, 31 moderadas y 10 masivas) tratados mediante embolizacion de arterias bronquiales y arterias sistemicas no bronquiales con n-butil- cianoacrilato entre noviembre de 2013 y enero de 2020. Las variables principales estudiadas son tasa de exito tecnico, tasa de exito clinico, tasas de recurrencia y complicaciones. Se ha realizado un analisis estadistico descriptivo y un analisis de supervivencia mediante el metodo de Kaplan-Meier. Resultados En 55 (100%) pacientes se ha realizado la embolizacion con exito tecnico y en 54 (98,2%), con exito clinico. Durante el seguimiento (media, 23,8 meses; rango intercuartilico, 9,7-38,2) ha recurrido en 5 de los 54 (9,3%) pacientes. La tasa de no recurrencia al ano ha sido del 91,9%, y a los 2 y 4 anos, del 88,7% despues del procedimiento inicial. Ha habido 6 (10,9%) complicaciones menores relacionadas con el procedimiento y ninguna mayor. Conclusiones La embolizacion de arterias bronquiales y arterias sistemicas no bronquiales con n-butil-cianoacrilato es segura y eficaz para controlar la hemoptisis con tasas de recurrencia bajas.
Published: 2023

9. Epilepsia y gestación. Factores asociados con la presencia de crisis en la gestación

Author: J. Ciurans, M. Codina, C. García-Esperón, Laia Grau-López, J.L. Becerra, A. Fumanal, S. Barambio, M. Jiménez, and E. Chíes
Subjects: Gynecology, 03 medical and health sciences, medicine.medical_specialty, 0302 clinical medicine, business.industry, Medicine, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract: Resumen Introduccion El manejo de la epilepsia durante la gestacion requiere un control optimo de las crisis, evitando los potenciales efectos teratogenicos del tratamiento antiepileptico. Objetivos Describir las caracteristicas clinicas y los resultados perinatales de las pacientes con epilepsia gestantes. Analizar los factores que se asocian a la presencia de crisis durante la gestacion. Describir los farmacos antiepilepticos mas utilizados y analizar los cambios en el regimen terapeutico en dos periodos: de 2000-2010 y 2011-2018. Metodos Se realizo un estudio prospectivo observacional de pacientes con epilepsia que notificaron su gestacion en el periodo de 2000-2018. Se evaluo a las pacientes en el primer y segundo trimestre de gestacion, tras el parto y al ano. Se recogieron variables demograficas, relacionadas con la epilepsia, perinatales y obstetricas. Resultados Se incluyeron 101 gestaciones. La edad media fue de 32,6 anos, el 55,4% tenia una epilepsia focal, el 38,6% una epilepsia generalizada y el 5,9% indeterminada. Se registraron 90 nacidos vivos, nueve abortos espontaneos y cinco malformaciones congenitas, cuatro de ellas en monoterapia con valproato. En 40 gestaciones (39,6%) se registraron crisis, siendo tonico-clonicas generalizadas en 16 (40%). Las variables asociadas con la presencia de crisis durante el embarazo fueron el mal control el ano previo a la gestacion (66,7% vs. 15,1%, p Conclusiones Los factores asociados con la presencia de crisis durante la gestacion fueron el mal control previo, el tratamiento con dos o mas farmacos antiepilepticos y la ausencia de tratamiento. Los farmacos mas utilizados fueron lamotrigina, valproato y levetiracetam, con un incremento de este ultimo y un descenso de valproato en el periodo mas reciente (2011-2018).
Published: 2023

10. Protocol for the development of the international population registry for aphasia after stroke (I-PRAISE)

Author: Erin Godecke, R. Mc Menamin, M. Gil, Linda Williams, A. Lifshitz Ben Basat, Madeline Cruice, C. Mendez-Orellana, Karen Sage, Sarah J. Wallace, İlknur Maviş, K. Sprecht, Marialuisa Gandolfi, Per Östberg, Dominique A Cadilhac, L. Martinez Jiminez, H. Robson, Ann Charlotte Laska, M. Blom Johansson, R. Grima, M. van de Sandt-Koenderman, Luis M. T. Jesus, Evy Visch-Brink, Fofi Constantinidou, Marian C. Brady, Guadalupe Dávila, Tarja Kukkonen, H. Obrig, Caterina Breitenstein, Maria Kambanaros, Myzoon Ali, Marcelo L. Berthier, E. Wehling, S. Wielaert, [Ali, M.] Glasgow Caledonian Univ, NMAHP Res Unit, A433 Govan Mbeki Bldg, Glasgow G4 0BA, Lanark, Scotland, [Brady, M. C.] Glasgow Caledonian Univ, NMAHP Res Unit, A433 Govan Mbeki Bldg, Glasgow G4 0BA, Lanark, Scotland, [Ben Basat, A. Lifshitz] Ariel Univ, Dept Commun Disorders, Ariel, Israel, [Berthier, M.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Cognit Neurol & Aphasia Unit, Ctr Invest Medicosanitarias, Malaga, Spain, [Davila, G.] Univ Malaga, Inst Invest Biomed Malaga IBIMA, Cognit Neurol & Aphasia Unit, Ctr Invest Medicosanitarias, Malaga, Spain, [Blom Johansson, M.] Uppsala Univ, Dept Neurosci, Speech Language Pathol, Uppsala, Sweden, [Breitenstein, C.] Univ Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany, [Cadilhac, D. A.] Monash Univ, Sch Clin Sci, Dept Med, Monash Hlth, Melbourne, Vic, Australia, [Constantinidou, F.] Univ Cyprus Nicosia, Dept Psychol, Nicosia, Cyprus, [Constantinidou, F.] Univ Cyprus Nicosia, Ctr Appl Neurosci, Nicosia, Cyprus, [Cruice, M.] City Univ London, London, England, [Davila, G.] Univ Malaga, Fac Psychol & Speech Therapy, Area Psychobiol, Malaga, Spain, [Gandolfi, M.] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy, [Gil, M.] Loewenstein Hosp & Rehabil Ctr, Dept Commun Disorders, Raanana, Israel, [Grima, R.] Univ Malta Imsida, Dept Commun Therapy, Fac Hlth Sci, Msida, Malta, [Godecke, E.] Edith Cowan Univ, Sch Med & Hlth Sci, Churchlands, WA, Australia, [Godecke, E.] Sir Charles Gairdner Hosp, Speech Pathol Dept, Nedlands, WA, Australia, [Godecke, E.] Ctr Res Excellence Aphasia Recovery & Rehabil, Melbourne, Vic, Australia, [Jesus, L.] Univ Aveiro, Sch Hlth Sci ESSUA, Aveiro, Portugal, [Jesus, L.] Univ Aveiro, Inst Elect & Informat Engn Aveiro IEETA, Aveiro, Portugal, [Jiminez, L. Martinez] Univ Talca, Talca, Chile, [Kambanaros, M.] Univ South Australia, Allied Hlth & Human Performance, Adelaide South, Australia, [Kukkonen, T.] Tampere Univ Hosp, Pirkanmaa Hosp Dist, Dept ENT Phoniatry, Tampere, Finland, [Laska, A.] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden, [Mavis, I] Anadolu Univ, Speech & Language Therapy Dept, Eskisehir, Turkey, [Mc Menamin, R.] Natl Univ Ireland, Sch Hlth Sci, Discipline Speech & Language Therapy, Galway, Ireland, [Mendez-Orellana, C.] Pontificia Univ Catolica Chile, Fac Med, Dept Ciencias Salud, Carrera Fonoaudiol, Santiago, Chile, [Obrig, H.] Univ Hosp Leipzig, Clin Cognit Neurol, Leipzig, Germany, [Obrig, H.] MPI Human Cognit & Brain Sci, Leipzig, Germany, [Ostberg, P.] Karolinska Inst, Dept Clin Sci Intervent & Technol CLINTEC, Stockholm, Sweden, [Robson, H.] UCL, Psychol & Language Sci, London, England, [Sage, K.] Manchester Metropolitan Univ, Fac Hlth Psychol & Social Care, Dept Nursing, Manchester, Lancs, England, [Van De Sandt-koenderman, M.] Rijndam Rehabil Ctr, Dept Rehabil Med, Rotterdam, Netherlands, [Wielaert, S.] Rijndam Rehabil Ctr, Dept Rehabil Med, Rotterdam, Netherlands, [Van De Sandt-koenderman, M.] Erasmus MC, Rotterdam, Netherlands, [Wielaert, S.] Erasmus MC, Rotterdam, Netherlands, [Sprecht, K.] Univ Bergen, Fac Psychol, Dept Biol & Med Psychol, Bergen, Norway, [Visch-Brink, E.] Erasmus MC, Dept Neurol & Neurosurg, Rotterdam, Netherlands, [Wehling, E.] Haukeland Hosp, Dept Phys Med & Rehabil, Bergen, Norway, [Wallace, S. J.] Univ Queensland, Sch Hlth & Rehabil Sci, Queensland Aphasia Res Ctr, Brisbane, Qld, Australia, [Williams, L. J.] Univ Edinburgh, Usher Inst, Edinburgh, Midlothian, Scotland, Tavistock Trust for Aphasia, Ali, M, Lifshitz Ben Basat, A, Berthier, M, Blom Johansson, M, Kambanaros, M, Brady, MC, Tampere University, Department of Neurosciences and Rehabilitation, Welfare Sciences, Research & Education, Radiology & Nuclear Medicine, Neurology, Neurosurgery, Rehabilitation Medicine, and Department of Marketing Management
Subjects: Linguistics and Language, medicine.medical_specialty, data collection, 515 Psychology, medicine.medical_treatment, Population, registry, behavioral disciplines and activities, Language and Linguistics, Language assessment, Rating scale, Aphasia, Övrig annan medicin och hälsovetenskap, Developmental and Educational Psychology, medicine, Speech, Controlled-trial, protocol, Lesion, Western Aphasia Battery, education, outcome assessment, Stroke, Language, education.field_of_study, Rehabilitation, Communication, 3112 Neurosciences, Reliability, LPN and LVN, medicine.disease, Other Medical Sciences not elsewhere specified, Neurology, Otorhinolaryngology, RC0321, Physical therapy, Therapy, Neurology (clinical), medicine.symptom, Speech-Language Pathology, Psychology
Abstract: Background We require high-quality information on the current burden, the types of therapy and resources available, methods of delivery, care pathways and long-term outcomes for people with aphasia. Aim To document and inform international delivery of post-stroke aphasia treatment, to optimise recovery and reintegration of people with aphasia. Methods & Procedures Multi-centre, prospective, non-randomised, open study, employing blinded outcome assessment, where appropriate, including people with post-stroke aphasia, able to attend for 30 minutes during the initial language assessment, at first contact with a speech and language therapist for assessment of aphasia at participating sites. There is no study-mandated intervention. Assessments will occur at baseline (first contact with a speech and language therapist for aphasia assessment), discharge from Speech and Language Therapy (SLT), 6 and 12-months post-stroke. Our primary outcome is changed from baseline in the Amsterdam Nijmegen Everyday Language Test (ANELT/Scenario Test for participants with severe verbal impairments) at 12-months post-stroke. Secondary outcomes at 6 and 12 months include the Therapy Outcome Measure (TOMS), Subjective Index of Physical and Social Outcome (SIPSO), Aphasia Severity Rating Scale (ASRS), Western Aphasia Battery Aphasia Quotient (WAB-AQ), stroke and aphasia quality of life scale (SAQoL-39), European Quality of Life Scale (EQ-5D), lesion description, General Health Questionnaire (GHQ-12), resource use, and satisfaction with therapy provision and success. We will collect demography, clinical data, and therapy content. Routine neuroimaging and medication administration records will be accessed where possible; imaging will be pseudonymised and transferred to a central reading centre. Data will be collected in a central registry. We will describe demography, stroke and aphasia profiles and therapies available. International individual participant data (IPD) meta-analyses will examine treatment responder rates based on minimal detectable change & clinically important changes from baseline for primary and secondary outcomes at 6 and 12 months. Multivariable meta-analyses will examine associations between demography, therapy, medication use and outcomes, considering service characteristics. Where feasible, costs associated with treatment will be reported. Where available, we will detail brain lesion size and site, and examine correlations with SLT and language outcome at 12 months. Conclusion International differences in care, resource utilisation and outcomes will highlight avenues for further aphasia research, promote knowledge sharing and optimise aphasia rehabilitation delivery. IPD meta-analyses will enhance and expand understanding, identifying cost-effective and promising approaches to optimise rehabilitation to benefit people with aphasia.
Published: 2022

11. Esophageal and gastric malignancies after bariatric surgery: a retrospective global study

Author: Chetan Parmar, Roxanna Zakeri, Mohamed Abouelazayem, Thomas H. Shin, Ali Aminian, Tala Mahmoud, Barham K. Abu Dayyeh, Melissa Y. Wee, Laura Fischer, Freek Daams, Kamal Mahawar, Carlos Sosa Gallardo, Cataldo Agustin, Fernando Wright, Ignacio Fuente, Miguel Carbajo, Patricio Cal, Jacob Chisholm, Lilian Kow, Michael H.L. Tan, Philip Gan, Sivakumar Gananadha, Daniel M. Felsenreich, Gerhard Prager, Chris Matthys, Jacques M. Himpens, Marc A.M.R.M. Focquet, Almino Ramos, Manoel Galvano Nato, Thiago Vidal, Amin Andalib, Aya Siblini, Lorenzo Ferri, Lina Abdarabo, Yehonatan Nevo, Radu Pescarus, Wah Yang, Hosam Hamed, Arnaud Liagre, Damien Bergeat, De Montrichard Marie, Francesco Martini, François Regis, Laurent Genser, Mehdi Skalli, Marius Nedelcu, Milan Smejkal, Radwan Kassir, Regenet Nicolas, Christine Stier, Dan-Sebastian Nedelcut, Grigorios Christodoulidis, Amar Vennapusa, Mohammad Kermansaravi, Asnat Raziel, Nasser Sakran, Alberto Oldani, Cristian Eugeniu Boru, Fouzia Mécheri, Francesca Ciccarese, Giovanni Carlo Cesana, Mario Musella, Matteo Uccelli, Mirto Foletto, Pasquale Auricchio, Stefano Olmi, Yosuke Seki, Anne Kasteleijn, Gerhard Van 'T Hof, Jan A. Apers, Judith W.H. Hart, Justin S.L. Van De Sande, Marijn Takkenberg, Pierre B.G.M. Feskens, Rob Snoekx, Victor D. Plat, Jorunn Sandvik, Piotr Kalinowski, Celso Nabais, Ahmed Z. Al-Bahrani, Mohammad Al Zoubi, Carla Bettonica, Javier Osorio, Javier Tejedor-Tejada, Lourdes M. Sanz, Marta Cuadrado, Rajesh Gianchandani Moorjani, Fringeli Yannick, Michel Suter, Yves Borbély, Zehetner Joerg, Juan S. Barajas-Gamboa, Matthew Kroh, Aaron P. Kisiel, Anna Kamocka, Arul Immanuel, Bruno Sgromo, Bussa Gopinath, David Khoo, Samrat Mukherjee, Dimitrios Pournaras, Tim Underwood, Ewen A. Griffiths, Glenn V. Miller, Helen Jaretzke, Jan Dmitrewski, Martin S. Wadley, Ragad Al-Housni, Richard S. Gillies, Rishi Singhal, Shaun R. Preston, Steven John Robinson, William J. Hawkins, Marco Adamo, Mohamed El Kalaawy, James Gossage, Christopher B. Crawford, Veeravich Jaruvongvanich, Parmar, C., Zakeri, R., Abouelazayem, M., Shin, T. H., Aminian, A., Mahmoud, T., Abu Dayyeh, B. K., Wee, M. Y., Fischer, L., Daams, F., Mahawar, K., Gallardo, C. S., Agustin, C., Wright, F., Fuente, I., Carbajo, M., Cal, P., Chisholm, J., Kow, L., Tan, M. H. L., Gan, P., Gananadha, S., Felsenreich, D. M., Prager, G., Matthys, C., Himpens, J. M., Focquet, M. A. M. R. M., Ramos, A., Nato, M. G., Vidal, T., Andalib, A., Siblini, A., Ferri, L., Abdarabo, L., Nevo, Y., Pescarus, R., Yang, W., Hamed, H., Liagre, A., Bergeat, D., Marie, D. M., Martini, F., Regis, F., Genser, L., Skalli, M., Nedelcu, M., Smejkal, M., Kassir, R., Nicolas, R., Stier, C., Nedelcut, D. -S., Christodoulidis, G., Vennapusa, A., Kermansaravi, M., Raziel, A., Sakran, N., Oldani, A., Boru, C. E., Mecheri, F., Ciccarese, F., Cesana, G. C., Musella, M., Uccelli, M., Foletto, M., Auricchio, P., Olmi, S., Seki, Y., Kasteleijn, A., Van 'T Hof, G., Apers, J. A., Hart, J. W. H., Van De Sande, J. S. L., Takkenberg, M., Feskens, P. B. G. M., Snoekx, R., Plat, V. D., Sandvik, J., Kalinowski, P., Nabais, C., Al-Bahrani, A. Z., Al Zoubi, M., Bettonica, C., Osorio, J., Tejedor-Tejada, J., Sanz, L. M., Cuadrado, M., Moorjani, R. G., Yannick, F., Suter, M., Borbely, Y., Joerg, Z., Barajas-Gamboa, J. S., Kroh, M., Kisiel, A. P., Kamocka, A., Immanuel, A., Sgromo, B., Gopinath, B., Khoo, D., Mukherjee, S., Pournaras, D., Underwood, T., Griffiths, E. A., Miller, G. V., Jaretzke, H., Dmitrewski, J., Wadley, M. S., Al-Housni, R., Gillies, R. S., Singhal, R., Preston, S. R., Robinson, S. J., Hawkins, W. J., Adamo, M., El Kalaawy, M., Gossage, J., Crawford, C. B., Jaruvongvanich, V., Surgery, CCA - Cancer Treatment and quality of life, Amsterdam Gastroenterology Endocrinology Metabolism, and Plastic, Reconstructive and Hand Surgery
Subjects: Adult, obesity, Sleeve gastrectomy, medicine.medical_specialty, Palliative treatment, bariatric surgery, esophageal cancer, esophagogastric cancer, gtastric cancer, metabolic surgery, adult, female, gastrectomy, humans, middle aged, retrospective studies, treatment outcome, gastric bypass, morbid, stomach neoplasms, medicine.medical_treatment, Esophageal cancer, Esophagogastric cancer, Population, Gastric Bypass, Bariatric Surgery, Gastrectomy, Stomach Neoplasms, medicine, Humans, In patient, Adjustable gastric band, education, Retrospective Studies, Bariatric surgery, education.field_of_study, business.industry, Cancer, Middle Aged, medicine.disease, Obesity, Obesity, Morbid, Surgery, Treatment Outcome, Adenocarcinoma, Female, Metabolic surgery, Gastric cancer, business
Abstract: Background Bariatric surgery can influence the presentation, diagnosis, and management of gastrointestinal cancers. Oesophago-Gastric (OG) malignancies in patients who have had a prior bariatric procedure have not been fully characterised. Objective To characterise OG malignancies after bariatric procedures. Setting University Hospital, United Kingdom. Methods We performed a retrospective, multi-centre observational study of patients with OG malignancies after bariatric surgery to characterise this condition. Results This study includes 170 patients from 75 centres in 25 countries who underwent bariatric procedures between 1985 and 2020. At the time of the bariatric procedure, the mean age was 50.2 ± 10 years and the mean weight 128.8 ± 28.9 kg. Females comprised 57.3% (n=98) of the population. Most (n=64) patients underwent a Roux-en-Y Gastric Bypass (RYGB) followed by Adjustable Gastric Band (AGB) (n = 46) and Sleeve Gastrectomy (SG) (n = 43). Time to cancer diagnosis after bariatric surgery was 9.5 ± 7.4 years and mean weight at diagnosis was 87.4 ± 21.9 kg. The time lag was 5.9 ± 4.1 years after SG compared to 9.4 ± 7.1 years after RYGB and 10.5 ± 5.7 years after AGB. One-third of patients presented with metastatic disease. The majority of tumours were adenocarcinoma (82.9%). Approximately 1 in 5 patients underwent palliative treatment from the outset. Time from diagnosis to mortality was under one year for most patients who died over the intervening period. Conclusions The OGMOS (Oesophago-Gastric Malignancies after Obesity/ Bariatric Surgery) study presents the largest series to date of patients developing OG malignancies after bariatric surgery and attempts to characterise this condition.
Published: 2022

12. Sex-, Age-, and Race-Related Normal Values of Right Ventricular Diastolic Function Parameters: Data from the World Alliance Societies of Echocardiography Study

Author: Gregory M. Scalia, James N. Kirkpatrick, Cristiane Carvalho Singulane, Ricardo Ronderos, Edwin S. Tucay, Kofo O. Ogunyankin, Roberto M. Lang, Laurie Soulat-Dufour, Masao Daimon, Masaaki Takeuchi, Seung Woo Park, Denisa Muraru, Ana Clara Tude Rodrigues, Ravi R Kasliwal, Tatsuya Miyoshi, Mark J. Monaghan, Niklas Hitschrich, Marcus Schreckenberg, Yun Zhang, Anita Sadeghpour, Rodolfo Citro, Wendy Tsang, Pedro Gutierrez-Fajardo, Victor Mor-Avi, Michael Blankenhagen, Amita Singh, Federico M. Asch, Vivekanandan Amuthan, Karima Addetia, Carvalho Singulane, C, Singh, A, Miyoshi, T, Addetia, K, Soulat-Dufour, L, Schreckenberg, M, Blankenhagen, M, Hitschrich, N, Amuthan, V, Citro, R, Daimon, M, Gutierrez-Fajardo, P, Kasliwal, R, Kirkpatrick, J, Monaghan, M, Muraru, D, Ogunyankin, K, Park, S, Tude Rodrigues, A, Ronderos, R, Sadeghpour, A, Scalia, G, Takeuchi, M, Tsang, W, Tucay, E, Zhang, Y, Mor-Avi, V, Asch, F, and Lang, R
Subjects: Male, medicine.medical_specialty, Heart Ventricles, Diastole, Normal values, Right atrial, Normal value, Age groups, Reference Values, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Diastolic function, Aged, Tricuspid valve, business.industry, MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, Deceleration time, medicine.anatomical_structure, Echocardiography, Right ventricular diastolic function, Ventricular Function, Right, Cardiology, Female, Cardiology and Cardiovascular Medicine, business
Abstract: Background: Although the assessment of right ventricular (RV) diastolic function is feasible, it has garnered far less momentum for use compared with its left ventricular counterpart. The scarcity of data defining normative RV diastolic function and the fact that implications of RV diastolic dysfunction in different disease states on outcomes are less well known both hinder integration into routine clinical assessment. The aim of this study was to establish normal values of RV diastolic parameters stratified by sex, age, and race using data from the World Alliance Societies of Echocardiography study. Methods: A subset of 888 normal subjects from the World Alliance Societies of Echocardiography database were analyzed, including measurements of tricuspid valve (TV) inflow E- and A-wave velocities, E-wave deceleration time, and TV annular tissue Doppler e′ and a′ velocities. Additionally, right atrial (RA) maximal volume and RA peak reservoir strain were measured. Patients were grouped by age ([removed]65 years) and stratified by sex and race. Differences were analyzed using unpaired t tests. Results: Compared with men, women had significantly higher TV e′ and E-wave and A-wave velocities, though differences were modest. Increasing age was associated with stepwise lower TV E wave, e′ velocity, and TV E/A ratio and higher a′ velocity and E/e′ ratio. RA peak reservoir strain was also lower, and RA end-systolic volume trended toward being smaller for older age groups. Asian subjects demonstrated significantly higher a′ velocities, lower E wave, the smallest RA end-systolic volumes, and the lowest RA peak strain values compared with white subjects of both sexes. Conclusions: This study provides normal values for parameters used in the assessment of RV diastolic function stratified by race, sex, and age. The results demonstrate significant differences in RV diastolic parameters between age groups, which manifest in both individual parameters and composite ratios of TV inflow and annular velocities. Although limited sex- and race-related differences were also noted, age appears to have the most significant impact on RV diastolic parameters. These findings may aid in refining current normative values.
Published: 2022

13. Staged embolisation of a giant torcular dural sinus malformation in a neonate

Author: Evan Luther, Robert M. Starke, Hunter King, and Aria M. Jamshidi
Subjects: Intracranial Arteriovenous Malformations, medicine.medical_specialty, Cranial Sinuses, Dural sinus, Pregnancy, Medicine, Humans, Child, Central Nervous System Vascular Malformations, Surgical approach, medicine.diagnostic_test, business.industry, Ultrasound, Infant, Newborn, Infant, Interventional radiology, General Medicine, medicine.disease, Embolization, Therapeutic, Hydrocephalus, In utero, Female, Radiology, Neurosurgery, business
Abstract: Torcular dural sinus malformations (tDSMs) represent a rare subset of paediatric cerebrovascular malformations and are often diagnosed antenatally via ultrasound. The management of these in utero lesions remains controversial as previous studies suggested elective termination of the pregnancy because of their presumably high mortality and severe long-term morbidity. However, more recent evaluations have suggested that the overall prognosis for infants harbouring these lesions may be much better than previously believed. As such, we present the case of a neonate with a giant tDSM, diagnosed in utero, who was treated postnatally via staged transarterial and transvenous embolisation to alleviate worsening obstructive hydrocephalus and brainstem compression. We provide details regarding the surgical approach and long-term neurological outcomes for this patient. To the best of our knowledge, this is one of the largest reported tDSM presented in the literature.
Published: 2023

14. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

Author: G. Pellejero, Jose Gutierrez, R. Malý, M. Basaglia, L. Chasco, P. Suchon, R. Le Mao, Laurent Bertoletti, F. Martins, J. Caprini, A. Braester, F. Galeano-Valle, Hanh My Bui, J. Alonso, Y. Sato, G. Vidal, Y. Nishimoto, C. Tolosa, E. Nofuentes-Pérez, A.M. Díaz-Brasero, N. Ait Abdallah, M.D. Adarraga, R. Sánchez-Martínez, L. Font, Raquel López-Reyes, Inna Tzoran, Karine Lacut, J. del Toro, Andris Skride, Ana Jaureguizar, Joseph A. Caprini, C. Amado, R. García de la Garza, A.M. Camon, S. Merla, Luciano López-Jiménez, G. Salgueiro, Sebastian Schellong, Alfonso Muriel, F. Bilora, S. Lainez-Justo, B. Suárez-Rodríguez, Carme Font, F. Beddar Chaib, I. Francisco, C. Jiménez-Alfaro, P. Azcarate-Agüero, Maurizio Ciammaichella, J.A. Porras, N. Vo Hong, F. Martín-Martos, Dominique Farge-Bancel, D. Farge-Bancel, José Luis Lobo, M. Giménez-Suau, E. Grau, F. García-Bragado, Ángeles Blanco-Molina, Carmen Fernández-Capitán, María del Carmen Díaz-Pedroche, C. Grange, Adriana Visonà, L. Guirado, P. Villares, P. López-Miguel, José María Pedrajas, S. Accassat, Beatriz Valero, B. Crichi, Juan J. López-Núñez, Luis Jara-Palomares, G. Sarlon-Bartoli, J. Lima, C. Bortoluzzi, Alicia Lorenzo, C. de Ancos, M.A. Fidalgo, Philippe Debourdeau, Pablo Javier Marchena, C. Rodríguez-Matute, A.I. Farfán-Sedano, José Luis Fernández-Reyes, J.C. Escribano, Juan I. Arcelus, M. Barrón, I. Quere, Remedios Otero, A. De Angelis, P. Morange, Peter Verhamme, G. Kenet, P. Prandoni, Pedro Ruiz-Artacho, C. Siniscalchi, A. Zaicenko, M. Olid-Velilla, C. García-Díaz, B. Barrón-Andrés, T. Sancho, Fernando Uresandi, Javier Trujillo-Santos, A. Muñoz-Blanco, A. Villalobos, A. Dubois-Silva, J. Moisés, J. Osorio, M.I. Mercado, J.M. Suriñach, M.A. Aibar, M.D. Joya, Cihan Ay, J.A. Díaz-Peromingo, H. Bounameaux, Diego Martínez-Urbistondo, Thomas Vanassche, L. Bertoletti, Marijan Bosevski, Farès Moustafa, M. Martín del Pozo, J.F. Sánchez-Muñoz-Torrero, H.M. Bui, Ingrid Pabinger, M.C. Olivares, M. García de Herreros, M.J. Núñez-Fernández, B. Zalunardo, J.F. Varona, Stephan Nopp, Behnood Bikdeli, B. Brandolin, B. Bikdeli, Olga Madridano, Manuel Monreal, M.J. Jaras, Alessandra Bura-Rivière, Abílio Reis, J. Portillo, O. Espitia, J. Catella, Aitor Ballaz, F. Esposito, R. Barba, R. Valle, H. Helfer, I. Tzoran, J.B. López-Sáez, P. Ruiz-Artacho, M.A. García, J. Aibar, C. Gómez-Cuervo, C. Gabara, A. Latorre, J. Ruiz-Ruiz, Benjamin Brenner, S. Fonseca, S. Schellong, Raffaele Pesavento, Barry M. Brenner, Silvia Soler, Paolo Prandoni, Victor F. Tapson, Ana Maestre, Pierpaolo Di Micco, M. Muñoz, J. Criado, D. Jiménez, Antonella Tufano, G. Krstevski, B. Valero, Henri Bounameaux, M.I. Torres, G. Poenou, Isabelle Mahé, Aída Gil-Díaz, A. Asuero, S. Otalora, V. Rosa, L. Vela, E. Imbalzano, C. Vandenbriele, C. Barbagelata, Jana Hirmerova, J. Meireles, David Jiménez, Lucia Mazzolai, L. Hernández-Blasco, M. Bosevski, Gili Kenet, C. Mella, M. Monreal, J.R. Vela, P. Di Micco, Carlos Zamora, K. Flores, P. Demelo-Rodríguez, Radovan Malý, J. Birzulis, J.A. Nieto, J. Castro, M.V. Di Campli, Francis Couturaud, Raquel Barba, Jaureguizar, A., Jimenez, D., Bikdeli, B., Ruiz-Artacho, P., Muriel, A., Tapson, V., Lopez-Reyes, R., Valero, B., Kenet, G., Monreal, M., Prandoni, P., Brenner, B., Farge-Bancel, D., Barba, R., Di Micco, P., Bertoletti, L., Schellong, S., Tzoran, I., Reis, A., Bosevski, M., Bounameaux, H., Maly, R., Verhamme, P., Caprini, J. A., Bui, H. M., Adarraga, M. D., Aibar, J., Aibar, M. A., Alonso, J., Amado, C., Arcelus, J. I., Asuero, A., Azcarate-Aguero, P., Ballaz, A., Barbagelata, C., Barron, M., Barron-Andres, B., Blanco-Molina, A., Beddar Chaib, F., Camon, A. M., Castro, J., Chasco, L., Criado, J., de Ancos, C., del Toro, J., Demelo-Rodriguez, P., Diaz-Brasero, A. M., Diaz-Pedroche, M. C., Diaz-Peromingo, J. A., Di Campli, M. V., Dubois-Silva, A., Escribano, J. C., Esposito, F., Farfan-Sedano, A. I., Fernandez-Capitan, C., Fernandez-Reyes, J. L., Fidalgo, M. A., Flores, K., Font, C., Font, L., Francisco, I., Gabara, C., Galeano-Valle, F., Garcia, M. A., Garcia-Bragado, F., Garcia de Herreros, M., Garcia de la Garza, R., Garcia-Diaz, C., Gil-Diaz, A., Gomez-Cuervo, C., Gimenez-Suau, M., Grau, E., Guirado, L., Gutierrez, J., Hernandez-Blasco, L., Jara-Palomares, L., Jaras, M. J., Jimenez-Alfaro, C., Joya, M. D., Lainez-Justo, S., Latorre, A., Lima, J., Lobo, J. L., Lopez-Jimenez, L., Lopez-Miguel, P., Lopez-Nunez, J. J., Lopez-Saez, J. B., Lorenzo, A., Madridano, O., Maestre, A., Marchena, P. J., Martin del Pozo, M., Martin-Martos, F., Martinez-Urbistondo, D., Mella, C., Mercado, M. I., Moises, J., Munoz, M., Munoz-Blanco, A., Nieto, J. A., Nofuentes-Perez, E., Nunez-Fernandez, M. J., Olid-Velilla, M., Olivares, M. C., Osorio, J., Otalora, S., Otero, R., Pedrajas, J. M., Pellejero, G., Porras, J. A., Portillo, J., Rodriguez-Matute, C., Rosa, V., Ruiz-Ruiz, J., Salgueiro, G., Sanchez-Martinez, R., Sanchez-Munoz-Torrero, J. F., Sancho, T., Soler, S., Suarez-Rodriguez, B., Surinach, J. M., Torres, M. I., Tolosa, C., Trujillo-Santos, J., Uresandi, F., Valle, R., Varona, J. F., Vela, L., Vela, J. R., Vidal, G., Villalobos, A., Villares, P., Zamora, C., Ay, C., Nopp, S., Pabinger, I., Vanassche, T., Vandenbriele, C., Hirmerova, J., Accassat, S., Ait Abdallah, N., Bura-Riviere, A., Catella, J., Couturaud, F., Crichi, B., Debourdeau, P., Espitia, O., Grange, C., Helfer, H., Lacut, K., Le Mao, R., Mahe, I., Morange, P., Moustafa, F., Poenou, G., Sarlon-Bartoli, G., Suchon, P., Quere, I., Braester, A., Basaglia, M., Bilora, F., Bortoluzzi, C., Brandolin, B., Ciammaichella, M., De Angelis, A., Imbalzano, E., Merla, S., Pesavento, R., Siniscalchi, C., Tufano, A., Visona, A., Vo Hong, N., Zalunardo, B., Nishimoto, Y., Sato, Y., Birzulis, J., Skride, A., Zaicenko, A., Fonseca, S., Martins, F., Meireles, J., Krstevski, G., and Mazzolai, L.
Subjects: Male, Registrie, Pulmonary and Respiratory Medicine, medicine.medical_specialty, pulmonary embolism, Critical Care and Intensive Care Medicine, Logistic regression, Heart Rate, Internal medicine, Heart rate, medicine, In patient, Aged, Aged, 80 and over, business.industry, medicine.disease, mortality, Pulmonary embolism, Prospective Studie, Increased risk, Spain, Cardiology, Positive relationship, Female, Cardiology and Cardiovascular Medicine, business, Human
Abstract: Background: The association between heart rate (HR) and pulmonary embolism (PE) outcomes has not been well studied. Furthermore, optimal cutoffs to identify low-risk and intermediate- to high-risk patients are not well known. Research Question: Does an association exist between baseline HR and PE outcome across the continuum of HR values? Study Design and Methods: The current study included 44,331 consecutive nonhypotensive patients with symptomatic PE from the Registro Informatizado de la Enfermedad TromboEmbólica registry between 2001 and 2021. Outcomes included 30-day all-cause and PE-specific mortality. We used hierarchical logistic regression to assess the association between admission HR and outcomes. Results: A positive relationship was found between admission HR and 30-day all-cause and PE-related mortality. Considering an HR of 80 to 99 beats/min as a reference, patients in the higher HR strata showed higher rates of all-cause death (adjusted OR, 1.5 for HR of 100-109 beats/min; adjusted OR, 1.7 for HR of 110-119 beats/min; adjusted OR, 1.9 for HR of 120-139 beats/min; and adjusted OR, 2.4 for HR of ≥ 140 beats/min). Patients in the lower strata of HR showed significantly lower rates of 30-day all-cause mortality compared with the same reference group (adjusted OR, 0.6 for HR of 60-79 beats/min; and adjusted OR, 0.5 for HR of < 60 beats/min). The findings for 30-day PE-related mortality were similar. For identification of low-risk patients, a cutoff value of 80 beats/min (vs 110 beats/min) increased the sensitivity of the simplified Pulmonary Embolism Severity Index (sPESI) from 93.4% to 98.8%. For identification of intermediate- to high-risk patients, a cutoff value of 140 beats/min (vs 110 beats/min) increased the specificity of the Bova score from 93.2% to 98.0%. Interpretation: In nonhypotensive patients with acute symptomatic PE, a high HR portends an increased risk of all-cause and PE-related mortality. Modifying the HR cutoff in the sPESI and the Bova score improves prognostication of patients with PE.
Published: 2022

15. Impact of Missing Data on Identifying Risk Factors for Postoperative Complications in Hand Surgery

Author: Suresh K. Nayar, Aviram M. Giladi, John V. Ingari, Keith T. Aziz, and Dawn M. LaPorte
Subjects: medicine.medical_specialty, Databases, Factual, 030230 surgery, Odds, 03 medical and health sciences, 0302 clinical medicine, Postoperative Complications, Risk Factors, Internal medicine, medicine, Humans, Orthopedics and Sports Medicine, In patient, Major complication, 030222 orthopedics, business.industry, Hand surgery, Research findings, medicine.disease, Missing data, Hand, Comorbidity, Quality Improvement, Acs nsqip, Surgery, business
Abstract: Background The mismanagement of missing data in large clinical databases may lead to inaccurate findings. The purpose of this study was to demonstrate the effects of missing data on hand surgery research findings using an analysis of postoperative morbidity in patients undergoing hospital-based hand surgery. Methods The National Surgical Quality Improvement Program database was queried for patients undergoing common hand and upper extremity surgery between 2011 and 2016. Major and minor postoperative complications were identified. Demographics, comorbidity, and preoperative laboratory values were identified, and the percentage missing of each was tabulated. To demonstrate how missing data can alter analysis results, these variables were evaluated for an association with major complications using multivariable regression on 3 separate cohorts: (1) all patients; (2) all patients after exclusion of any patient entry with >10% of missing data; and (3) after removal of any patient entry with any missing data. Results Groups 1, 2, and 3 had 48 370, 23 118, and 6280 patients, respectively. There were 14 variables associated with increased odds of major complications in group 1, yet only 10 and 9 variables for groups 2 and 3, respectively. Six variables were associated with increased major complications across all 3 groups, whereas only 1 was associated with decreased odds of major complications across all groups. Conclusions Filtering patient cohorts according to the amount of missing patient information affected analyses of predictors for major complications associated with hospital-based hand surgery. These findings highlight the importance of considering and addressing missing data in large database studies.
Published: 2023

16. Stereotactic radiosurgery versus active surveillance for asymptomatic, skull-based meningiomas: an international, multicenter matched cohort study

Author: Ahmed M. Nabeel, Abdurrahman I. Islim, Violaine Delabar, Selçuk Peker, Douglas Kondziolka, Yavuz Samanci, Roberto Martínez Álvarez, Khaled Abdelkarim, Ronald J. Benveniste, Michael D. Jenkinson, Reem M Emad, Manjul Tripathi, Kenneth E. Bernstein, Greg Bowden, Dade Lunsford, Georgios Mantziaris, Herwin Speckter, David Mathieu, Jaromir Hanuska, Nuria Martinez Moreno, Sameh R. Tawadros, Amr M N El-Shehaby, Camilo Albert, Cheng-Chia Lee, Stylianos Pikis, Huai-Che Yang, Jason P. Sheehan, Dev N Patel, Roman Liscak, Wael A. Reda, Peker, Selçuk (ORCID 0000-0003-3057-3355 & YÖK ID 11480), Samancı, Yavuz, Mantziaris, Georgios, Pikis, Stylianos, Nabeel, Ahmed M., Reda, Wael A., Tawadros, Sameh R., El-Shehaby, Amr M. N., Abdelkarim, Khaled, Emad, Reem M., Delabar, Violaine, Mathieu, David, Lee, Cheng-chia, Yang, Huai-che, Liscak, Roman, Hanuska, Jaromir, Alvarez, Roberto Martinez, Moreno, Nuria Martinez, Tripathi, Manjul, Speckter, Herwin, Albert, Camilo, Benveniste, Ronald J., Bowden, Greg N., Patel, Dev N., Kondziolka, Douglas, Bernstein, Kenneth, Lunsford, L. Dade, Jenkinson, Michael D., Islim, Abdurrahman I., Sheehan, Jason, Koç University Hospital, and School of Medicine
Subjects: medicine.medical_specialty, Cancer Research, medicine.medical_treatment, Radiosurgery, Skull Base Neoplasms, Asymptomatic, Matched cohort, parasitic diseases, medicine, Humans, Watchful Waiting, Retrospective Studies, business.industry, Oncology, Clinical neurology, Skull, Treatment Outcome, medicine.anatomical_structure, Neurology, Radiology, Neurology (clinical), medicine.symptom, Meningioma, business, Skull-base, Stereotactic
Abstract: Objective: the optimal management of asymptomatic, skull-based meningiomas is not well defined. The aim of this study is to compare the imaging and clinical outcomes of patients with asymptomatic, skull-based meningiomas managed either with upfront stereotactic radiosurgery (SRS) or active surveillance. Methods: this retrospective, multicenter study involved patients with asymptomatic, skull-based meningiomas. The study end-points included local tumor control and the development of new neurological deficits attributable to the tumor. Factors associated with tumor progression and neurological morbidity were also analyzed. Results: the combined unmatched cohort included 417 patients. Following propensity score matching for age, tumor volume, and follow-up 110 patients remained in each cohort. Tumor control was achieved in 98.2% and 61.8% of the SRS and active surveillance cohorts, respectively. SRS was associated with superior local tumor control (p < 0.001, HR = 0.01, 95% CI = 0.002-0.13) compared to active surveillance. Three patients (2.7%) in the SRS cohort and six (5.5%) in the active surveillance cohort exhibited neurological deterioration. One (0.9%) patient in the SRS-treated and 11 (10%) patients in the active surveillance cohort required surgical management of their meningioma during follow-up. Conclusions: SRS is associated with superior local control of asymptomatic, skull-based meningiomas as compared to active surveillance and does so with low morbidity rates. SRS should be offered as an alternative to active surveillance as the initial management of asymptomatic skull base meningiomas. Active surveillance policies do not currently specify the optimal time to intervention when meningioma growth is noted. Our results indicate that if active surveillance is the initial management of choice, SRS should be recommended when radiologic tumor progression is noted and prior to clinical progression., NA
Published: 2022

17. Albuminuria as a risk factor for mild cognitive impairment and dementia-what is the evidence?

Author: Bikbov B., Soler M. J., Pesic V., Capasso G., Unwin R., Endres M., Remuzzi G., Perico N., Gansevoort R., Mattace-Raso F., Bruchfeld A., Figurek A., Hafez G., Trepiccione Francesco, CONNECT Action, Bikbov, B., Soler, M. J., Pesic, V., Capasso, G., Unwin, R., Endres, M., Remuzzi, G., Perico, N., Gansevoort, R., Mattace-Raso, F., Bruchfeld, A., Figurek, A., Hafez, G., Trepiccione, Francesco, Connect, Action, Internal Medicine, and University of Zurich
Subjects: medicine.medical_specialty, 10017 Institute of Anatomy, Renal function, 610 Medicine & health, Review, 030204 cardiovascular system & hematology, albuminuria, 03 medical and health sciences, 0302 clinical medicine, mild cognitive impairment, Risk Factors, mental disorders, medicine, Dementia, Albuminuria, Humans, Cognitive Dysfunction, Endothelial dysfunction, Risk factor, Cognitive decline, AcademicSubjects/MED00340, Intensive care medicine, Cross-Sectional Studie, Transplantation, glomerular filtration rate, business.industry, Risk Factor, medicine.disease, 3. Good health, Cross-Sectional Studies, Nephrology, Relative risk, Disease Progression, 570 Life sciences, biology, medicine.symptom, business, 030217 neurology & neurosurgery, chronic kidney disease, dementia, Kidney disease, Human
Abstract: Kidney dysfunction can profoundly influence many organ systems, and recent evidence suggests a potential role for increased albuminuria in the development of mild cognitive impairment (MCI) or dementia. Epidemiological studies conducted in different populations have demonstrated that the presence of increased albuminuria is associated with a higher relative risk of MCI or dementia both in cross-sectional analyses and in studies with long-term follow-up. The underlying pathophysiological mechanisms of albuminuria’s effect are as yet insufficiently studied, with several important knowledge gaps still present in a complex relationship with other MCI and dementia risk factors. Both the kidney and the brain have microvascular similarities that make them sensitive to endothelial dysfunction involving different mechanisms, including oxidative stress and inflammation. The exact substrate of MCI and dementia is still under investigation, however available experimental data indicate that elevated albuminuria and low glomerular filtration rate are associated with significant neuroanatomical declines in hippocampal function and grey matter volume. Thus, albuminuria may be critical in the development of cognitive impairment and its progression to dementia. In this review, we summarize the available evidence on albuminuria’s link to MCI and dementia, point to existing gaps in our knowledge and suggest actions to overcome them. The major question of whether interventions that target increased albuminuria could prevent cognitive decline remains unanswered. Our recommendations for future research are aimed at helping to plan clinical trials and to solve the complex conundrum outlined in this review, with the ultimate goal of improving the lives of patients with chronic kidney disease., Graphical Abstract Graphical Abstract
Published: 2022

18. The Rapid Naming Test: Development and initial validation in typically aging adults

Author: Sabrina J. Erlhoff, Michelle You, Molly E. Zimmerman, Sladjana Lukic, Adam M. Staffaroni, Gil D. Rabinovici, Kaitlin B. Casaletto, Katherine L. Possin, Jordan Stiver, Renaud La Joie, Samantha M Walters, Joel H. Kramer, and Maria Luisa Gorno-Tempini
Subjects: medicine.medical_specialty, Aging, Amyloid beta-Peptides, Reproducibility of Results, Cognition, Audiology, Neuropsychological Tests, Word finding, Test (assessment), Psychiatry and Mental health, Clinical Psychology, Neuropsychology and Physiological Psychology, Arts and Humanities (miscellaneous), Tip of the tongue, Developmental and Educational Psychology, Complaint, medicine, Humans, Psychology, Pathological, Biomarkers, Aged, Language
Abstract: Progressive word-finding difficulty is a primary cognitive complaint among healthy older adults and a symptom of pathological aging. Classic measures of visual confrontation naming, however, show c...
Published: 2023

19. Smartphone-based Anterior Segment Imaging: A Comparative Diagnostic Accuracy Study of a Potential Tool for Blindness Prevalence Surveys

Author: Gopal Bhandari, N. Venkatesh Prajna, Robi N. Maamari, Muthiah Srinivasan, Thomas M. Lietman, Sadhan Bhandari, Prajna Lalitha, Daniel A. Fletcher, Valerie M Stevens, Ashish Kumar, Ferhina S. Ali, Jason S Melo, and Jeremy D. Keenan
Subjects: medicine.medical_specialty, Visual acuity, genetic structures, Epidemiology, Magnification, Diagnostic accuracy, Blindness, Cicatrix, Corneal Opacity, Ophthalmology, Cornea, medicine, Prevalence, Humans, business.industry, Corneal opacity, corneal ulcer, medicine.disease, eye diseases, Slit-lamp Examination, medicine.anatomical_structure, sense organs, Smartphone, medicine.symptom, business
Abstract: Purpose To determine if smartphone photography could be a useful adjunct to blindness prevalence surveys by providing an accurate diagnosis of corneal opacity. Methods A total of 174 patients with infectious keratitis who had undergone corneal culturing over the past 5 years were enrolled in a diagnostic accuracy study at an eye hospital in South India. Both eyes had an ophthalmologist-performed slit lamp examination, followed by anterior segment photography with a handheld digital single lens reflex (SLR) camera and a smartphone camera coupled to an external attachment that provided magnification and illumination. The diagnostic accuracy of photography was assessed relative to slit lamp examination. Results In total, 90 of 174 enrolled participants had a corneal opacity in the cultured eye and no opacity in the contralateral eye, and did not have a penetrating keratoplasty or missing photographs. Relative to slit lamp examination, the sensitivity of corneal opacity diagnosis was 68% (95%CI 58-77%) using the smartphone's default settings and 59% (95%CI 49-69%) using the SLR, and the specificity was 97% (95%CI 93-100%) for the smartphone and 97% (95%CI 92-100%) for the SLR. The sensitivity of smartphone-based corneal opacity diagnosis was higher for larger scars (81% for opacities 2 mm in diameter or larger), more visually significant scars (100% for eyes with visual acuity worse than 20/400), and more recent scars (85% for eyes cultured in the past 12 months). Conclusion The diagnostic performance of a smartphone coupled to an external attachment, while somewhat variable, demonstrated high specificity and high sensitivity for all but the smallest opacities.
Published: 2023

20. Diagnosis of Sweet's syndrome in otolaryngology

Author: Marijke R van Dijk, Anouk W M A Schaeffers, Digna M A Kamalski, and Danique M S Berger
Subjects: Sweet's syndrome, Adult, medicine.medical_specialty, Referral, medicine.diagnostic_test, business.industry, Signs and symptoms, General Medicine, medicine.disease, Dermatology, Skin Diseases, Sweet Syndrome, Lesion, Leukemia, Myeloid, Acute, Otolaryngology, Otorhinolaryngology, Biopsy, medicine, Humans, In patient, Female, Myeloid leukaemia, medicine.symptom, business, Skin
Abstract: Sweet’s syndrome (acute febrile neutrophilic dermatosis) consists of acute onset of painful cutaneous erythematous lesions, mostly found in the upper extremities followed by the head and neck region, particularly in patients with underlying malignancies. We describe the case of a woman in her mid-30s, who was treated for acute myeloid leukaemia and presented with a severe painful and progressive erythematous lesion of the retroauricular skin. Clinical features, laboratory tests, blood cultures and histological biopsy yielded a diagnosis of Sweet’s syndrome. The treatment consisted of oral and topical corticosteroids and her signs and symptoms resolved within 1 week. Although Sweet’s syndrome is uncommon, awareness among otolaryngologists is crucial to ensure a prompt diagnosis, cure and referral to an oncologist (if not already involved) for patients with Sweet’s syndrome in the head and neck area.
Published: 2023

21. Using Generalized Polyspike Train to Predict Drug-Resistant Idiopathic Generalized Epilepsy

Author: Ramya Raghupathi, Jay Pathmanathan, Danielle A. Becker, Armina T Omole, Taneeta M. Ganguly, James J Gugger, Barbara M. Decker, Michael A. Gelfand, Russell T. Shinohara, Erin C. Conrad, Etsegenet F. Tizazu, Nanak Chugh, Kathryn A. Davis, and Colin A Ellis
Subjects: medicine.medical_specialty, Drug Resistant Epilepsy, Physiology, Drug resistance, Electroencephalography, 050105 experimental psychology, Article, Idiopathic generalized epilepsy, 03 medical and health sciences, 0302 clinical medicine, Interquartile range, Physiology (medical), Internal medicine, medicine, Humans, 0501 psychology and cognitive sciences, EEG feature, Survival analysis, medicine.diagnostic_test, business.industry, 05 social sciences, Odds ratio, Immunoglobulin E, medicine.disease, Confidence interval, Neurology, Case-Control Studies, Epilepsy, Generalized, Neurology (clinical), business, 030217 neurology & neurosurgery
Abstract: Introduction The authors tested the hypothesis that the EEG feature generalized polyspike train (GPT) is associated with drug-resistant idiopathic generalized epilepsy (IGE). Methods The authors conducted a single-center case-control study of patients with IGE who had outpatient EEGs performed between 2016 and 2020. The authors classified patients as drug-resistant or drug-responsive based on clinical review and in a masked manner reviewed EEG data for the presence and timing of GPT (a burst of generalized rhythmic spikes lasting less than 1 second) and other EEG features. A relationship between GPT and drug resistance was tested before and after controlling for EEG duration. The EEG duration needed to observe GPT was also calculated. Results One hundred three patients were included (70% drug-responsive and 30% drug-resistant patients). Generalized polyspike train was more prevalent in drug-resistant IGE (odds ratio, 3.8; 95% confidence interval, 1.3-11.4; P = 0.02). This finding persisted when controlling for EEG duration both with stratification and with survival analysis. A median of 6.5 hours (interquartile range, 0.5-12.7 hours) of EEG recording was required to capture the first occurrence of GPT. Conclusions The findings support the hypothesis that GPT is associated with drug-resistant IGE. Prolonged EEG recording is required to identify this feature. Thus, >24-hour EEG recording early in the evaluation of patients with IGE may facilitate prognostication.
Published: 2023

22. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

Author: Strauss, S.J., Frezza, A.M., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J.Y., Bolle, S., Bonvalot, S., Boukovinas, I., Bovee, J.V.M.G., Boye, K., Brennan, B., Brodowicz, T., Buonadonna, A., Alava, E. de, Tos, A.P. dei, Muro, X.G. del, Dufresne, A., Eriksson, M., Fagioli, F., Fedenko, A., Ferraresi, V., Ferrari, A., Gaspar, N., Gasperoni, S., Gelderblom, H., Gouin, F., Grignani, G., Gronchi, A., Haas, R., Hassan, A.B., Hecker-Nolting, S., Hindi, N., Hohenberger, P., Joensuu, H., Jones, R.L., Jungels, C., Jutte, P., Kager, L., Kasper, B., Kawai, A., Kopeckova, K., Krakorova, D.A., Cesne, A. le, Grange, F. le, Legius, E., Leithner, A., Pousa, A.L., Martin-Broto, J., Merimsky, O., Messiou, C., Miah, A.B., Mir, O., Montemurro, M., Morland, B., Morosi, C., Palmerini, E., Pantaleo, M.A., Piana, R., Piperno-Neumann, S., Reichardt, P., Rutkowski, P., Safwat, A.A., Sangalli, C., Sbaraglia, M., Scheipl, S., Schoffski, P., Sleijfer, S., Strauss, D., Hall, K.S., Trama, A., Unk, M., Sande, M.A.J. van de, Graaf, W.T.A. van der, Houdt, W.J. van, Frebourg, T., Ladenstein, R., Casali, P.G., Stacchiotti, S., ESMO Guidelines Comm, EURACAN, GENTURIS, ERN PaedCan, European Society for Medical Oncology, Strauss S.J., Frezza A.M., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Blay J.Y., Bolle S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brennan B., Brodowicz T., Buonadonna A., de Alava E., Dei Tos A.P., Garcia del Muro X., Dufresne A., Eriksson M., Fagioli F., Fedenko A., Ferraresi V., Ferrari A., Gaspar N., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Gronchi A., Haas R., Hassan A.B., Hecker-Nolting S., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kager L., Kasper B., Kawai A., Kopeckova K., Krakorova D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morland B., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schoffski P., Sleijfer S., Strauss D., Sundby Hall K., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Ladenstein R., Casali P.G., Stacchiotti S., Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Public Health Research (PHR), and Man, Biomaterials and Microbes (MBM)
Subjects: medicine.medical_specialty, diagnosis, Medizin, bone sarcoma, Bone Neoplasm, Bone Sarcoma, Follow-Up Studie, 03 medical and health sciences, 0302 clinical medicine, follow-up, medicine, 030304 developmental biology, Osteosarcoma, 0303 health sciences, treatment, business.industry, Sarcoma, Hematology, Guideline, clinical practice guideline, management, 3. Good health, Clinical Practice, diagnosi, Oncology, Diagnosis treatment, 030220 oncology & carcinogenesis, Radiology, business, Human
Abstract: A. Kawai43, K. Kopeckova44, D. A. Krakorova45, A. Le Cesne46, F. Le Grange1, E. Legius47, A. Leithner48, A. Lopez Pousa49, J. Martin-Broto36, O. Merimsky50, C. Messiou51, A. B. Miah52, O. Mir53, M. Montemurro54, B. Morland55, C. Morosi56, E. Palmerini57, M. A. Pantaleo58, R. Piana59, S. Piperno-Neumann60, P. Reichardt61, P. Rutkowski62, A. A. Safwat63, C. Sangalli64, M. Sbaraglia19, S. Scheipl48, P. Schoffski65, S. Sleijfer66, D. Strauss67, K. Sundby Hall13, A. Trama68, M. Unk69, M. A. J. van de Sande70, W. T. A. van der Graaf66,71, W. J. van Houdt72, T. Frebourg73x, R. Ladenstein41z, P. G. Casali2,74z &
Published: 2021

23. Neutrophilic dermatosis of the dorsal hands: A review of 123 cases

Author: David Pisani, Daniel Micallef, M. J. Boffa, and Maria Bonnici
Subjects: medicine.medical_specialty, business.industry, Sweet Syndrome, Neutrophilic dermatosis of the dorsal hands, Dermatology, Dapsone, medicine.disease, Inflammatory bowel disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Patient age, Female preponderance, 030220 oncology & carcinogenesis, Erythematous plaque, medicine, Proper treatment, business, medicine.drug
Abstract: Background Neutrophilic dermatosis of the dorsal hands is an uncommon localised variant of Sweet syndrome first described in 1995. It is characterised by tender erythematous plaques, pustules and bullae on the dorsa of the hands. Literature Review A total of 123 cases of NDDH are included in this review. The mean patient age was 62.1 years and there was a slight female preponderance. 78.0% of cases had reported bilateral involvement and other sites were affected in almost a third of cases. Underlying disease was found in around 40% of patients, with the most common associations being haematological disorders (gammopathies, myelodysplasias or malignancies), recent infection, solid organ tumours and inflammatory bowel disease. Systemic and/or topical corticosteroids were employed in the treatment of 88.1% of cases while dapsone, colchicine and tetracyclines were the commonest steroid-sparing agents used. Improvement was often rapid and complete resolution the norm. Conclusions Whilst being uncommon, NDDH is frequently misdiagnosed and thus, its exact prevalence is probably underestimated. This may have significant implications including treatment delays or incorrect management. Moreover, recognition of NDDH is important since a correct diagnosis should trigger a search for underlying diseases and proper treatment with corticosteroids and/or steroid-sparing agents which is almost invariably curative.
Published: 2023

24. The Cannabis-Dependent Relationship Between Methadone Treatment Dose and Illicit Opioid Use in a Community-Based Cohort of People Who Use Drugs

Author: Thomas Kerr, Zach Walsh, M. Eugenia Socías, M.-J. Milloy, Stephanie Lake, Ziva D. Cooper, Jane A. Buxton, Nadia Fairbairn, and Kanna Hayashi
Subjects: Pharmacology, medicine.medical_specialty, Methadone maintenance, biology, business.industry, Craving, Opioid use disorder, medicine.disease, biology.organism_classification, Complementary and alternative medicine, Internal medicine, mental disorders, Cohort, medicine, Pharmacology (medical), Dosing, Cannabis, medicine.symptom, business, Cohort study, Methadone, medicine.drug
Abstract: Background: Methadone maintenance treatment (MMT) is an effective treatment for opioid use disorder. However, subtherapeutic dosing may lead to continued opioid use by failing to suppress opioid withdrawal and craving. Preclinical and pilot experimental research suggests that cannabinoids may reduce opioid withdrawal and craving. We sought to test whether the association between low methadone dose and illicit opioid use differs according to concurrent cannabis use patterns. Methods: Data for this study were derived from two community-recruited cohorts of people (≥18 years old) who use illicit drugs in Vancouver, Canada. We used generalized estimating equations to estimate the adjusted association between lower daily MMT dose (
Published: 2023

25. What matters to psychology trainees when making decisions about internship and postdoctoral training sites: Differences between racial/ethnic minority and White VA trainees

Author: Jeffrey T. Bates, Darlene M Davis, Jessica A. Chen, Zhen Hadassah Cheng, Daryl Fujii, Jamylah Jackson, Stephanie N Wong, and Christine M Rosner
Subjects: Licensure, medicine.medical_specialty, education.field_of_study, media_common.quotation_subject, education, Population, Ethnic group, PsycINFO, Work related, Clinical Psychology, Family medicine, Internship, medicine, Pacific islanders, Psychology, Applied Psychology, Diversity (politics), media_common
Abstract: It is projected that by 2045, racial/ethnic minorities in the U.S. will become the majority. Unfortunately, the numbers of racial/ethnic minority psychologists have not kept up with population trends. This discrepancy poses challenges for many psychology training sites, including the Department of Veterans Affairs (VA). There is a lack of data on what factors are important for psychology applicants, including racial/ethnic minority trainees when they are considering internship and postdoctoral training sites. This quality improvement project surveyed 237 VA psychology trainees (59% psychology interns, 32.5% psychology postdoctoral fellows, 69.6% White, 9.3% multiracial, 6.8% Asian American or Pacific Islander, 5.1% Black/African American, 4.2% Latinx American, 0.8% Native American, 0.8% Middle Eastern) to study what factors are important when considering training sites. Results indicated that overall, racial/ethnic minority and White trainees endorsed similar primary factors when considering training programs. Site related factors (e.g., perceived workload, training opportunities) and future work related factors (e.g., ease of licensure, obtaining a first job) were top considerations regardless of race/ethnicity. The groups diverged in secondary factors with racial/ethnic minorities desiring infusion of diversity in training more than White applicants and White applicants considering quality of life factors such as extracurricular opportunities and convenience of daily living more important than racial/ethnic minority applicants. Qualitative data indicated applicants perceived VA training sites to be more welcoming and offer more opportunities for learning about diversity than non-VA sites. Recommendations for recruiting psychology trainees in general, and then specifically for racial/ethnic minority applicants are discussed. (PsycInfo Database Record (c) 2021 APA, all rights reserved).
Published: 2023

26. Physical Therapy in Systemic Sclerosis: The Patient Perspective

Author: Jeska K de Vries-Bouwstra, Cornelia H. M. van den Ende, Nina M van Leeuwen, Thea P. M. Vliet Vlieland, Madelon C. Vonk, Sophie I E Liem, Gerrie M W Boerrigter, Lian de Pundert, Julia Spierings, and Marisca R Schriemer
Subjects: medicine.medical_specialty, Massage, Referral, business.industry, MEDLINE, Primary care, All institutes and research themes of the Radboud University Medical Center, Rheumatology, Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5], Physical therapy, Medicine, Aerobic exercise, Lack of knowledge, In patient, business, Range of motion
Abstract: Contains fulltext : 290708.pdf (Publisher’s version ) (Open Access) OBJECTIVE: To assess the use, satisfaction, needs, and preferences regarding physical therapy (PT) in patients with systemic sclerosis (SSc). METHODS: A total of 405 SSc patients, treated in the Leiden University Medical Center multidisciplinary care program and fulfilling American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) 2013 SSc criteria, received a questionnaire containing 37 questions on use and satisfaction regarding PT over a 2-year period, and their needs and preferences for future PT. RESULTS: A total of 204 SSc patients (median age 63 years, 81% female) completed the questionnaire. One hundred twenty-eight patients (63%) had used or were using PT in a primary care setting. For 39% of patients not using PT, lack of referral or lack of knowledge was the reason for not using it. The most frequently reported active treatments were muscle-strengthening (n = 92 [72%]), range of motion (n = 77 [60%]), and aerobic exercises (n = 72 [56%]). Specific SSc hand- and mouth-opening exercises were reported by 20 (15%) and 7 (6%) patients, respectively. Manual treatment (massage or passive mobilization) was reported by 83 patients (65%). The mean ± SD satisfaction score (range 0-10) was 8.2 ± 1.6. Regarding patients' needs, 96 patients (47%) of the total group wanted to receive more information concerning PT, and 128 (63%) wanted to continue, start, or restart PT in the near future, with 56 of the 128 patients (44%) favoring individual treatment on a continuous basis. CONCLUSION: We observed a significant variation in the use and content of PT for SSc patients in a primary care setting. Our results suggest potential underuse of PT care, in particular for hand and oral dysfunction, and underpin the need for initiatives to improve the quality and accessibility of PT care for SSc patients. 01 januari 2023
Published: 2023

27. Differences in swimming smoothness between elite and non-elite swimmers

Author: Hein A.M. Daanen, Bart M A Coolen, Peter J. Beek, Sander P. M. Ganzevles, M.J. Truijens, AMS - Sports and Work, Physiology, IBBA, and Faculty of Behavioural and Movement Sciences
Subjects: medicine.medical_specialty, SDG 16 - Peace, 0206 medical engineering, SDG 16 - Peace, Justice and Strong Institutions, Jerk, Physical Therapy, Sports Therapy and Rehabilitation, 030229 sport sciences, 02 engineering and technology, technique, 020601 biomedical engineering, Jerk cost, Justice and Strong Institutions, 03 medical and health sciences, 0302 clinical medicine, Physical medicine and rehabilitation, Sprint, efficiency, Elite, medicine, accelerometry, Orthopedics and Sports Medicine, daily monitoring, Mathematics
Abstract: The aim of the study was to investigate whether jerk cost (JC) can discriminate between swimming levels. Nine elite and nine non-elite swimmers swam a 50-m front-crawl sprint wearing a 3D accelerometer on their back between the inferior angles of the scapulae. Lap times and JC were calculated from the acceleration signal and compared between groups and between swimmers within a group. The elite swimmers swam significantly faster lap times than the non-elite swimmers (p < 0.001). They did so with significantly lower levels of JC compared to the non-elite swimmers (p = 0.005). Furthermore, a stepwise multiple linear regression showed JC accounted for 32.9% of the variation in lap time of the elite swimmers. These results indicate that it is possible to discriminate elite from non-elite swimmers using JC: elite swimmers swim with lower JCs than non-elite swimmers. Additionally, swimming at higher speed is associated with more accelerations and decelerations in both elite and non-elite swimmers, which is reflected by higher JCs and lower smoothness. In sum, JC provides an index of swimming technique that is easy to use in training practice.
Published: 2023

28. The Appendix Orchestrates T-Cell Mediated Immunosurveillance in Colitis-Associated Cancer

Author: Tourneur-Marsille J, Nathalie Guedj, Mathieu Uzzan, M. Collard, Yves Panis, Jean-Pierre Hugot, Dumay A, Jean-Noël Freund, Maryline Roy, Xavier Treton, Eric Ogier-Denis, M. Albuquerque, Service de Chirurgie colorectale [Hôpital Beaujon], Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Service de Gastroentérologie [Hôpital Beaujon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Interface de Recherche Fondamentale et Appliquée en Cancérologie (IRFAC - Inserm U1113), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Paul Strauss : Centre Régional de Lutte contre le Cancer (CRLCC)-Fédération de Médecine Translationelle de Strasbourg (FMTS), Oncogenesis, Stress, Signaling (OSS), and Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: medicine.medical_specialty, Lymphocyte, medicine.medical_treatment, [SDV.CAN]Life Sciences [q-bio]/Cancer, Gastroenterology, Internal medicine, Laparotomy, medicine, Appendectomy, Ulcerative Colitis, Colitis, Hepatology, business.industry, Inflammatory Bowel Disease, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, Appendicitis, Ulcerative colitis, Appendix, Immunosurveillance, medicine.anatomical_structure, [SDV.IMM.IA]Life Sciences [q-bio]/Immunology/Adaptive immunology, business, CD8
Abstract: ObjectiveWhile appendectomy may reduce colorectal inflammation in patients with ulcerative colitis (UC), appendectomy has been suggested to be associated with an increased risk of colitis-associated cancer (CAC). The aim of this study was to explore the mechanism underlying the appendectomy-associated increased risk of CAC.DesignFive-week-old male BALB/c mice underwent appendectomy, appendicitis induction or sham laparotomy. They were then exposed to azoxymethane/dextran sodium sulfate (AOM/DSS) to induce CAC. Mice were sacrificed 12 weeks later, and colons were taken for pathological analysis and immunohistochemistry (CD3 and CD8 staining). Human colonic tumors from 21 UC patients who underwent surgical resection for CAC were immunophenotyped and stratified according to the appendectomy status.ResultsWhile appendectomy significantly reduced colitis severity and increased CAC number, appendicitis induction without appendectomy led to opposite results. Intra-tumor CD3+ and CD8+ T-cell densities were lower after appendectomy and higher after appendicitis induction compared to the sham laparotomy group. Blocking lymphocyte trafficking to the colon with the anti-α4β7 integrin antibody or a sphingosine-1-phosphate receptor agonist suppressed the inducing effect of the appendectomy on tumors’ number and on CD3+/CD8+ intra-tumoral density. CD8+ or CD3+ T cells isolated from inflammatory neo-appendix and intravenously injected into AOM/DSS-treated recipient mice increased CD3+/CD8+ T-cell tumor infiltration and decreased tumor number. In UC patients with a history of appendectomy, intra-tumor CD3+ and CD8+ T-cell densities were decreased compared to UC patients without history of appendectomy.ConclusionsIn UC, appendectomy could suppress a major site of T-cell priming resulting in a less efficient CAC immunosurveillance.Significance of this studyWhat is already known on this subject?The protective effect of preemptive appendectomy is currently investigated as a therapy for refractory ulcerative colitis (UC), with encouraging results.An increased risk of developing colitis-associated cancer (CAC) caused by this promising treatment has been identified.Since it is commonly accepted that CAC is related to colitis severity and extent, this finding is counterintuitive and the mechanisms of this paradoxical effect remain unknown.What are the new findings?In a mouse model of CAC, less extended colitis associated with an increased number of tumors was observed. Intra-tumor T-cell infiltration was significantly reduced after appendectomy. Blocking lymphocyte trafficking to the colon with current or experimental UC treatments mimicked the appendectomy-associated phenotype whereas neo-appendicitis or appendix-primed T-cell injection in recipient mice increased intra-tumor T-cell infiltration and strengthened protection against CAC.In UC patients with CAC, appendectomy was associated with a decreased intra-tumor T-cell infiltration.These findings suggest that, in UC, appendectomy could suppress a major site of T-cell priming in the colon, resulting in a reduced CAC immunosurveillance.How might it impact on clinical practice in the foreseeable future?This work emphasizes the fact that precautions will be necessary if appendectomy becomes an accepted therapeutic option for the treatment of refractory UC.Innovative cell-based therapies and immunotherapies, such as the administration of stimulated autologous appendicular T cells in patients with CAC are promising options.
Published: 2023

29. Work Ability in Patients With Stage I to IV Colon Cancer

Author: Mira D, Franken, Geraldine, Vink, Wilhelmina M U, van Grevenstein, Helena M, Verkooijen, Cornelis J A, Punt, Miriam, Koopman, Anne M, May, David D E, Zimmerman, Interne Geneeskunde, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, and MUMC+: MA Medische Oncologie (9)
Subjects: medicine.medical_specialty, Colorectal cancer, Population, Work Capacity Evaluation, Disease, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], All institutes and research themes of the Radboud University Medical Center, Internal medicine, medicine, Humans, Prospective Studies, Stage (cooking), Prospective cohort study, education, Neoplasm Staging, Retrospective Studies, education.field_of_study, business.industry, Colonic Neoplasms/surgery, Gastroenterology, Cancer, General Medicine, medicine.disease, Comorbidity, Cohort, business
Abstract: BACKGROUND: Colon cancer affects a patient's ability to work. Many patients who have colon cancer are employed at the time of diagnosis.OBJECTIVE: We evaluated work ability during the first 2 years after colon cancer diagnosis.DESIGN: This study is a national prospective study, the Prospective Dutch ColoRectal Cancer cohort, including clinical data and patient-reported outcomes.SETTINGS: Data were collected in 59 medical centers in the Netherlands.PATIENTS: Patients MAIN OUTCOME MEASURES: Work ability was assessed at baseline, 3, 6, 12, 18, and 24 months. The Work Ability Index (range, 0 to 49) was evaluated using linear mixed models. Outcomes were matched to population controls without cancer.RESULTS: Of 390 patients, 84% had paid employment. Work ability of patients with stage I to IV colon cancer was significantly lower at the time of diagnosis than in matched population controls (31 ± 8.2 and 41 ± 5.6). Patients with stage I to III disease receiving surgery only regained Work Ability Index scores comparable to matched population controls at 18 months. Patients receiving adjuvant systemic treatment initially demonstrated a decrease in work ability with improvements from 6 months onward and normalization at 24 months. Patients with stage IV disease did not demonstrate improvements in work ability outcomes over time. Work ability scores were negatively influenced by the administration of systemic treatment and ≥1 comorbidities.LIMITATIONS: Only patients with patient-reported outcomes and work at baseline were included in this analysis. Also, questionnaire response rates decreased over time.CONCLUSIONS: Work ability in patients with colon cancer is decreased for a prolonged time. Recovery depends on disease stage, type of treatment, and comorbidities. Patients with stage I to III disease treated with curative surgery alone were the first to regain work ability, followed by patients who receive adjuvant chemotherapy. Patients with stage IV disease did not regain work ability. See Video Abstract at http://links.lww.com/DCR/B759 .CAPACIDAD LABORAL EN PACIENTES CON CNCER DE COLON EN ESTADIO IIV RESULTADOS PROSPECTIVOS DE CNCER COLORECTAL EN UNA COHORTE HOLANDESA: ANTECEDENTES:El cáncer de colon afecta la capacidad de trabajo en un paciente. Muchos pacientes con cáncer de colon están empleados en el momento del diagnóstico.OBJETIVO:Evaluamos la capacidad laboral durante los dos primeros años posteriores al diagnóstico de cáncer de colon.DISEÑO:Es un estudio prospectivo nacional, la cohorte de cáncer colorrectal holandés, incluye datos clínicos y resultados informados por los pacientes.ENTORNO CLINICO:Se recopilaron datos de 59 centros médicos en los Países Bajos.PACIENTES:Se seleccionaron pacientes < 67 años, con cáncer de colon en estadio I-IV, que completaron los cuestionarios de índice de capacidad para el trabajo.PRINCIPALES MEDIDAS DE VALORACIÓN:La capacidad para el trabajo se evaluó al inicio, a los 3, 6, 12, 18 y 24 meses. El índice de capacidad para el trabajo (que va de 0 a 49) se evaluó mediante modelos lineales mixtos. Los resultados fueron comparados con el grupo control sin cáncer.RESULTADOS:De 390 pacientes, el 84% tenía un empleo remunerado. La capacidad de trabajo de los pacientes en estadio I-IV fue significativamente menor en el momento del diagnóstico en comparación con el grupo control (31 ± 8,2 y 41 ± 5,6, respectivamente). Los pacientes con enfermedad en estadio I-III que recibieron cirugía lograron recuperar puntajes del índice de capacidad laboral comparables a los controles a los 18 meses. Los pacientes que recibieron tratamiento sistémico adyuvante inicialmente demostraron una disminución en la capacidad de trabajo con mejoras a partir de los 6 meses en adelante y una normalización a los 24 meses. Los pacientes en estadio IV no demostraron mejoras en los resultados de la capacidad laboral a lo largo del tiempo. Las puntuaciones de capacidad para el trabajo se vieron influidas negativamente por la administración del tratamiento sistémico y la existencia de ≥1 comorbilidades.LIMITACIONES:En este análisis solo se incluyeron los pacientes con resultados y trabajo desde el inicio del estudio. Además, las tasas de respuesta al cuestionario disminuyeron con el tiempo.CONCLUSIONES:La capacidad de trabajo en pacientes con cáncer de colon se reduce durante un tiempo prolongado. La recuperación depende del estadio de la enfermedad, el tipo de tratamiento y la comorbilidad. Los pacientes con enfermedad en estadio I-III tratados con cirugía curativa exclusivamente, son los primeros en recuperar la capacidad para trabajar, seguidos de los pacientes que reciben quimioterapia adyuvante. Los pacientes con enfermedad en estadio IV no recuperan la capacidad para trabajar. Consulte Video Resumen en http://links.lww.com/DCR/B759 . (Traducción- Dr. Ingrid Melo ).
Published: 2023

30. Prenatal medication use in a prospective pregnancy cohort by pre-pregnancy obesity status

Author: Angela C. Ranzini, Yassaman Vafai, William A. Grobman, Stefanie N. Hinkle, Cuilin Zhang, Roger B. Newman, Edwina Yeung, Rajeshwari Sundaram, Katherine L. Grantz, Edward K. Chien, Anthony Sciscione, Nicole Gerlanc, Melissa M. Smarr, Jagteshwar Grewal, Daniel W. Skupski, and Deborah A. Wing
Subjects: medicine.medical_specialty, Article, Body Mass Index, 03 medical and health sciences, 0302 clinical medicine, Pregnancy, medicine, Humans, 030212 general & internal medicine, Prospective Studies, Obesity, Progesterone, Medication use, 030219 obstetrics & reproductive medicine, Obstetrics, Pre pregnancy, business.industry, nutritional and metabolic diseases, Obstetrics and Gynecology, medicine.disease, Diabetes, Gestational, Pediatrics, Perinatology and Child Health, Cohort, Female, business, Body mass index
Abstract: BACKGROUND: The association between obesity (body mass index (BMI) ≥ 30 kg/m(2)) and pattern of medication use during pregnancy in the United States is not well-studied. Higher prepregnancy BMI may be associated with increases or decreases in medication use across pregnancy as symptoms (e.g. reflux) or comorbidities (e.g. gestational diabetes) requiring treatment that may be associated with higher BMI could also change with advancing gestation. OBJECTIVES: To determine whether prenatal medication use, by the number and types of medications, varies by pre-pregnancy obesity status. METHODS: In a secondary data analysis of a racially/ethnically diverse prospective cohort of pregnant women with low risk for fetal abnormalities enrolled in the first trimester of pregnancy and followed to delivery (singleton, 12 United States clinical sites), free text medication data were obtained at enrollment and up to five follow-up visits and abstracted from medical records at delivery. RESULTS: In 436 women with obesity and 1750 women without obesity (pre-pregnancy BMI, 19–29.9 kg/m(2)), more than 70% of pregnant women (77% of women with and 73% of women without obesity) reported taking at least one medication during pregnancy, respectively (adjusted risk ratio (aRR)=1.10, 95% confidence interval (CI)=1.01, 1.20), with 81% reporting two and 69% reporting three or more. A total of 17 classes of medications were identified. Among medication classes consumed by at least 5% of all women, the only class that differed between women with and without obesity was hormones and synthetic substitutes (including steroids, progesterone, diabetes, and thyroid medications) in which women with obesity took more medications (11 vs. 5%, aRR = 1.9, 95% CI = 1.38, 2.61) compared to women without obesity. Within this class, a higher percentage of women with obesity took diabetes medications (2.3 vs. 0.7%) and progesterone (3.4 vs. 1.3%) than their non-obese counterparts. Similar percentages of women with and without obesity reported consuming medications in the remaining medication classes including central nervous system agents (50 and 46%), gastrointestinal drugs (43 and 40%), anti-infective agents (23 and 21%), antihistamines (20 and 17%), autonomic drugs (10 and 9%), and respiratory tract agents (7 and 6%), respectively (p > 0.05 for all adjusted comparisons). There were no differences in medication use by obesity status across gestation. Since the study exclusion criteria limited the non-obese group to women without thyroid disease, in a sensitivity analysis we excluded all women who reported thyroid medication intake and still a higher proportion of women with obesity took the hormones and synthetic substitutes class compared to women without obesity. CONCLUSION: Our findings suggest that pre-pregnancy obesity in otherwise healthy women is associated with a higher use of only selected medications (such as diabetes medications and progesterone) during pregnancy, while the intake of other more common medication types such as analgesics, antibiotics, and antacids does not vary by pre-pregnancy obesity status. As medication safety information for prenatal consumption is insufficient for many medications, these findings highlight the need for a more in-depth examination of factors associated with prenatal medication use.
Published: 2023

31. The Association of Postoperative Opioid Prescriptions with Patient Outcomes

Author: Vidhya Gunaseelan, Michael J. Englesbe, Mark C. Bicket, Craig S. Brown, Kao-Ping Chua, Jennifer F. Waljee, Chad M. Brummett, Yen-Ling Lai, and Ryan Howard
Subjects: Adult, Male, medicine.medical_specialty, Quality of life, Internal medicine, medicine, Humans, Practice Patterns, Physicians', Adverse effect, Retrospective Studies, Pain, Postoperative, business.industry, Incidence (epidemiology), Retrospective cohort study, Emergency department, Middle Aged, Confidence interval, Analgesics, Opioid, Prescriptions, Opioid, Cohort, Quality of Life, Surgery, Female, business, medicine.drug
Abstract: Objective To compare outcomes after surgery between patients who were not prescribed opioids and patients who were prescribed opioids. Summary of background data Postoperative opioid prescriptions carry significant risks. Understanding outcomes among patients who receive no opioids after surgery may inform efforts to reduce these risks. Methods We performed a retrospective study of adult patients who underwent surgery between January 1, 2019 and October 31, 2019. The primary outcome was the composite incidence of an emergency department visit, readmission, or reoperation within 30 days of surgery. Secondary outcomes were postoperative pain, satisfaction, quality of life, and regret collected via postoperative survey. A multilevel, mixed-effects logistic regression was performed to evaluate differences between groups. Results In a cohort of 22,345 patients, mean age (standard deviation) was 52.1 (16.5) years and 13,269 (59.4%) patients were female. About 3175 (14.2%) patients were not prescribed opioids, of whom 422 (13.3%) met the composite adverse event endpoint compared to 2255 (11.8%) of patients not prescribed opioids (P = 0.015). Patients not prescribed opioids had a similar probability of adverse events {11.7% [95% confidence interval (CI) 10.2%-13.2%] vs 11.9% (95% CI 10.6%-13.3%]}. Among 12,872 survey respondents, patients who were not prescribed an opioid had a similar rate of high satisfaction [81.7% (95% CI 77.3%-86.1%) vs 81.7% (95% CI 77.7%-85.7%)] and no regret [(93.0% (95% CI 90.8%-95.2%) vs 92.6% (95% CI 90.4%-94.7%)]. Conclusions Patients who were not prescribed opioids after surgery had similar clinical and patient-reported outcomes as patients who were prescribed opioids. This suggests that minimizing opioids as part of routine postoperative care is unlikely to adversely affect patients.
Published: 2023

32. Successful WEBectomy during embolization of temporal arteriovenous malformation-associated flow-related basilar aneurysms

Author: Cyril Dargazanli, Vincent Costalat, Federico Cagnazzo, Mohamed M Abdelrady, and Imad Derraz
Subjects: medicine.medical_specialty, Solitaire Cryptographic Algorithm, business.industry, medicine.medical_treatment, Endovascular Procedures, Arteriovenous malformation, Intracranial Aneurysm, General Medicine, Case presentation, medicine.disease, Embolization, Therapeutic, Arteriovenous Malformations, Treatment Outcome, medicine, Device migration, Humans, Female, Radiology, Embolization, Endovascular treatment, Complication, business, Stent retriever, Aged, Retrospective Studies
Abstract: Objective Intra-procedural WEB device migration is a scarcely reported complication that necessitates prompt intervention. Case Presentation Endovascular treatment of two broad necked flow-related aneurysms was planned aided by WEB-SL (Woven EndoBridge-single layer) devices in a 71-year-old female with known left temporal arteriovenous malformation. Inadvertent distal migration occurred while performing a control angiogram with an automated iodine injector. Immediate retrieval was successfully performed using a Solitaire stent-retriever. Conclusion To our knowledge, we report for the first time the successful retrieval of a distally migrated WEB using a stent-retriever device.
Published: 2023

33. Pre- and post-season visio-vestibular function in healthy adolescent athletes

Author: Declan A Patton, Colin M. Huber, Daniel J. Corwin, Matthew F. Grady, Catherine C. McDonald, Christina L. Master, Patricia R Roby, Susan S. Margulies, Kristy B. Arbogast, and Kristina B. Metzger
Subjects: Vestibular system, medicine.medical_specialty, Adolescent, Tandem gait, business.industry, Physical Therapy, Sports Therapy and Rehabilitation, medicine.disease, Gait, Athletes, Relative risk, Concussion, Athletic Injuries, medicine, Physical therapy, Humans, Orthopedics and Sports Medicine, Female, Prospective Studies, Seasons, business, Prospective cohort study, Generalized estimating equation, Brain Concussion, Balance (ability)
Abstract: Objective To evaluate pre - to post-season differences in individual subtests of the Visio-Vestibular Examination (VVE) in healthy middle and high school athletes. Methods This prospective cohort study recruited participants from a private suburban United States secondary school. Participants completed a demographic questionnaire prior to the start of their season. A proxy for head impact exposure was estimated by incorporating previously published head impact frequencies by team and sport. The VVE was completed pre - and post-season and consisted of 9 subtests: smooth pursuit, horizontal/vertical saccades and gaze stability, binocular convergence, left/right monocular accommodation, and complex tandem gait. Generalized estimating equations were employed to assess the relative risk of an abnormal VVE outcome based on testing session (pre - vs. post-season). Results Participants included middle and high school athletes (n = 115; female = 59 (51.3%); median age at first assessment = 14.9 years, [IQR = 13.6, 16.0]) during 2017/18 - 2019/20 school years. During pre-season testing, accommodation (10.0%) and complex tandem gait (9.2%) had the largest proportion of abnormal outcomes, while smooth pursuits (10.6%) and convergence (9.5%) had the largest proportion of abnormal outcomes post-season. When assessing the effect of testing session on the relative risk of any abnormal VVE subtest, there were no significant findings (P ≥ 0.25). Additionally, there were no significant effects of testing session when adjusting for estimated head impact exposure for any VVE subtest (P ≥ 0.25). Conclusions Visio-vestibular function as measured by the VVE does not change from pre - to post-season in otherwise healthy adolescent athletes. Our findings suggest that the VVE may be stable and robust to typical neurodevelopment occurring in this dynamic age group and help inform post-injury interpretation of visio-vestibular impairments.
Published: 2023

34. Accuracy of the International Classification of Diseases, 9th Revision for Identifying Infantile Eye Disease

Author: Launia J. White, Tina M. Hendricks, Sasha A. Mansukhani, Timothy T. Xu, Cole E. Bothun, Brian G. Mohney, and Erick D. Bothun
Subjects: Pediatrics, medicine.medical_specialty, Eye Diseases, Epidemiology, Eye disease, Population, International Classification of Diseases, Predictive Value of Tests, Lacrimal Duct Obstruction, Medicine, Pseudostrabismus, Humans, education, Child, Retrospective Studies, education.field_of_study, business.industry, Medical record, Retrospective cohort study, medicine.disease, Conjunctivitis, Anisocoria, Ophthalmology, Nasolacrimal duct obstruction, Pediatrics, Perinatology and Child Health, Cohort, Pediatric ophthalmology, business, Nasolacrimal Duct
Abstract: PURPOSE To determine the predictive value of International Classification of Diseases, 9th Revision (ICD-9) codes for identifying infantile eye diagnoses. METHODS Population-based retrospective cohort study of all residents of Olmsted County, Minnesota diagnosed at ≤1 year of age with an ocular disorder. The medical records of all infants diagnosed with any ocular disorder from January 1, 2005, through December 31, 2014, were identified. To assess ICD-9 code accuracy, the medical records of all diagnoses with ≥20 cases were individually reviewed and compared to their corresponding ICD-9 codes. Main outcome measures included positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity of ICD-9 codes. RESULTS In a cohort of 5,109 infants with ≥1 eye-related ICD-9 code, 10 ocular diagnoses met study criteria. The most frequent diagnoses were conjunctivitis (N = 1,695) and congenital nasolacrimal duct obstruction (N = 1,250), while the least common was physiologic anisocoria (N = 23). The PPVs ranged from 8.3% to 88.0%, NPVs from 96.3% to 100%, sensitivity from 3.0% to 98.7%, and specificity from 72.6% to 99.9%. ICD-9 codes were most accurate at identifying physiologic anisocoria (PPV: 88.0%) and least accurate at identifying preseptal cellulitis (PPV: 8.3%). In eye specialists versus non-eye specialists, there was a significant difference in PPV of ICD-9 codes for conjunctivitis (26.8% vs. 63.9%, p
Published: 2023

35. Simultaneous use of alcohol and cigarettes in a mixed psychiatric sample: Daily-life associations with smoking motives, craving, stimulation, sedation, and affect

Author: Ashley C. Helle, Andrea M. Wycoff, Sarah A. Griffin, Courtney A. Motschman, Thomas M. Piasecki, and Timothy J. Trull
Subjects: medicine.medical_specialty, Sedation, Multilevel model, Medicine (miscellaneous), Alcohol, Craving, Stimulation, PsycINFO, medicine.disease, Affect (psychology), Psychiatry and Mental health, Clinical Psychology, chemistry.chemical_compound, chemistry, medicine, medicine.symptom, Psychiatry, Psychology, Borderline personality disorder
Abstract: Co-use of alcohol and cigarettes is common and associated with greater negative consequences compared to use of either substance alone. Furthermore, alcohol and cigarettes are often used at the same time, and these "simultaneous" use events are associated with greater consumption of each substance. Given the prevalence and negative consequences associated with this pattern, we sought to identify proximal predictors and reinforcers of simultaneous use in individuals with a range of emotional and behavioral dysregulation who may be at greater risk of experiencing substance-related problems. Specifically, 41 adults who drank alcohol and smoked cigarettes (28 with borderline personality disorder and 13 community individuals) completed 21 days of ecological momentary assessment (EMA). First, we used multilevel models on cigarette-use moments to examine whether momentary cigarette motive endorsement differed based on whether participants were also drinking alcohol in that moment. Second, we used multilevel models on all EMA moments to examine whether simultaneous use was associated with greater craving and reinforcing effects compared to use of either substance alone. Participants reported greater enhancement and social motives for smoking cigarettes when also drinking alcohol compared to when they were only smoking. Participants also reported greater alcohol craving, greater sedation, attenuated positive affect, and greater fear following simultaneous use compared to use of either substance alone. Our results add to a growing body of research characterizing proximal influences on simultaneous substance use. Findings highlight potential treatment targets for individuals seeking to better understand or cut down on their use of alcohol, cigarettes, or both. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
Published: 2022

36. Yield of Adding chest CT to Abdominal CT to Detect COVID-19 in Patients Presenting with Acute Gastrointestinal Symptoms (SCOUT-3)

Author: Alexander B. J. Borgstein, Jaap Stoker, Hester A. Gietema, J van Rossen, Suzanne S. Gisbertz, Colin A. Russell, T van Rees Veillinga, Carl A. J. Puylaert, Jan M. Prins, R G Orsini, Marc G. Besselink, Alvin X. Han, Kammy Keywani, J C G Scheijmans, Mark E. Lobatto, M J Scheerder, Marja A. Boermeester, Rogier P. Voermans, Surgery, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Beeldvorming, MUMC+: DA BV Medisch Specialisten Radiologie (9), Amsterdam Gastroenterology Endocrinology Metabolism, Graduate School, AII - Infectious diseases, Radiology and Nuclear Medicine, Gastroenterology and Hepatology, Infectious diseases, and AII - Inflammatory diseases
Subjects: Adult, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Gastrointestinal Diseases, Abdominal ct, Chest ct, chest CT, RADS, 03 medical and health sciences, 0302 clinical medicine, Primary outcome, CO-RADS, medicine, Humans, In patient, Pandemics, Adult patients, business.industry, Background data, COVID-19, Thorax, Multicenter study, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Surgery, Radiology, GI-symptoms, Tomography, X-Ray Computed, business
Abstract: OBTECTIVE: To determine the incremental yield of standardized addition of chest CT to abdominal CT to detect COVID-19 in patients presenting with primarily acute gastrointestinal symptoms requiring abdominal imaging. SUMMARY BACKGROUND DATA: Around 20% of patients with COVID-19 present with gastrointestinal symptoms. COVID-19 might be neglected in these patients, as the focus could be on finding abdominal pathology. During the COVID-19 pandemic several centers have routinely added chest CT to abdominal CT to detect possible COVID-19 in patients presenting with gastrointestinal symptoms. However, the incremental yield of this strategy is unknown. METHODS: This multicenter study in six Dutch centers included consecutive adult patients presenting with acute non-traumatic gastrointestinal symptoms, who underwent standardized combined abdominal and chest CT between March 15, 2020 and April 30, 2020. All CT scans were read for signs of COVID-19 related pulmonary sequelae using the CO-RADS score. The primary outcome was the yield of high COVID-19 suspicion (CO-RADS 4-5) based on chest CT. RESULTS: A total of 392 patients were included. Radiologic suspicion for COVID-19 (CO-RADS 4-5) was present in 17 (4.3%) patients, eleven of which were diagnosed with COVID-19. Only five patients with CO-RADS 4-5 presented without any respiratory symptoms and were diagnosed with COVID-19. No relation with community prevalence could be detected. CONCLUSION: The yield of adding chest CT to abdominal CT to detect COVID-19 in patients presenting with acute gastrointestinal symptoms is extremely low with an additional detection rate of around 1%.
Published: 2022

37. Study the Relationship of MDCT Staging in Disease Extent with the Systemic Sclerosis Disease Parameters

Author: Hanan Sayed M. Abozaid, Aya M. Gamal, Ahmed A. Hafez, Ahmed Abdellatif Awad, Yasmine S. Makarem, Marwa A.A. Galal, Gehan Seif Eldein, Abeer M Ghandour, Eman H El-Hakeim, Rania M. Gamal, and Fatma H. El-Nouby
Subjects: medicine.medical_specialty, Pulmonary disease, Disease, Gastroenterology, Pulmonary function testing, Scleroderma, Localized, FEV1/FVC ratio, Rheumatology, Fibrosis, Internal medicine, medicine, Humans, Prospective Studies, Scleroderma, Systemic, business.industry, Incidence (epidemiology), Interstitial lung disease, General Medicine, University hospital, medicine.disease, Cross-Sectional Studies, Female, Lung Diseases, Interstitial, Tomography, X-Ray Computed, business
Abstract: Background and objectives The highest incidence of death in systemic sclerosis due to pulmonary disease raises the need for early detection and treatment. The study aim is the assessment of interstitial pulmonary disease by Multi Detector High Resolution CT (MDCT) and finds its relationship with the other disease parameters and the Pulmonary Function tests (PFT). Patients and methods A prospective cross-sectional study was performed in Assiut University Hospitals from May 2018 to January 2020 and included 62 consecutive SSc female patients. Demographic, clinical, Laboratory, PFT and MDCT assessment were conducted for all participants. Results The coarseness of fibrosis was 8.32 (range 0.0–17), the average proportion of ground-glass opacification was 28.3% (range, 0.0%–75%). Honey-comb pattern was seen in (52.5%). Mean Extent of disease was 46.25 ± 3.7 (range 5–81). Restrictive deficit found in 42 patients. Significant relation was found between the extent of disease and the percentage predicted FVC (r = 0.373, p 0.018) and FEV1/FVC (r = 0.593, p 0.000) and coarseness of fibrosis and proportion of ground glass opacification correlated inversely with VC (r = −0.385, p = 0.014, r = −0.376, p = 0.017 respectively), Rayanud's phenomena, modified Rodnan Skin Score and Medsger's general are positively correlated with MDCT disease extent. Conclusion Scoring of systemic sclerosis (SSc) related interstitial lung disease (SSc-ILD) could be applicable as one of the important tools for disease assessment.
Published: 2022

38. Long-term Follow-up of a Randomized Clinical Trial Comparing Endovascular Revascularization Plus Supervised Exercise with Supervised Exercise only for Intermittent Claudication

Author: M.R.H.M. van Sambeek, Farzin Fakhry, Ellen V. Rouwet, L van der Laan, M. J. E. van Rijn, Nicole Verhofstad, Sanne Klaphake, J P van Brussel, Alex Derom, M. G. Myriam Hunink, Guido N. M. Stultiens, A van Petersen, Joep A.W. Teijink, Mariella Orsini, P. T. den Hoed, Wolter H. Hoffmann, L.C. van Dijk, Ingrid Hulst, G.H. Ho, Dimitris Rizopoulos, Jan J. Wever, H.J.M. Verhagen, Surgery, Radiology & Nuclear Medicine, Epidemiology, and Public Health
Subjects: medicine.medical_specialty, business.industry, medicine.medical_treatment, Critical limb ischemia, Walking, Intermittent Claudication, Revascularization, Intermittent claudication, law.invention, Exercise Therapy, Treatment Outcome, Quality of life, Randomized controlled trial, law, Post-hoc analysis, Clinical endpoint, medicine, Physical therapy, Quality of Life, Humans, Surgery, medicine.symptom, Treadmill, business, Follow-Up Studies
Abstract: Objective: The goal of this study was to assess the long-term effectiveness of combination therapy for intermittent claudication, compared with supervised exercise only. Background: Supervised exercise therapy is recommended as first-line treatment for intermittent claudication by recent guidelines. Combining endovascular revascularization plus supervised exercise shows promising results; however, there is a lack of long-term follow-up. Methods: The ERASE study is a multicenter randomized clinical trial, including patients between May 2010 and February 2013 with intermittent claudication. Interventions were combination of endovascular revascularization plus supervised exercise (n = 106) or supervised exercise only (n = 106). Primary endpoint was the difference in maximum walking distance at long-term follow-up. Secondary endpoints included differences in pain-free walking distance, ankle-brachial index, quality of life, progression to critical limb ischemia, and revascularization procedures during follow-up. This randomized trial report is based on a post hoc analysis of extended follow-up beyond that of the initial trial. Patients were followed up until 31 July 2017. Data were analyzed according to the intention-to-treat principle. Results: Median long-term follow-up was 5.4 years (IQR 4.9-5.7). Treadmill test was completed for 128/212 (60%) patients. Whereas the difference in maximum walking distance significantly favored combination therapy at 1-year follow-up, the difference at 5-year follow-up was no longer significant (53 m; 99% CI-225 to 331; P = 0.62). No difference in pain-free walking distance, ankle-brachial index, and quality of life was found during long-term follow-up. We found that supervised exercise was associated with an increased hazard of a revascularization procedure during follow-up (HR 2.50; 99% CI 1.27-4.90; P < 0.001). The total number of revascularization procedures (including randomized treatment) was lower in the exercise only group compared to that in the combination therapy group (65 vs 149). Conclusions: Long-term follow up after combination therapy versus supervised exercise only, demonstrated no significant difference in walking distance or quality of life between the treatment groups. Combination therapy resulted in a lower number of revascularization procedures during follow-up but a higher total number of revascularizations including the randomized treatment. Trial Registration: Netherlands Trial Registry Identifier: NTR2249.
Published: 2022

39. Nutritional management and clinical outcome of critically ill patients with COVID-19: A retrospective study in a tertiary hospital

Author: M. Miguélez, C. Velasco, M. Camblor, J. Cedeño, C. Serrano, I. Bretón, L. Arhip, M. Motilla, M.L. Carrascal, P. Olivares, A. Morales, N. Brox, and C. Cuerda
Subjects: Male, medicine.medical_specialty, Critical Illness, medicine.medical_treatment, Lung injury, Overweight, Critical Care and Intensive Care Medicine, law.invention, Tertiary Care Centers, Critically ill patients, law, Internal medicine, medicine, Humans, Outcome, Retrospective Studies, Mechanical ventilation, Nutrition and Dietetics, business.industry, Mortality rate, Malnutrition, COVID-19, Retrospective cohort study, medicine.disease, Intensive care unit, Intensive Care Units, Parenteral nutrition, Nutritional medical therapy, Female, medicine.symptom, business
Abstract: Background & aims Severe COVID-19 infection is characterized by an inflammatory response and lung injury that can evolve into an acute respiratory distress syndrome that needs support treatment in intensive care unit. Nutritional treatment is an important component of the management of critically ill patients and should be started in the first 48 h of ICU admission to avoid malnutrition. This study describes the characteristics of the patients treated in a tertiary hospital in Madrid during the months of March–May 2020 (first wave), the medical nutrition treatment employed and its influence in the clinical outcome of these patients. Methods This is a retrospective study including COVID-19 patients admitted in ICU that needed medical nutrition treatment (MNT). Collected variables included sex, age, BMI, underlying diseases, time from hospitalisation to ICU admission, type of respiratory support (invasive mechanical ventilation (IMV) or high flow nasal cannula (HFNC) or non-invasive ventilation (non-IMV)), caloric and protein requirements (25 kcal/kg adjusted body weight (ABW), 1.3 g/kg ABW/day), MNT type (enteral nutrition (EN), parenteral nutrition (PN), mixed EN + PN), total calories (including propofol) and proteins administered, percentage of caloric and protein goal in ICU day 4th and 7th, metabolic complications, acute kidney failure (AKF), length of stay (LOS) and mortality. Data are expressed as mean ± SD, median (IQR) or frequencies. Statistical analysis was performed with the IBM SPSS Statistics for Windows, Version 25.0. p
Published: 2022

40. New creatinine- And cystatin C-based equations to estimate GFR without race

Author: Lesley A, Inker, Nwamaka D, Eneanya, Josef, Coresh, Hocine, Tighiouart, Dan, Wang, Yingying, Sang, Deidra C, Crews, Alessandro, Doria, Michelle M, Estrella, Marc, Froissart, Morgan E, Grams, Tom, Greene, Anders, Grubb, Vilmundur, Gudnason, Orlando M, Gutiérrez, Roberto, Kalil, Amy B, Karger, Michael, Mauer, Gerjan, Navis, Robert G, Nelson, Emilio D, Poggio, Roger, Rodby, Peter, Rossing, Andrew D, Rule, Elizabeth, Selvin, Jesse C, Seegmiller, Michael G, Shlipak, Vicente E, Torres, Wei, Yang, Shoshana H, Ballew, Sara J, Couture, Neil R, Powe, Andrew S, Levey, Chronic Kidney Disease Epidemiology Collaboration, Andresdottir, M.B., Gudmundsdottir, H., Indridason, O.S., Palsson, R., Kasiske, B., Weir, M., Pesavento, T., Kalil, R., Feldman, H., Anderson, A., Go, A., Hsu, C.Y., Chapman, A.B., Landsittel, D.P., Mrug, M., Yu, ASL, Steffes, M., Braffett, B.H., Wyatt, C., Krishnasami, Z., Hellinger, J., Abraham, A., Lieske, J.C., Shafi, T., Post, W., Rossing, P., Rossert, J., Stengel, B., Galecki, A., Spino, C., Mauer, M., Karger, A., Zinman, B., Klein, R., Parving, H.H., Looker, H.C., Knowler, W.C., Klintmalm, G.B., Velez, R., Selvin, E., Wang, D., Value, Affordability and Sustainability (VALUE), and Groningen Kidney Center (GKC)
Subjects: Male, Kidney Disease, 030232 urology & nephrology, Datasets as Topic, urologic and male genital diseases, Medical and Health Sciences, GLOMERULAR-FILTRATION-RATE, chemistry.chemical_compound, 0302 clinical medicine, 030212 general & internal medicine, Renal Insufficiency, Chronic, Adult, African Continental Ancestry Group, Aged, Algorithms, Continental Population Groups, Creatinine/blood, Cystatin C/blood, Female, Glomerular Filtration Rate, Humans, Middle Aged, Renal Insufficiency, Chronic/blood, Renal Insufficiency, Chronic/epidemiology, Renal Insufficiency, Chronic/ethnology, Renal Insufficiency, Chronic/physiopathology, United States/epidemiology, CALIBRATION, biology, General Medicine, female genital diseases and pregnancy complications, PREVALENCE, Background current, Creatinine, Lower prevalence, NATIONAL-HEALTH, medicine.medical_specialty, Urology, Renal and urogenital, Renal function, Black People, 03 medical and health sciences, Clinical Research, Diabetes mellitus, General & Internal Medicine, medicine, Cystatin C, Renal Insufficiency, Chronic, SERUM CREATININE, business.industry, Prevention, Racial Groups, Chronic Kidney Disease Epidemiology Collaboration, medicine.disease, Confidence interval, United States, chemistry, biology.protein, business, Kidney disease
Abstract: New Equations for Estimating GFR without Race Equations for estimating GFR with serum creatinine overestimate measured GFR in Blacks. The authors report new equations, without race as an inflation factor, using cystatin C and creatinine that reduced errors in estimation between Black participants and non-Black participants.Background Current equations for estimated glomerular filtration rate (eGFR) that use serum creatinine or cystatin C incorporate age, sex, and race to estimate measured GFR. However, race in eGFR equations is a social and not a biologic construct. Methods We developed new eGFR equations without race using data from two development data sets: 10 studies (8254 participants, 31.5% Black) for serum creatinine and 13 studies (5352 participants, 39.7% Black) for both serum creatinine and cystatin C. In a validation data set of 12 studies (4050 participants, 14.3% Black), we compared the accuracy of new eGFR equations to measured GFR. We projected the prevalence of chronic kidney disease (CKD) and GFR stages in a sample of U.S. adults, using current and new equations. Results In the validation data set, the current creatinine equation that uses age, sex, and race overestimated measured GFR in Blacks (median, 3.7 ml per minute per 1.73 m(2) of body-surface area; 95% confidence interval [CI], 1.8 to 5.4) and to a lesser degree in non-Blacks (median, 0.5 ml per minute per 1.73 m(2); 95% CI, 0.0 to 0.9). When the adjustment for Black race was omitted from the current eGFR equation, measured GFR in Blacks was underestimated (median, 7.1 ml per minute per 1.73 m(2); 95% CI, 5.9 to 8.8). A new equation using age and sex and omitting race underestimated measured GFR in Blacks (median, 3.6 ml per minute per 1.73 m(2); 95% CI, 1.8 to 5.5) and overestimated measured GFR in non-Blacks (median, 3.9 ml per minute per 1.73 m(2); 95% CI, 3.4 to 4.4). For all equations, 85% or more of the eGFRs for Blacks and non-Blacks were within 30% of measured GFR. New creatinine-cystatin C equations without race were more accurate than new creatinine equations, with smaller differences between race groups. As compared with the current creatinine equation, the new creatinine equations, but not the new creatinine-cystatin C equations, increased population estimates of CKD prevalence among Blacks and yielded similar or lower prevalence among non-Blacks. Conclusions New eGFR equations that incorporate creatinine and cystatin C but omit race are more accurate and led to smaller differences between Black participants and non-Black participants than new equations without race with either creatinine or cystatin C alone. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases.)
Published: 2021

41. Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations

Author: Tim Niehues, Catherine Waruiru, Conleth Feighery, Uwe Schauer, Virginie Courteille, Kai Lehmberg, Ingo Müller, I. Esteves, Henner Morbach, Michael Borte, Patrick Hundsdoerfer, Klaus Schwarz, Ewelina Gowin, Alessandro Aiuti, Andreas Holbro, Federica Barzaghi, João Farela Neves, Dagmar Graf, Hannah Tamary, Veneta Milenova, Benedikt Boetticher, Eleonora Gambineri, Vera Goda, Alia Eldash, Jan-Christian Wasmuth, Fabio Candotti, Svetlana O. Sharapova, Markus Metzler, Juergen Brunner, Anna Hilfanova, Brindusa Ruxandra Capilna, Pere Soler-Palacín, Arnau Antolí, Horst von Bernuth, Vassilios Lougaris, Maria Carrabba, Bernd H. Belohradsky, Julian Thalhammer, Nathalie de Vergnes, Peter Olbrich, Peter Kopač, Leif G. Hanitsch, Alexandra Nieters, Filomeen Haerynck, Juliana Gabzdilova, Sezin Aydemir, Rabab El Hawary, Patrick F.K. Yong, Maria Giovanna Danieli, Alberto Tommasini, Sandra Steinmann, Ulrich Baumann, Figen Dogu, Elisabeth Förster-Waldl, Carolina Marasco, Donato Amodio, Lorenzo Lodi, Xavier Solanich, Caterina Cancrini, Brigita Sitkauskiene, Torsten Witte, Clementina Vanessa, Nima Rezaei, Jean-Christophe Goffard, Kirsten Wittke, Emmanouil Liatsis, Helen Baxendale, Susana L. Silva, Bodo Grimbacher, Henrike Ritterbusch, Evangelia Farmaki, Safa Meshaal, Sujal Ghosh, Larysa Kostyuchenko, David Edgar, Simone Cesaro, R Zeuner, Nerea Salmón Rodríguez, Isabella Quinti, Stephan Ehl, Pauline Brosselin, Joerg C. Henes, Pilar Llobet Agulló, Rosa Maria Dellepiane, Andrea Meinhardt, Marina Kojić, Georgios Sogkas, Stephan Borte, Catharina Schuetz, Suheyla Ocak, Karin Marschall, Lukas M. Gasteiger, Stefan Raffac, Sofia Tantou, Sadia Noorani, Matthaios Speletas, Philippe Randrianomenjanahary, Ursula Holzer, Ayca Kiykim, Johannes G. Liese, Angelo Vacca, Gisela Fecker, Ekrem Unal, Koen J. van Aerde, Alba Parra-Martínez, Kaan Boztug, Sophie Stiehler, Sybille Landwehr-Kenzel, Claudio Pignata, Jennifer Neubert, Janine Reichenbach, Shahnaz Parvin, Sarah Goddard, Andrea Schroll, Dirk Holzinger, Asghar Aghamohammadi, Hassan Abolhassani, Johannes Trück, Estela Paz-Artal, Shereen M. Reda, Anna Shcherbina, Maria Raptaki, Jaroslava Orosova, Beata Wolska-Kuśnierz, Tessa Kerre, Gerrit Ahrenstorf, Ben Zion Garty, Dirk Foell, Benjamin Becker, Ulrike F. Demel, Androniki Kapousouzi, Abraham Rutgers, Klaus Warnatz, Gemma Rocamora Blanch, Stephan Rusch, Luis M. Allende, Dalia Abd Elaziz, Safa Baris, Jorisvan Montfrans, Dominik T. Schneider, Raphael Scheible, Juana Gil-Herrera, Gerhard Kindle, Annarosa Soresina, Giovanna Fabio, Uwe Wintergerst, Emilia Faria, Maria Fasshauer, Silvia Ricci, Aisha Elmarsafy, Barbara Pietrucha, Carsten Speckmann, Nizar Mahlaoui, Ulrich Heininger, Isabelle Meyts, Matthew Buckland, Efimia Papadopoulou-Alataki, Robin Kobbe, A Herwadkar, Sebastian F. N. Bode, Ali Sobh, László Maródi, Baldassarre Martire, Chiara Azzari, Maximilian Heeg, Katja Masjosthusmann, Michael H. Albert, Matteo Chinello, Juan Luis Santos-Pérez, Aarnoud Huissoon, Tanya I. Coulter, Hendrik Schulze-Koops, Norbert Graf, Radwa Alkady, Jolanta Bernatoniene, Seraina Prader, Alenka Gagro, Joachim Roesler, Taco W. Kuijpers, Ewa Więsik-Szewczyk, Maria Elena Maccari, Conrad Ferdinand Lippert, Miriam González-Amores, Johannes Dirks, Daniel E Pleguezuelo, Christof M. Kramm, Anders Fasth, Volker Schuster, Olov Ekwall, Nikolaus Rieber, Javier Carbone, Petra Kaiser-Labusch, Diana Ernst, Lucia Augusta Baselli, Luis Ignacio Gonzalez-Granado, Maria Kanariou, Stefanie S. V. Henriet, Sigune Goldacker, Kerstin Felgentreff, Oana Joean, Fine Roosens, Fabian Hauck, Eva C. Schwaneck, Milos Jesenak, Manfred Hoenig, Lenka Kapustova, Christoph Boesecke, Alain Fischer, Sara Pereira da Silva, Julia Körholz, Ansgar Schulz, Carolynne Schwarze-Zander, Mikko Seppänen, Nermeen Galal, Nora Naumann-Bartsch, Tomaz Garcez, Peter Ciznar, Klara M. Posfay-Barbe, Zelimir Pavle Eric, Reinhold E. Schmidt, Hermann J. Girschick, Sabine Heine, Anika-Kerstin Biegner, Annick A. J. M. van de Ven, Stefan Schreiber, J. Merlijn van den Berg, Nurit Assia Batzir, Alexandra Jablonka, Kim Stol, Gregor Dückers, Antonios G.A. Kolios, Ioannis Kakkas, Christian Klemann, Marina N. Guseva, Sofia Grigoriadou, Elif Karakoc-Aydiner, Antonio Marzollo, Peter D. Arkwright, Urs C. Steiner, Sara Sebnem Kilic, Romina Dieli-Crimi, Gergely Kriván, Monika Sparber-Sauer, Marco Cazzaniga, Fulvio Porta, Paraskevi Maggina, Tomas Milota, Robbert G. M. Bredius, Martine Pergent, Klaus Tenbrock, Jana Pachlopnik Schmid, Florentia Dimitriou, Cathal Laurence Steele, Helen Bourne, Anna Bobcakova, Gerd Horneff, Judith Potjewijd, Marc Schmalzing, Tobias Ankermann, Paul Ryan, Oksana Boyarchuk, Necil Kutukculer, Carl Friedrich Classen, Zita Chovancová, Moira Thomas, Cinzia Milito, Michaela Bitzenhofer-Grüber, Faranaz Atschekzei, Eva Hlaváčková, Viviana Moschese, Julie Smet, Hans-Hartmut Peter, Carla Teixeira, Sabine M El-Helou, Suzanne de Kruijf Bazen, Helmut Wittkowski, Donate Jakoby, Marina Garcia-Prat, Esther de Vries, Richard Herriot, Sven Kracker, Alessandro Plebani, Lisa Göschl, Laura Hora Marques, Anna Sediva, Jiri Litzman, Mark M. Gompels, Renate Krüger, Şefika İlknur Kökçü Karadağ, Nadine Binder, Anna Szaflarska, Peter Jandus, Lisa Ibberson, Johann Greil, Ulf Schulze-Sturm, Mehtap Sirin, Aydan Ikinciogullari, Edyta Heropolitańska-Pliszka, Michael E. Weiss, Alla Skapenko, Lukas Wisgrill, Hana Alachkar, Uta Behrends, Silvia Sánchez-Ramón, Maria N. Hatzistilianou, Otilia Petrovicova, Darko Richter, Zoreh Nademi, Jürgen K. Rockstroh, Sohilla Lotfy, Markus G. Seidel, Timothy Ronan Leahy, Audra Blažienė, Translational Immunology Groningen (TRIGR), Paediatric Infectious Diseases / Rheumatology / Immunology, AII - Inflammatory diseases, ARD - Amsterdam Reproduction and Development, University of Zurich, Ehl, Stephan, Thalhammer, J., Kindle, G., Nieters, A., Rusch, S., Seppanen, M. R. J., Fischer, A., Grimbacher, B., Edgar, D., Buckland, M., Mahlaoui, N., Ehl, S., Boztug, K., Brunner, J., Demel, U. F., Forster-Waldl, E., Gasteiger, L. M., Goschl, L., Kojic, M., Schroll, A., Seidel, M. G., Wintergerst, U., Wisgrill, L., Sharapova, S. O., Goffard, J. -C., Kerre, T., Meyts, I., Roosens, F., Smet, J., Haerynck, F., Eric, Z. P., Milenova, V., Gagro, A., Richter, D., Chovancova, Z., Hlavackova, E., Litzman, J., Milota, T., Sediva, A., Elaziz, D. A., Alkady, R. S., El Sayed El Hawary, R., Eldash, A. S., Galal, N., Lotfy, S., Meshaal, S. S., Reda, S. M., Sobh, A., Elmarsafy, A., Brosselin, P., Courteille, V., De Vergnes, N., Kracker, S., Pergent, M., Randrianomenjanahary, P., Ahrenstorf, G., Albert, M. H., Ankermann, T., Atschekzei, F., Baumann, U., Becker, B. C., Behrends, U., Belohradsky, B. H., Biegner, A. -K., Binder, N., Bode, S. F. N., Boesecke, C., Boetticher, B., Borte, M., Borte, S., Classen, C. F., Dirks, J., Duckers, G., El-Helou, S., Ernst, D., Fasshauer, M., Fecker, G., Felgentreff, K., Foell, D., Ghosh, S., Girschick, H. J., Goldacker, S., Graf, N., Graf, D., Greil, J., Hanitsch, L. G., Hauck, F., Heeg, M., Heine, S. I., Henes, J. C., Hoenig, M., Holzer, U., Holzinger, D., Horneff, G., Hundsdoerfer, P., Jablonka, A., Jakoby, D., Joean, O., Kaiser-Labusch, P., Klemann, C., Kobbe, R., Korholz, J., Kramm, C. M., Kruger, R., Landwehr-Kenzel, S., Lehmberg, K., Liese, J. G., Lippert, C. F., Maccari, M. E., Masjosthusmann, K., Meinhardt, A., Metzler, M., Morbach, H., Muller, I., Naumann-Bartsch, N., Neubert, J., Niehues, T., Peter, H. -H., Rieber, N., Ritterbusch, H., Rockstroh, J. K., Roesler, J., Schauer, U., Scheible, R., Schmalzing, M., Schmidt, R. E., Schneider, D. T., Schreiber, S., Schuetz, C., Schulz, A., Schulze-Koops, H., Schulze-Sturm, U., Schuster, V., Schwaneck, E. C., Schwarz, K., Schwarze-Zander, C., Sirin, M., Skapenko, A., Sogkas, G., Sparber-Sauer, M., Speckmann, C., Steinmann, S., Stiehler, S., Tenbrock, K., von Bernuth, H., Warnatz, K., Wasmuth, J. -C., Weiss, M., Witte, T., Wittke, K., Wittkowski, H., Zeuner, R. A., Farmaki, E., Hatzistilianou, M. N., Kakkas, I., Kanariou, M. G., Kapousouzi, A., Liatsis, E., Maggina, P., Papadopoulou-Alataki, E., Raptaki, M., Speletas, M., Tantou, S., Goda, V., Krivan, G., Marodi, L., Abolhassani, H., Aghamohammadi, A., Rezaei, N., Feighery, C., Leahy, T. R., Ryan, P., Batzir, N. A., Garty, B. Z., Tamary, H., Aiuti, A., Amodio, D., Azzari, C., Barzaghi, F., Baselli, L. A., Cancrini, C., Carrabba, M., Cazzaniga, M., Cesaro, S., Chinello, M., Danieli, M. G., Dellepiane, R. M., Fabio, G., Gambineri, E., Lodi, L., Lougaris, V., Marasco, C., Martire, B., Marzollo, A., Milito, C., Moschese, V., Pignata, C., Plebani, A., Porta, F., Quinti, I., Ricci, S., Soresina, A., Tommasini, A., Vacca, A., Vanessa, C., Blaziene, A., Sitkauskiene, B., Gowin, E., Heropolitanska-Pliszka, E., Pietrucha, B., Szaflarska, A., Wiesik-Szewczyk, E., Wolska-Kusnierz, B., Esteves, I., Faria, E., Marques, L. H., Neves, J. F., Silva, S. L., Teixeira, C., Pereira da Silva, S., Capilna, B. R., Guseva, M. N., Shcherbina, A., Bobcakova, A., Ciznar, P., Gabzdilova, J., Jesenak, M., Kapustova, L., Orosova, J., Petrovicova, O., Raffac, S., Kopac, P., Allende, L. M., Antoli, A., Blanch, G. R., Carbone, J., Dieli-Crimi, R., Garcia-Prat, M., Gil-Herrera, J., Gonzalez-Granado, L. I., Agullo, P. L., Olbrich, P., Parra-Martinez, A., Paz-Artal, E., Pleguezuelo, D. E., Rodriguez, N. S., Sanchez-Ramon, S., Santos-Perez, J. L., Solanich, X., Soler-Palacin, P., Gonzalez-Amores, M., Ekwall, O., Fasth, A., Bitzenhofer-Gruber, M., Candotti, F., Dimitriou, F., Heininger, U., Holbro, A., Jandus, P., Kolios, A. G. A., Marschall, K., Schmid, J. P., Posfay-Barbe, K. M., Prader, S., Reichenbach, J., Steiner, U. C., Truck, J., Bredius, R. G., de Kruijf- Bazen, S., de Vries, E., Henriet, S. S. V., Kuijpers, T. W., Potjewijd, J., Rutgers, A., Stol, K., van Aerde, K. J., Van den Berg, J. M., van de Ven, A. A. J. M., Montfrans, J., Aydemir, S., Baris, S., Dogu, F., Ikinciogullari, A., Karakoc-Aydiner, E., Kilic, S. S., Kiykim, A., Kokcu Karadag, S. I., Kutukculer, N., Ocak, S., Unal, E., Boyarchuk, O., Hilfanova, A., Kostyuchenko, L. V., Alachkar, H., Arkwright, P. D., Baxendale, H. E., Bernatoniene, J., Coulter, T. I., Garcez, T., Goddard, S., Gompels, M. M., Grigoriadou, S., Herriot, R., Herwadkar, A., Huissoon, A., Ibberson, L., Nademi, Z., Noorani, S., Parvin, S., Steele, C. L., Thomas, M., Waruiru, C., Yong, P. F. K., and Bourne, H.
Subjects: 0301 basic medicine, Male, Pediatrics, syndromic, Sex Factor, Disease, registry, medicine.disease_cause, Cohort Studies, 0302 clinical medicine, Primary Immunodeficiency Disease, inborn error of immunity, Immunology and Allergy, warning signs, Age Factor, Registries, Family history, presenting symptom, Child, Primary immunodeficiency, Granuloma, autoimmune, immune dysregulation, inflammatory, Adult, Autoimmune Diseases, Female, Humans, Infections, Lymphoproliferative Disorders, Middle Aged, Primary Immunodeficiency Diseases, Sex Factors, Age Factors, 10177 Dermatology Clinic, Infections/epidemiology, 3. Good health, Settore MED/02, Warning signs, Lymphoproliferative Disorder, 2723 Immunology and Allergy, Infection, Human, medicine.medical_specialty, Immunology, 610 Medicine & health, Malignancy, primary immunodeficiency, Autoimmune Disease, 03 medical and health sciences, Immunity, Autoimmune Diseases/epidemiology, medicine, 2403 Immunology, business.industry, warning sign, Common variable immunodeficiency, Granuloma/epidemiology, Immune dysregulation, medicine.disease, Primary Immunodeficiency Diseases/epidemiology, 030104 developmental biology, Lymphoproliferative Disorders/epidemiology, Cohort Studie, business, 030215 immunology
Abstract: BACKGROUND: Inborn errors of immunity (IEI) are rare diseases, which makes diagnosis a challenge. A better description of the initial presenting manifestations should improve awareness and avoid diagnostic delay. Although increased infection susceptibility is a well-known initial IEI manifestation, less is known about the frequency of other presenting manifestations.OBJECTIVE: We sought to analyze age-related initial presenting manifestations of IEI including different IEI disease cohorts.METHODS: We analyzed data on 16,486 patients of the European Society for Immunodeficiencies Registry. Patients with autoinflammatory diseases were excluded because of the limited number registered.RESULTS: Overall, 68% of patients initially presented with infections only, 9% with immune dysregulation only, and 9% with a combination of both. Syndromic features were the presenting feature in 12%, 4% had laboratory abnormalities only, 1.5% were diagnosed because of family history only, and 0.8% presented with malignancy. Two-third of patients with IEI presented before the age of 6 years, but a quarter of patients developed initial symptoms only as adults. Immune dysregulation was most frequently recognized as an initial IEI manifestation between age 6 and 25 years, with male predominance until age 10 years, shifting to female predominance after age 40 years. Infections were most prevalent as a first manifestation in patients presenting after age 30 years.CONCLUSIONS: An exclusive focus on infection-centered warning signs would have missed around 25% of patients with IEI who initially present with other manifestations.
Published: 2021

42. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension

Author: Cheryl Lassen, Victor F. Tapson, Irene M. Lang, Sean Gaine, Richard N. Channick, Olivier Sitbon, Shu-Fang Hsu Schmitz, Kelly Chin, Vallerie V. McLaughlin, Nazzareno Galiè, Lewis J. Rubin, Marius M. Hoeper, J. Gerry Coghlan, Galiè, Nazzareno, Gaine, Sean, Channick, Richard, Coghlan, J. Gerry, Hoeper, Marius M., Lang, Irene M., McLaughlin, Vallerie V., Lassen, Cheryl, Rubin, Lewis J., Hsu Schmitz, Shu-Fang, Sitbon, Olivier, Tapson, Victor F., and Chin, Kelly M.
Subjects: medicine.medical_specialty, Survival, Hypertension, Pulmonary, Population, Selexipag, Pulmonary arterial hypertension, Placebo, chemistry.chemical_compound, Internal medicine, Acetamides, medicine, Clinical endpoint, Humans, Pharmacology (medical), Long-term outcomes, Combination therapy, Adverse effect, education, Antihypertensive Agents, education.field_of_study, business.industry, Brief Report, GRIPHON, PAH, General Medicine, Tolerability, Long-term outcome, Discontinuation, Regimen, chemistry, Pyrazines, Safety, business, Open-label extension
Abstract: Introduction In the event-driven GRIPHON randomised-controlled trial, the oral prostacyclin receptor agonist selexipag significantly reduced the risk of disease progression (composite primary endpoint of morbidity/mortality), compared with placebo, in patients with pulmonary arterial hypertension (PAH). The ongoing open-label extension study (GRIPHON OL) collects further data on long-term safety, tolerability, and survival of PAH patients treated with selexipag. Methods Patients randomised to selexipag or placebo in GRIPHON could enter GRIPHON OL either after experiencing a morbidity event during double-blind treatment or at the end of the study. Patients were followed for adverse events (AE) and survival from selexipag initiation up to 3 days and 30 days after end of treatment, respectively. Data are presented up to a cut-off date of 1 September 2019. Results Overall, 953 patients in GRIPHON and GRIPHON OL were treated with selexipag. At the time of selexipag initiation, 81.2% of patients were receiving background PAH therapy. Median (min, max) exposure to selexipag was 31.7 months (0, 106), corresponding to a total of 3054.4 patient-years. The most frequently reported AEs were related to known prostacyclin-related effects or underlying disease. There were 305 (32.0%) patients who experienced an AE leading to treatment discontinuation. Survival during GRIPHON and GRIPHON OL was assessed for the 574 patients randomised to selexipag in GRIPHON. Kaplan–Meier survival estimates (95%CI) at 1, 3, 5 and 7 years were 92.0% (89.4, 94.0), 79.3% (75.4, 82.6), 71.2% (66.5, 75.3) and 63.0% (57.4, 68.1), respectively. Conclusions These results provide the longest follow-up period published to date for a PAH therapy. The safety profile of selexipag over this extended treatment period was consistent with that observed in GRIPHON. A large proportion of the population was receiving background therapy at selexipag initiation, providing further insight into the long-term safety of selexipag as part of a combination therapy regimen. Trial Registration ClinicalTrials.gov Identifiers: NCT01106014 and NCT01112306 Supplementary Information The online version contains supplementary material available at 10.1007/s12325-021-01898-1.
Published: 2021

43. Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project

Author: Trifiro, G., Isgro, V., Ingrasciotta, Y., Ientile, V., L'Abbate, L., Foti, S. S., Belleudi, V., Poggi, F., Fontana, A., Moretti, U., Lora, R., Sabaini, A., Senesi, I., Sorrentino, C., Puzo, M. R., Padula, A., Fusco, M., Giordana, R., Solfrini, V., Puccini, A., Rossi, P., Del Zotto, S., Leoni, O., Zanforlini, M., Ancona, D., Bavaro, V., Garau, D., Ledda, S., Scondotto, S., Allotta, A., Tuccori, M., Gini, R., Bucaneve, G., Franchini, D., Cavazzana, A., Biasi, V., Spila Alegiani, S., Massari, M., Andretta, I., Tanaglia, M., Carriero, A., Sassano, S., De Sarro, G., Mirarchi, S., Palleria, C., Sarro, C., Balestrieri, M., Rostan, S., Capuano, A., Bernardi, F. F., Trama, U., Russo, A., Fumo, M. G., Addis, A., Musicco, F., Sapigni, E., Mazzetti, I., Podetti, D., Potenza, A. M., Nikitina, V., Ricciardelli, R., Mogheiseh, N., Croce, S., Pettinelli, A., Ejlli, L., Fortino, I., Ercolanoni, M., Mazzone, A., Nisic, A., Schiatti, S., Ludergnani, M., Mancini, M., Patregnani, L., Fabbietti, P., Antonicelli, E., Mangano, A., Campomori, A., Urru, S. A., Costa, G., Guarrera, G. M., Stella, P., Serra, E., Carta, P., Vannacci, A., Lucenteforte, E., Parrilli, M., Convertino, I., De Giorgi, M., Rocchi, R. E., Rossi, M., Scroccaro, G., Deambrosis, P., Grindelli, G., Ferroni, E., Trifiro, G., Isgro, V., Ingrasciotta, Y., Ientile, V., L'Abbate, L., Foti, S. S., Belleudi, V., Poggi, F., Fontana, A., Moretti, U., Lora, R., Sabaini, A., Senesi, I., Sorrentino, C., Puzo, M. R., Padula, A., Fusco, M., Giordana, R., Solfrini, V., Puccini, A., Rossi, P., Del Zotto, S., Leoni, O., Zanforlini, M., Ancona, D., Bavaro, V., Garau, D., Ledda, S., Scondotto, S., Allotta, A., Tuccori, M., Gini, R., Bucaneve, G., Franchini, D., Cavazzana, A., Biasi, V., Spila Alegiani, S., Massari, M., Andretta, I., Tanaglia, M., Carriero, A., Sassano, S., De Sarro, G., Mirarchi, S., Palleria, C., Sarro, C., Balestrieri, M., Rostan, S., Capuano, A., Bernardi, F. F., Trama, U., Russo, A., Fumo, M. G., Addis, A., Musicco, F., Sapigni, E., Mazzetti, I., Podetti, D., Potenza, A. M., Nikitina, V., Ricciardelli, R., Mogheiseh, N., Croce, S., Pettinelli, A., Ejlli, L., Fortino, I., Ercolanoni, M., Mazzone, A., Nisic, A., Schiatti, S., Ludergnani, M., Mancini, M., Patregnani, L., Fabbietti, P., Antonicelli, E., Mangano, A., Campomori, A., Urru, S. A., Costa, G., Guarrera, G. M., Stella, P., Serra, E., Carta, P., Vannacci, A., Lucenteforte, E., Parrilli, M., Convertino, I., De Giorgi, M., Rocchi, R. E., Rossi, M., Scroccaro, G., Deambrosis, P., Grindelli, G., and Ferroni, E.
Subjects: Male, medicine.medical_specialty, Population, Postmarketing surveillance, Rate ratio, REGISTRIES, Retrospective Studie, Internal medicine, BIOSIMILARS, medicine, Adalimumab, Humans, Pharmacology (medical), Original Research Article, education, Adverse effect, ANTI-TNF THERAPY, RHEUMATOID-ARTHRITIS, RISK, PHARMACOVIGILANCE, BIOSIMILARS, EXPERIENCE, REGISTRIES, PSORIASIS, MEDICINES, ACCESS, Biosimilar Pharmaceuticals, Retrospective Studies, RISK, Delivery of Health Care, Female, Infliximab, Italy, SARS-CoV-2, COVID-19, Pharmacology, education.field_of_study, PSORIASIS, business.industry, Biosimilar, ANTI-TNF THERAPY, General Medicine, medicine.disease, RHEUMATOID-ARTHRITIS, PHARMACOVIGILANCE, MEDICINES, EXPERIENCE, Immune-mediated inflammatory diseases, ACCESS, business, Human, Biosimilar Pharmaceutical, Biotechnology, medicine.drug
Abstract: Background Biological drugs have improved the management of immune-mediated inflammatory diseases (IMIDs) despite being associated with important safety issues such as immunogenicity, infections, and malignancies in real-world settings. Objective The aim of this study was to explore the potential of a large Italian multi-database distributed network for use in the postmarketing surveillance of biological drugs, including biosimilars, in patients with IMID. Methods A retrospective cohort study was conducted using 13 Italian regional claims databases during 2010–2019. A tailor-made R-based tool developed for distributed analysis of claims data using a study-specific common data model was customized for this study. We measured the yearly prevalence of biological drug users and the frequency of switches between originator and biosimilars for infliximab, etanercept, and adalimumab separately and stratified them by calendar year and region. We then calculated the cumulative number of users and person-years (PYs) of exposure to individual biological drugs approved for IMIDs. For a number of safety outcomes (e.g., severe acute respiratory syndrome coronavirus 2 [SARS-COV-2] infection), we conducted a sample power calculation to estimate the PYs of exposure required to investigate their association with individual biological drugs approved for IMIDs, considering different strengths of association. Results From a total underlying population of almost 50 million inhabitants from 13 Italian regions, we identified 143,602 (0.3%) biological drug users, with a cumulative exposure of 507,745 PYs during the entire follow-up. The mean age ± standard deviation of biological drug users was 49.3 ± 16.3, with a female-to-male ratio of 1.2. The age-adjusted yearly prevalence of biological drug users increased threefold from 0.7 per 1000 in 2010 to 2.1 per 1000 in 2019. Overall, we identified 40,996 users of biosimilars of tumor necrosis factor (TNF)-α inhibitors (i.e., etanercept, adalimumab, and infliximab) in the years 2015–2019. Of these, 46% (N = 18,845) switched at any time between originator and biosimilars or vice versa. To investigate a moderate association (incidence rate ratio 2) between biological drugs approved for IMIDs and safety events of interest, such as optic neuritis (lowest background incidence rate 10.4/100,000 PYs) or severe infection (highest background incidence rate 4312/100,000 PYs), a total of 43,311 PYs and 104 PYs of exposure to individual biological drugs, respectively, would be required. As such, using this network, of 15 individual biological drugs approved for IMIDs, the association with those adverse events could be investigated for four (27%) and 14 (93%), respectively. Conclusion The VALORE project multi-database network has access to data on more than 140,000 biological drug users (and > 0.5 million PYs) from 13 Italian regions during the years 2010–2019, which will be further expanded with the inclusion of data from other regions and more recent calendar years. Overall, the cumulated amount of person-time of exposure to biological drugs approved for IMIDs provides enough statistical power to investigate weak/moderate associations of almost all individual compounds and the most relevant safety outcomes. Moreover, this network may offer the opportunity to investigate the interchangeability of originator and biosimilars of several TNFα inhibitors in different therapeutic areas in real-world settings. Supplementary Information The online version contains supplementary material available at 10.1007/s40259-021-00498-3.
Published: 2021

44. Management of anaphylaxis due to COVID-19 vaccines in the elderly

Author: Paulo Augusto Moreira Camargos, Radolslaw Gawlik, Mirko Petrovic, Gunter J. Sturm, Kristof Nekam, Sergio Bonini, Zhanat Ispayeva, Marilyn Urrutia Pereira, Jean Bousquet, Antti Lauerma, Menachem Rottem, Arzu Yorgancioglu, Hubert Blain, Antonio Cherubini, Mário Morais-Almeida, Nathalie Salles, Charlotte G. Mortz, Sylwia Smolinska, Davor Plavec, A. Bedbrook, Torsten Zuberbier, Helga Kraxner, M. Beatrice Bilò, Sinthia Bosnic-Anticevich, Gaëtan Gavazzi, Finbarr C. Martin, Alvaro A. Cruz, K. S. Bennoor, Isabella Annesi-Maesano, Mohamed H. Shamji, Karin Hoffmann-Sommergruber, Marina Atanaskovic-Markovic, Carsten Bindslev-Jensen, Lan Tt Le, Isabel Skypala, Ana Todo-Bom, Vincenzo Patella, Lorenzo Cecchi, Charlotte Suppli Ulrik, Oscar Palomares, Joaquin Sastre, Hans Jürgen Hoffmann, Knut Brockow, Eva Untersmayr, Martin Hrubisko, Bernadette Eberlein, Aziz Sheikh, Milan Sova, Osman M. Yusuf, Violeta Kvedariene, G. Walter Canonica, Dana Wallace, Ioana Agache, Milena Sokolowska, Jos M. G. A. Schols, Susan Waserman, Stéphanie Miot, Carla Irani, Regina E Roller-Winsberger, Michael Levin, Yves Rolland, Emma Montella, Bilun Gemicioglu, Bolesław Samoliński, Stefano Del Giacco, Madda lenaIllario, Yehia El-Gamal, Olga Lourenço, Jean-Christoph Roger J-P Caubet, Luisa Brussino, Marysia Recto, De Yun Wang, Igor Kaidashev, Renaud Louis, Antonino Romano, Mario E. Zernotti, Jacques Reynes, Pedro Carreiro-Martins, Alexandra F. Santos, Marek Niedoszytko, M. Gotua, Musa Khaitov, Thomas B. Casale, Andrea Matucci, Bernardo Sousa-Pinto, Rafael Stelmach, Dejan Dokic, Joana Vitte, Motohiro Ebisawa, Maria Teresa Ventura, Joaquim Mullol, Tomas Chivato, Petr Panzner, Oliver Pfaar, Sanna Toppila-Salmi, Ioanna Tsiligianni, Wytske Fokkens, Alessandra Vultaggio, H. Neffen, Juan Carlos Ivancevich, Ya-dong Gao, Anna Sediva, Maja Hofmann, Ana Maria Carriazo, João Fonseca, Marek Jutel, A. Benetos, Nhân Pham-Thi, Mona Al-Ahmad, Arunas Valiulis, Mihaela Zidarn, Elizabeth Angier, Yoshitaka Okamoto, Montserrat Fernandez-Rivas, Cezmi A. Akdis, Philip W. Rouadi, Olivier Guérin, John Farrell, Mikaela Odemyr, George Christoff, Vera Mahler, Claus Bachert, Edward F. Knol, Wienczyslawa Czarlewski, Robyn E O'Hehir, Victoria Cardona, Ludger Klimek, Tari Haahtela, Vincent Le Moing, Branislava Milenkovic, Carmen Rondon, Kaja Julge, Jolanta Walusiak-Skorupa, Nikolaos G. Papadopoulos, Aslı Gelincik, Markus Ollert, Piotr Kuna, Leyla Namazova-Baranova, Margitta Worm, Annick Barbaud, Elena Camelia Berghea, Todor A. Popov, Derek K. Chu, María José Torres, Faradiba Sarquis Serpa, Nicola Scichilone, Amir Hamzah Abdul Latiff, Frederico S. Regateiro, Gianni Passalacqua, Humboldt-Universität zu Berlin, Microbes évolution phylogénie et infections (MEPHI), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), Institut Hospitalier Universitaire Méditerranée Infection (IHU Marseille), Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Humboldt University Of Berlin, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Transylvania University, Wrocław Medical University, Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Cagliari, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Università Politecnica delle Marche [Ancona] (UNIVPM), Medical Consulting Czarlewski, Universiti Putra Malaysia, University of Southampton, Institut Desbrest de santé publique (IDESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), University of Belgrade [Belgrade], Ghent University Hospital, CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Dhaka Shishu Hospital [Bangladesh], University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), Odense University Hospital (OUH), Italian National Research Council, National Research Council [Italy] (CNR), The University of Sydney, Technische Universität München = Technical University of Munich (TUM), Università degli studi di Torino = University of Turin (UNITO), Universidade Federal de Minas Gerais = Federal University of Minas Gerais [Belo Horizonte, Brazil] (UFMG), IRCCS Research Hospital, Milan, Vall d'Hebron University Hospital [Barcelona], Centro Hospitalar de Lisboa Central E.P.E, University of South Florida [Tampa] (USF), Geneva University Hospital (HUG), Azienda Usl Toscana centro [Firenze], Софийски университет = Sofia University, McMaster University [Hamilton, Ontario], State University of Bahia, Institute of Public Health of Republic of North Macedonia [Skopje], Ain Shams University (ASU), Sagamihara National Hospital [Kanagawa, Japan], Instituto de Investigación Sanitaria del Hospital Clínico San Carlos [Madrid, Spain] (IdISSC), Amsterdam UMC - Amsterdam University Medical Center, Universidade do Porto = University of Porto, Wuhan University [China], CHU Grenoble, Silesian University of Medicine, Istanbul Faculty of Medicine, Cerrahpasa Faculty of Medicine, Istanbul University, Centre Hospitalier Universitaire de Nice (CHU Nice), Helsinki University Hospital [Helsinki, Finlande], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Medizinische Universität Wien = Medical University of Vienna, Aarhus University [Aarhus], Oncology Institute of St Elisabeth, University of Naples Federico II = Università degli studi di Napoli Federico II, St Joseph University, Hôtel-Dieu de France (HDF), Université Saint-Joseph de Beyrouth (USJ), Kazakh National Medical University, Servicio de Alergia e ImmunologiaBuenos Aires (Clinica Santa Isabel), Tartu University Institute of Clinical Medicine, Ukrainina Medical Stomatological Academy [Poltava, Ukraine], Federal Medicobiological Agency [Moscow, Russian Federation], University Medical Center [Utrecht], Semmelweis University [Budapest], Medical University of Łódź (MUL), Vilnius University [Vilnius], University of Medicine and Pharmacy (VIETNAM), University of Cape Town, CHU Sart Tilman, Université de Liège, University of Beira Interior [Portugal] (UBI), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), uBibliorum, Ear, Nose and Throat, AII - Inflammatory diseases, CHU Montpellier, Wroclaw Medical University [Wrocław, Pologne], University of Bari Aldo Moro (UNIBA), Service de Médecine Interne = Hôpital de jour de médecine [CHU Tenon], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Sagamihara National Hospital, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CHU Toulouse [Toulouse], RS: CAPHRI - R1 - Ageing and Long-Term Care, Health Services Research, Bousquet J., Agache I., Blain H., Jutel M., Ventura M.T., Worm M., Del Giacco S., Benetos A., Bilo B.M., Czarlewski W., Abdul Latiff A.H., Al-Ahmad M., Angier E., Annesi-Maesano I., Atanaskovic-Markovic M., Bachert C., Barbaud A., Bedbrook A., Bennoor K.S., Berghea E.C., Bindslev-Jensen C., Bonini S., Bosnic-Anticevich S., Brockow K., Brussino L., Camargos P., Canonica G.W., Cardona V., Carreiro-Martins P., Carriazo A., Casale T., Caubet J.-C., Cecchi L., Cherubini A., Christoff G., Chu D.K., Cruz A.A., Dokic D., El-Gamal Y., Ebisawa M., Eberlein B., Farrell J., Fernandez-Rivas M., Fokkens W.J., Fonseca J.A., Gao Y., Gavazzi G., Gawlik R., Gelincik A., Gemicioglu B., Gotua M., Guerin O., Haahtela T., Hoffmann-Sommergruber K., Hoffmann H.J., Hofmann M., Hrubisko M., Illario M., Irani C., Ispayeva Z., Ivancevich J.C., Julge K., Kaidashev I., Khaitov M., Knol E., Kraxner H., Kuna P., Kvedariene V., Lauerma A., Le L.T.T., Le Moing V., Levin M., Louis R., Lourenco O., Mahler V., Martin F.C., Matucci A., Milenkovic B., Miot S., Montella E., Morais-Almeida M., Mortz C.G., Mullol J., Namazova-Baranova L., Neffen H., Nekam K., Niedoszytko M., Odemyr M., O'Hehir R.E., Okamoto Y., Ollert M., Palomares O., Papadopoulos N.G., Panzner P., Passalacqua G., Patella V., Petrovic M., Pfaar O., Pham-Thi N., Plavec D., Popov T.A., Recto M.T., Regateiro F.S., Reynes J., Roller-Winsberger R.E., Rolland Y., Romano A., Rondon C., Rottem M., Rouadi P.W., Salles N., Samolinski B., Santos A.F., S Sarquis F., Sastre J., M. G. A. Schols J., Scichilone N., Sediva A., Shamji M.H., Sheikh A., Skypala I., Smolinska S., Sokolowska M., Sousa-Pinto B., Sova M., Stelmach R., Sturm G., Suppli Ulrik C., Todo-Bom A.M., Toppila-Salmi S., Tsiligianni I., Torres M., Untersmayr E., Urrutia Pereira M., Valiulis A., Vitte J., Vultaggio A., Wallace D., Walusiak-Skorupa J., Wang D.-Y., Waserman S., Yorgancioglu A., Yusuf O.M., Zernotti M., Zidarn M., Chivato T., Akdis C.A., Zuberbier T., Klimek L., HUS Inflammation Center, University of Helsinki, and Department of Dermatology, Allergology and Venereology
Subjects: Male, Allergy, Pediatrics, Eaaci Position Paper, COVID-19 vaccines, older (adults, GUIDELINES, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Medicine and Health Sciences, Immunology and Allergy, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, Geriatrics, MESH: Aged, RISK, Vaccines, [SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases, people), EPINEPHRINE, Epinephrine, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, COVID -19 vaccines, Anaphylaxis, medicine.drug, older (adults/people), medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), MESH: Covid-19, MESH: Epinephrine, Immunology, adrenaline, anaphylaxis, Aged, COVID-19 Vaccines, Humans, SARS-CoV-2, COVID-19, Settore MED/10 - Malattie Dell'Apparato Respiratorio, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Diabetes mellitus, Anaphylaxis/etiology, MESH: SARS-CoV-2, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, COVID‐19 vaccines, Older - Adults/people, Asthma, MESH: Humans, business.industry, adrenaline, anaphylaxis, COVID-19 vaccines, older (adults/people), medicine.disease, Obesity, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Male, MESH: Anaphylaxis, Older, 3121 General medicine, internal medicine and other clinical medicine, business, MESH: Covid-19 vaccines, 030215 immunology
Abstract: Submitted by (omml@ubi.pt) on 2021-07-05T10:47:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T10:49:11Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Rejected by Pessoa (pfep@ubi.pt), reason: Rever os nomes dos autores. Depois da correção é só voltar a submeter. on 2021-07-05T10:54:19Z (GMT) Submitted by (omml@ubi.pt) on 2021-07-05T11:52:24Z No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:34:51Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Approved for entry into archive by Pessoa (pfep@ubi.pt) on 2021-07-05T13:35:49Z (GMT) No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Made available in DSpace on 2021-07-05T13:35:49Z (GMT). No. of bitstreams: 1 2021_Bousquet J_A_COVID anaphylaxis.pdf: 12561118 bytes, checksum: 2f801ee76ad2cb3cbdaa02ffabea8e09 (MD5) Previous issue date: 2021-04-02 info:eu-repo/semantics/publishedVersion
Published: 2021

45. An international assessment of the adoption of enhanced recovery after surgery (ERAS®) principles across colorectal units in 2019–2020

Author: Pinkney T., Taylor H., Tong C., Schmitz N. -D., Morton D. G., Pinkney T. D., Bhangu A., Blackwell S., Dardanov D., Dulskas A., Gallo G., Glasbey J., Keatley J., Knowles C., Li Y. E., McCourt V., Minaya-Bravo A., Neary P., Nepogodiev D., Pata F., Pellino G., Sivrikoz E., van Ramshorst G., Zmora O., Perry R., Magill E. L., Abdalkoddus M., Abelevich A., Abraham S., Abraham-Nordling M., Adamina M., Agalar C., Agresta F., Ahallat M., Ahmad N., Aiupov R., Akca O., Aleksic A., Aleotti F., Alias D., Alonso J., Alonso Goncalves S., Alonso Martin J., Alonso Poza A., Alonso-Hernandez N., Alos Company R., Al-Saeedi M., Alvarez-Laso C., Alvarez-Gallego M., Amanatidis T., Americano M., Amorim E., Anandan L., Anania G., Ancans G., Andreev P., Andrejevic P., Antonacci N., Anwer M., Aonzo P., Arencibia B., Argeny S., Arieli H., Arnold S., Ashraf M., Aslam M., Atanasov B., Atif M., Atladottir J., Avital S., Awny S., Aytac B., Azahr N., Aznar-Puig S., Bailey S., Balalis D., Baldi C., Baldonedo R., Balducci G., Balestra F., Balestri R., Balfour A., Baloyiannis I., Banky B., Baral J., Baranyai Z., Barbashinov N., Bargallo J., Barisic G., Barugola G., Batashki I., Battersby N., Belev N., Belli A., Beltran de Heredia J., Bemelman W., Benavides Buleje J., Benckert A., Bernal-Sprekelsen J., Bertocchi E., Beuran M., Bhan C., Bianco F., Bilali S., Bilali V., Bintintan V., Birindelli A., Birsan T., Blanco Antona F., Blas J., Blasco-Segura T., Blom R., Bocchetti T., Boerma E., Bogdan M., Boland M., Bomans B., Borda N., Bowen M., Bradulskis S., Branagan G., Brankovic B., Brenna M., Brewer H., Broadhurst J., Bronder C., Brouwer R., Buccianti P., Buchs N., Buchwald P., Bugatti A., Bui A., Burcos T., Buskens C., Bustamante C., Caceres N., Cagigas Fernandez C., Calero-Lillo A., Camps I., Canda A., Caravaca-Garcia I., Carballo F., Carcoforo P., Carlander J., Carlos S., Caro A., Carpelan A., Carrasco Prats M., Carrillo Lopez M., Carvello M., Casal E., Casoni Pattacini G., Castellvi Valls J., Castillo Diego J., Cavallesco G., Cavenaile V., Cayetano L., Ceccotti A., Cervera-Aldama J., Chabok A., Chafai N., Chandrasinghe P., Chandratreya N., Chaudhri S., Chaudhry Z., Cherdancev D., Chernov A., Chevallay M., Chirletti P., Chouillard E., Chouliaras C., Chowdri N., Cillo M., Cini C., Ciubotaru C., Ciuce C., Claeys D., Cocorullo G., Codina-Cazador A., Colak E., Coletta D., Colombo F., Copaescu C., Corte Real J., Corver M., Cosic J., Costa S., Costa Pereira J., Costa Pereira C., Costa-Navarro D., Cotte E., Cracco N., Cristian D., Cuadrado M., Cuk V., Cunha M., Cunha J., Curinga R., Curletti G., Curtis N., Dabic D., Dainius E., d'Alessandro A., Daniels I., Darvin V., Dauser B., David G., Davidova O., Davies E., de Andres Asenjo B., De franciscis S., de Graaf E., De la Portilla F., De Luca E., De Nisco C., De Toma G., Defoort B., Den Boer F., Di Candido F., Di Saverio S., Diaz Pavon J., Dieguez Fernandez B., Diez-Alonso M., Dimitrijevic I., Dindelegan G., Djuric M., Domingos H., Doornebosch P., Dos Santos M., Drami I., Dudarovaska H., Dusek T., Dzhumabaev H., Eden Y., Egenvall M., Eismiontas V., El Sorogy M., Elgeidie A., Elhemaly M., El-Hussuna A., Ellul S., Elmore U., ElNakeeb A., Elrefai M., Emile S., Enrriquez-Navascues J., Epstein J., Escartin J., Escola D., Escuder J., Espin E., Espina B., Estefania D., Etienne J., Fabbri S., Falato A., Fares R., Farina P., Farkasova M., Farres R., Fasolini F., Fatayer T., Febles G., Feliu F., Feo C., Feoktistov D., Fernandez F., Fernandez Isart M., Fernando J., Ferreira G., Ferrer R., Ferreras Garcia C., Ferri M., Figueiredo N., Finotti E., Fitzgerald J., Flateh Backe I., Flor-Lorente B., Forero-Torres A., Foschi D., Francart D., Francois Y., Frasson M., Freil-Lanter C., Frois Borges M., Fuzun M., Gala T., Galleano R., Galvez P., Galvez Saldana A., Gamundi Cuesta M., Garcia Cabrera A., Garcia Egea J., Garcia Olmo D., Garcia-Gonzalez J., Garcia-Granero A., Garcia-Granero E., Garcia-Septiem J., Gardea A., Garipov M., Gefen R., Geraghty A., Gerkis S., Germanos S., Ghaffari S., Ghilles E., Gianotti L., Gil Santos M., Gilsanz Martin C., Gingert C., Gklavas A., Glehen O., Golda T., Gomez N., Gomez R., Gomez Ruiz M., Gonzalez Santin V., Graham B., Grainger J., Grama F., Gregoir T., Gregori M., Grolich T., Grosek J., Guadalajara H., Guckenheimer S., Guevara J., Gulotta G., Gupta S., Gurevich N., Gurjar S., Haapaniemi S., Hahnloser D., Hamad Y., Hamid M., Hanly A., Harris G., Harsanyi L., Hartig N., Hawkin P., Henriques P., Herbst F., Hermann N., Hernandez Garcia M., Hoch J., Hrora A., Huhtinen H., Iarumov N., Ilkanich A., Insua C., Ioannidis P., Iqbal M., Iqbal A., Isik A., Ismaiel M., Ivlev D., Jadhav V., Jareno S., Jehaes C., Jimenez V., Jimenez-Toscano M., Jimenez-Miramon J., Jimenez-Rodriguez R., Jonsson T., Jotautas V., Julia D., Juloski J., Jung B., Kala Z., Kalayci M., Kara Y., Karachun A., Karagul S., Karvonen J., Katorkin S., Katsoulis I., Katsounis D., Kaubrys M., Kaul N., Kefalou E., Keijzers M., Kelly M., Kenic M., Kennelly R., Khan J., Khan M., Kho H., Kinas V., Knight J., Kocian P., Koeter T., Kokobelyan A., Konsten J., Koolen L., Kosir J., Kostic I., Krdzic I., Kreisler Moreno E., Krivokapic Z., Krstev P., Krsul D., Kumarasinghe N., La Torre F., Labarga F., Ladra M., Lage Laredo A., Lahodzich N., Lai C., Lakkis Z., Lal R., Lamas S., Lang T., Latkauskas T., Lawes D., Lazar G., Lebedev K., Lebedeva M., Lefevre J., Lekic Vitlov V., Lemma M., Leo C., Leon C., Leventoglu S., Levy B., Li L., Licari L., Lizdenis P., Loftas P., Longhi M., Longstaff L., Lopez Dominguez J., Lopez-Lara M., Lora P., Lorenzon L., Lorusso D., Lozev I., Lozoya Trujillo R., Lukic D., Lunins R., Luzan R., Luzzi A., Maderuelo V., Madsboll T., Mahotin D., Majbar M., Makhmudov A., Malik K., Maly O., Mamaloudis I., Mamedli Z., Manatakis D., Mandi D., Mangell P., Marharint T., Mariani N., Maric B., Marimuthu K., Marinello F., Marino F., Markiewicz S., Markovic V., Marom G., Maroni N., Maroulis I., Marsanic P., Marsman H., Martens M., Marti M., Martinek L., Martinez S., Martinez D., Martinez Manzano A., Martins R., Maslyankov S., McArdle K., McDermott F., Mege D., Mehraj A., Mehta A., Mendrila D., Menendez P., Mercantini P., Metwally I., Mikalauskas S., Millan M., Mingoli A., Mirshekar-Syahkal B., Moggia E., Mohan S., Moller P., Mompart Garcia S., Monami B., Moniz Pereira P., Montroni I., Morel P., Moshev B., Mostovoy E., Mothe S., Mukhtar H., Muller P., Munch S., Munoz Camarena J., Munoz-Collado S., Muratore A., Muscara F., Muysoms F., Myrelid P., N. Lah N., Nail S., Narayanan A., Nastos K., Negoi I., Nesbakken A., Nestler G., Nestorovic M., Nesytykh A., Newton K., Ng Y., Ngu J., Nguyen B., Nijs Y., Nikberg M., Nimmersgern T., Nogues E., Norcic G., Nutautiene V., Nygren J., O'Brien J., Ochogavia Segui A., O'Kelly J., Oliveira-Cunha M., Omar W., Omar G., Onishchenko S., Onody P., Opocher E., Orhalmi J., Oshowo A., Otero J., Ozgen U., Pace K., Padin H., Papaconstantinou I., Papadopoulos A., Papadopoulos G., Papandrea M., Paral J., Parc Y., Paredes J., Parmar M., Parra Banos P., Parray F., Pascual Damieta M., Pascual Miguelanez I., Passot G., Pastor C., Paszt A., Patel P., Paterson H., Patron Uriburu J., Paulos A., Pavlov V., Pcolkins A., Pecic V., Pena Ros E., Penkov R., Pera Roman M., Perunicic V., Pery R., Petrovic D., Pezzolla F., Photi E., Pikarsky A., Piramanayagam B., Pisani Ceretti A., Planellas P., Platt E., Pletinckx P., Podda M., Poskus T., Poskus E., Pozdnyakov A., Pravosudov I., Previsic A., Prieto D., Prochazka V., Prodan A., Proud D., Psaila J., Psaras G., Pulighe F., Pullig F., Qureshi M., Rachadell J., Radovanovic Z., Radovanovic D., Raguan B., Rahman M., Raiss M., Ramirez Faraco M., Ramos J., Ramos-Prada J., Rantala A., Rao M., Rasulov A., Ratnatunga K., Raymond T., Refky B., Reggiani L., Regusci L., Reyes Diaz M., Richardson J., Richiteanu G., Rios A., Ris F., Rodriguez Garcia P., Roffi N., Romairone E., Romano G., Romero I., Romero de Diego A., Romero-Simo M., Roque C., Rosati R., Rossi B., Rossi E., Rossini R., Ruano A., Rubbini M., Rubio-Perez I., Ruffo G., Ruiz H., Ruiz Carmona M., Ryska O., Sabia D., Sacchi M., Sacco R., Sakr A., Saladzinskas Z., Salamone G., Salomon M., Salvans Ruiz S., Sammarco G., Sampietro G., Samsonov D., Samsonyuk V., Sanchez J., Sanchez Romero A., Sanchez-Guillen L., Santak G., Santamaria-Olabarrieta M., Santos J., Saraceno F., Saralegui Y., Sarici I., Savino G., Scabini S., Schafli J., Schiltz B., Schofield A., Schon M., Scurtu R., Segalini E., Segelman J., Segura-Sampedro J., Seicean R., Sekulic A., Selniahina L., Seretis F., Serrano Paz P., Shaikh I., Shalaby M., Shams N., Sharma A., Sharma G., Shukla A., Shussman N., Shweejawee Z., Sielezneff I., Sigurdsson H., Sileri P., Silva M., Simcikas D., Simoes J., Simonka Z., Singh B., Sivins A., Skroubis G., Skull A., Slavchev M., Slavin M., Smart N., Smart C., Smart P., Smedh K., Smolarek S., Sokmen S., Sokolov M., Solana Bueno A., Solar L., Sorrentino L., Sotona O., Spacca D., Spinelli A., Stanojevic G., Stearns A., Stefan S., Stift A., Stijns J., Stoyanov V., Straarup D., Strupas K., Stubbs B., Subocius A., Sudlow A., Suero C., Sungurtekin U., Svagzdys S., Syk I., Tamelis A., Tamhane R., Tamini N., Tamosiunas A., Tanis P., Tarasov N., Tate S., Tennakoon A., Teo N., Terzi C., Tezas S., Thabet W., Tham J., Thavanesan N., Theodosopoulos T., Thomas W., Tiret E., Tiselius C., Todorov G., Tomazic A., Tomulescu V., Torkington J., Totis M., Trostchansky I., Truan N., Tulchinsky H., Tutino R., Tzivanakis A., Tzovaras G., Ugolini G., Unger L., Upanishad I., Urbani L., Uth Ovesen A., Vaizey C., Vallribera F., Valsdottir E., Valverde I., Valverde-Sintas J., Van Belle K., Van Cleven S., van Hagen P., van Loon Y., van Ruler O., Van Wijck K., Varabei A., Varcada M., Varpe P., Vartic M., Velchuru V., Vencius J., Venskutonis D., Vercher D., Vermaas M., Vertruyen M., Verza L., Vescio G., Vezakis A., Vieira P., Vignali A., Vigorita V., Vila Tura M., Vinson-Bonnet B., Viso Pons L., Voloshin S., Voronin Y., Vukusic L., Wang X., Wang J., Wani R., Warusavitarne J., Wasserberg N., Weerts J., Weiss D., Weizman A., Westerduin E., Wheat J., White I., Wik T., Wilson J., Winter D., Wolthuis A., Wong M., Yahia S., Yamamoto T., Yanishev A., Yao C., Yildiz A., Yuksel O., Zain Z., Zakaria A., Zakaria Z., Zampitis N., Zarand A., Zarco-Pleguezuelos A., Zattoni D., Zelic M., Zeromskas P., Zhuravlev A., Zimmerman D., Zuhdy M., Zukanovic G., Surgery, CCA - Cancer Treatment and Quality of Life, Amsterdam Gastroenterology Endocrinology Metabolism, Graduate School, Amsterdam Neuroscience - Cellular & Molecular Mechanisms, Amsterdam Neuroscience - Neuroinfection & -inflammation, APH - Methodology, APH - Personalized Medicine, Pinkney, T, Taylor, H, Tong, C, Schmitz, N, Morton, D, Bhangu, A, Blackwell, S, Dardanov, D, Dulskas, A, Gallo, G, Glasbey, J, Keatley, J, Knowles, C, Li, Y, Mccourt, V, Minaya-Bravo, A, Neary, P, Nepogodiev, D, Pata, F, Pellino, G, Sivrikoz, E, van Ramshorst, G, Zmora, O, Perry, R, Magill, E, Abdalkoddus, M, Abelevich, A, Abraham, S, Abraham-Nordling, M, Adamina, M, Agalar, C, Agresta, F, Ahallat, M, Ahmad, N, Aiupov, R, Akca, O, Aleksic, A, Aleotti, F, Alias, D, Alonso, J, Alonso Goncalves, S, Alonso Martin, J, Alonso Poza, A, Alonso-Hernandez, N, Alos Company, R, Al-Saeedi, M, Alvarez-Laso, C, Alvarez-Gallego, M, Amanatidis, T, Americano, M, Amorim, E, Anandan, L, Anania, G, Ancans, G, Andreev, P, Andrejevic, P, Antonacci, N, Anwer, M, Aonzo, P, Arencibia, B, Argeny, S, Arieli, H, Arnold, S, Ashraf, M, Aslam, M, Atanasov, B, Atif, M, Atladottir, J, Avital, S, Awny, S, Aytac, B, Azahr, N, Aznar-Puig, S, Bailey, S, Balalis, D, Baldi, C, Baldonedo, R, Balducci, G, Balestra, F, Balestri, R, Balfour, A, Baloyiannis, I, Banky, B, Baral, J, Baranyai, Z, Barbashinov, N, Bargallo, J, Barisic, G, Barugola, G, Batashki, I, Battersby, N, Belev, N, Belli, A, Beltran de Heredia, J, Bemelman, W, Benavides Buleje, J, Benckert, A, Bernal-Sprekelsen, J, Bertocchi, E, Beuran, M, Bhan, C, Bianco, F, Bilali, S, Bilali, V, Bintintan, V, Birindelli, A, Birsan, T, Blanco Antona, F, Blas, J, Blasco-Segura, T, Blom, R, Bocchetti, T, Boerma, E, Bogdan, M, Boland, M, Bomans, B, Borda, N, Bowen, M, Bradulskis, S, Branagan, G, Brankovic, B, Brenna, M, Brewer, H, Broadhurst, J, Bronder, C, Brouwer, R, Buccianti, P, Buchs, N, Buchwald, P, Bugatti, A, Bui, A, Burcos, T, Buskens, C, Bustamante, C, Caceres, N, Cagigas Fernandez, C, Calero-Lillo, A, Camps, I, Canda, A, Caravaca-Garcia, I, Carballo, F, Carcoforo, P, Carlander, J, Carlos, S, Caro, A, Carpelan, A, Carrasco Prats, M, Carrillo Lopez, M, Carvello, M, Casal, E, Casoni Pattacini, G, Castellvi Valls, J, Castillo Diego, J, Cavallesco, G, Cavenaile, V, Cayetano, L, Ceccotti, A, Cervera-Aldama, J, Chabok, A, Chafai, N, Chandrasinghe, P, Chandratreya, N, Chaudhri, S, Chaudhry, Z, Cherdancev, D, Chernov, A, Chevallay, M, Chirletti, P, Chouillard, E, Chouliaras, C, Chowdri, N, Cillo, M, Cini, C, Ciubotaru, C, Ciuce, C, Claeys, D, Cocorullo, G, Codina-Cazador, A, Colak, E, Coletta, D, Colombo, F, Copaescu, C, Corte Real, J, Corver, M, Cosic, J, Costa, S, Costa Pereira, J, Costa Pereira, C, Costa-Navarro, D, Cotte, E, Cracco, N, Cristian, D, Cuadrado, M, Cuk, V, Cunha, M, Cunha, J, Curinga, R, Curletti, G, Curtis, N, Dabic, D, Dainius, E, D'Alessandro, A, Daniels, I, Darvin, V, Dauser, B, David, G, Davidova, O, Davies, E, de Andres Asenjo, B, De franciscis, S, de Graaf, E, De la Portilla, F, De Luca, E, De Nisco, C, De Toma, G, Defoort, B, Den Boer, F, Di Candido, F, Di Saverio, S, Diaz Pavon, J, Dieguez Fernandez, B, Diez-Alonso, M, Dimitrijevic, I, Dindelegan, G, Djuric, M, Domingos, H, Doornebosch, P, Dos Santos, M, Drami, I, Dudarovaska, H, Dusek, T, Dzhumabaev, H, Eden, Y, Egenvall, M, Eismiontas, V, El Sorogy, M, Elgeidie, A, Elhemaly, M, El-Hussuna, A, Ellul, S, Elmore, U, Elnakeeb, A, Elrefai, M, Emile, S, Enrriquez-Navascues, J, Epstein, J, Escartin, J, Escola, D, Escuder, J, Espin, E, Espina, B, Estefania, D, Etienne, J, Fabbri, S, Falato, A, Fares, R, Farina, P, Farkasova, M, Farres, R, Fasolini, F, Fatayer, T, Febles, G, Feliu, F, Feo, C, Feoktistov, D, Fernandez, F, Fernandez Isart, M, Fernando, J, Ferreira, G, Ferrer, R, Ferreras Garcia, C, Ferri, M, Figueiredo, N, Finotti, E, Fitzgerald, J, Flateh Backe, I, Flor-Lorente, B, Forero-Torres, A, Foschi, D, Francart, D, Francois, Y, Frasson, M, Freil-Lanter, C, Frois Borges, M, Fuzun, M, Gala, T, Galleano, R, Galvez, P, Galvez Saldana, A, Gamundi Cuesta, M, Garcia Cabrera, A, Garcia Egea, J, Garcia Olmo, D, Garcia-Gonzalez, J, Garcia-Granero, A, Garcia-Granero, E, Garcia-Septiem, J, Gardea, A, Garipov, M, Gefen, R, Geraghty, A, Gerkis, S, Germanos, S, Ghaffari, S, Ghilles, E, Gianotti, L, Gil Santos, M, Gilsanz Martin, C, Gingert, C, Gklavas, A, Glehen, O, Golda, T, Gomez, N, Gomez, R, Gomez Ruiz, M, Gonzalez Santin, V, Graham, B, Grainger, J, Grama, F, Gregoir, T, Gregori, M, Grolich, T, Grosek, J, Guadalajara, H, Guckenheimer, S, Guevara, J, Gulotta, G, Gupta, S, Gurevich, N, Gurjar, S, Haapaniemi, S, Hahnloser, D, Hamad, Y, Hamid, M, Hanly, A, Harris, G, Harsanyi, L, Hartig, N, Hawkin, P, Henriques, P, Herbst, F, Hermann, N, Hernandez Garcia, M, Hoch, J, Hrora, A, Huhtinen, H, Iarumov, N, Ilkanich, A, Insua, C, Ioannidis, P, Iqbal, M, Iqbal, A, Isik, A, Ismaiel, M, Ivlev, D, Jadhav, V, Jareno, S, Jehaes, C, Jimenez, V, Jimenez-Toscano, M, Jimenez-Miramon, J, Jimenez-Rodriguez, R, Jonsson, T, Jotautas, V, Julia, D, Juloski, J, Jung, B, Kala, Z, Kalayci, M, Kara, Y, Karachun, A, Karagul, S, Karvonen, J, Katorkin, S, Katsoulis, I, Katsounis, D, Kaubrys, M, Kaul, N, Kefalou, E, Keijzers, M, Kelly, M, Kenic, M, Kennelly, R, Khan, J, Khan, M, Kho, H, Kinas, V, Knight, J, Kocian, P, Koeter, T, Kokobelyan, A, Konsten, J, Koolen, L, Kosir, J, Kostic, I, Krdzic, I, Kreisler Moreno, E, Krivokapic, Z, Krstev, P, Krsul, D, Kumarasinghe, N, La Torre, F, Labarga, F, Ladra, M, Lage Laredo, A, Lahodzich, N, Lai, C, Lakkis, Z, Lal, R, Lamas, S, Lang, T, Latkauskas, T, Lawes, D, Lazar, G, Lebedev, K, Lebedeva, M, Lefevre, J, Lekic Vitlov, V, Lemma, M, Leo, C, Leon, C, Leventoglu, S, Levy, B, Li, L, Licari, L, Lizdenis, P, Loftas, P, Longhi, M, Longstaff, L, Lopez Dominguez, J, Lopez-Lara, M, Lora, P, Lorenzon, L, Lorusso, D, Lozev, I, Lozoya Trujillo, R, Lukic, D, Lunins, R, Luzan, R, Luzzi, A, Maderuelo, V, Madsboll, T, Mahotin, D, Majbar, M, Makhmudov, A, Malik, K, Maly, O, Mamaloudis, I, Mamedli, Z, Manatakis, D, Mandi, D, Mangell, P, Marharint, T, Mariani, N, Maric, B, Marimuthu, K, Marinello, F, Marino, F, Markiewicz, S, Markovic, V, Marom, G, Maroni, N, Maroulis, I, Marsanic, P, Marsman, H, Martens, M, Marti, M, Martinek, L, Martinez, S, Martinez, D, Martinez Manzano, A, Martins, R, Maslyankov, S, Mcardle, K, Mcdermott, F, Mege, D, Mehraj, A, Mehta, A, Mendrila, D, Menendez, P, Mercantini, P, Metwally, I, Mikalauskas, S, Millan, M, Mingoli, A, Mirshekar-Syahkal, B, Moggia, E, Mohan, S, Moller, P, Mompart Garcia, S, Monami, B, Moniz Pereira, P, Montroni, I, Morel, P, Moshev, B, Mostovoy, E, Mothe, S, Mukhtar, H, Muller, P, Munch, S, Munoz Camarena, J, Munoz-Collado, S, Muratore, A, Muscara, F, Muysoms, F, Myrelid, P, N. Lah, N, Nail, S, Narayanan, A, Nastos, K, Negoi, I, Nesbakken, A, Nestler, G, Nestorovic, M, Nesytykh, A, Newton, K, Ng, Y, Ngu, J, Nguyen, B, Nijs, Y, Nikberg, M, Nimmersgern, T, Nogues, E, Norcic, G, Nutautiene, V, Nygren, J, O'Brien, J, Ochogavia Segui, A, O'Kelly, J, Oliveira-Cunha, M, Omar, W, Omar, G, Onishchenko, S, Onody, P, Opocher, E, Orhalmi, J, Oshowo, A, Otero, J, Ozgen, U, Pace, K, Padin, H, Papaconstantinou, I, Papadopoulos, A, Papadopoulos, G, Papandrea, M, Paral, J, Parc, Y, Paredes, J, Parmar, M, Parra Banos, P, Parray, F, Pascual Damieta, M, Pascual Miguelanez, I, Passot, G, Pastor, C, Paszt, A, Patel, P, Paterson, H, Patron Uriburu, J, Paulos, A, Pavlov, V, Pcolkins, A, Pecic, V, Pena Ros, E, Penkov, R, Pera Roman, M, Perunicic, V, Pery, R, Petrovic, D, Pezzolla, F, Photi, E, Pikarsky, A, Piramanayagam, B, Pisani Ceretti, A, Planellas, P, Platt, E, Pletinckx, P, Podda, M, Poskus, T, Poskus, E, Pozdnyakov, A, Pravosudov, I, Previsic, A, Prieto, D, Prochazka, V, Prodan, A, Proud, D, Psaila, J, Psaras, G, Pulighe, F, Pullig, F, Qureshi, M, Rachadell, J, Radovanovic, Z, Radovanovic, D, Raguan, B, Rahman, M, Raiss, M, Ramirez Faraco, M, Ramos, J, Ramos-Prada, J, Rantala, A, Rao, M, Rasulov, A, Ratnatunga, K, Raymond, T, Refky, B, Reggiani, L, Regusci, L, Reyes Diaz, M, Richardson, J, Richiteanu, G, Rios, A, Ris, F, Rodriguez Garcia, P, Roffi, N, Romairone, E, Romano, G, Romero, I, Romero de Diego, A, Romero-Simo, M, Roque, C, Rosati, R, Rossi, B, Rossi, E, Rossini, R, Ruano, A, Rubbini, M, Rubio-Perez, I, Ruffo, G, Ruiz, H, Ruiz Carmona, M, Ryska, O, Sabia, D, Sacchi, M, Sacco, R, Sakr, A, Saladzinskas, Z, Salamone, G, Salomon, M, Salvans Ruiz, S, Sammarco, G, Sampietro, G, Samsonov, D, Samsonyuk, V, Sanchez, J, Sanchez Romero, A, Sanchez-Guillen, L, Santak, G, Santamaria-Olabarrieta, M, Santos, J, Saraceno, F, Saralegui, Y, Sarici, I, Savino, G, Scabini, S, Schafli, J, Schiltz, B, Schofield, A, Schon, M, Scurtu, R, Segalini, E, Segelman, J, Segura-Sampedro, J, Seicean, R, Sekulic, A, Selniahina, L, Seretis, F, Serrano Paz, P, Shaikh, I, Shalaby, M, Shams, N, Sharma, A, Sharma, G, Shukla, A, Shussman, N, Shweejawee, Z, Sielezneff, I, Sigurdsson, H, Sileri, P, Silva, M, Simcikas, D, Simoes, J, Simonka, Z, Singh, B, Sivins, A, Skroubis, G, Skull, A, Slavchev, M, Slavin, M, Smart, N, Smart, C, Smart, P, Smedh, K, Smolarek, S, Sokmen, S, Sokolov, M, Solana Bueno, A, Solar, L, Sorrentino, L, Sotona, O, Spacca, D, Spinelli, A, Stanojevic, G, Stearns, A, Stefan, S, Stift, A, Stijns, J, Stoyanov, V, Straarup, D, Strupas, K, Stubbs, B, Subocius, A, Sudlow, A, Suero, C, Sungurtekin, U, Svagzdys, S, Syk, I, Tamelis, A, Tamhane, R, Tamini, N, Tamosiunas, A, Tanis, P, Tarasov, N, Tate, S, Tennakoon, A, Teo, N, Terzi, C, Tezas, S, Thabet, W, Tham, J, Thavanesan, N, Theodosopoulos, T, Thomas, W, Tiret, E, Tiselius, C, Todorov, G, Tomazic, A, Tomulescu, V, Torkington, J, Totis, M, Trostchansky, I, Truan, N, Tulchinsky, H, Tutino, R, Tzivanakis, A, Tzovaras, G, Ugolini, G, Unger, L, Upanishad, I, Urbani, L, Uth Ovesen, A, Vaizey, C, Vallribera, F, Valsdottir, E, Valverde, I, Valverde-Sintas, J, Van Belle, K, Van Cleven, S, van Hagen, P, van Loon, Y, van Ruler, O, Van Wijck, K, Varabei, A, Varcada, M, Varpe, P, Vartic, M, Velchuru, V, Vencius, J, Venskutonis, D, Vercher, D, Vermaas, M, Vertruyen, M, Verza, L, Vescio, G, Vezakis, A, Vieira, P, Vignali, A, Vigorita, V, Vila Tura, M, Vinson-Bonnet, B, Viso Pons, L, Voloshin, S, Voronin, Y, Vukusic, L, Wang, X, Wang, J, Wani, R, Warusavitarne, J, Wasserberg, N, Weerts, J, Weiss, D, Weizman, A, Westerduin, E, Wheat, J, White, I, Wik, T, Wilson, J, Winter, D, Wolthuis, A, Wong, M, Yahia, S, Yamamoto, T, Yanishev, A, Yao, C, Yildiz, A, Yuksel, O, Zain, Z, Zakaria, A, Zakaria, Z, Zampitis, N, Zarand, A, Zarco-Pleguezuelos, A, Zattoni, D, Zelic, M, Zeromskas, P, Zhuravlev, A, Zimmerman, D, Zuhdy, M, Zukanovic, G, Pinkney T.D., Taylor H., Tong C., Schmitz N.-D., Morton D.G., Bhangu A., Blackwell S., Dardanov D., Dulskas A., Gallo G., Glasbey J., Keatley J., Knowles C., Li Y.E., McCourt V., Minaya-Bravo A., Neary P., Nepogodiev D., Pata F., Pellino G., Sivrikoz E., van Ramshorst G., Zmora O., Perry R., Magill E.L., Abdalkoddus M., Abelevich A., Abraham S., Abraham-Nordling M., Adamina M., Agalar C., Agresta F., Ahallat M., Ahmad N., Aiupov R., Akca O., Aleksic A., Aleotti F., Alias D., Alonso J., Alonso Goncalves S., Alonso Martin J., Alonso Poza A., Alonso-Hernandez N., Alos Company R., Al-Saeedi M., Alvarez-Laso C., Alvarez-Gallego M., Amanatidis T., Americano M., Amorim E., Anandan L., Anania G., Ancans G., Andreev P., Andrejevic P., Antonacci N., Anwer M., Aonzo P., Arencibia B., Argeny S., Arieli H., Arnold S., Ashraf M., Aslam M., Atanasov B., Atif M., Atladottir J., Avital S., Awny S., Aytac B., Azahr N., Aznar-Puig S., Bailey S., Balalis D., Baldi C., Baldonedo R., Balducci G., Balestra F., Balestri R., Balfour A., Baloyiannis I., Banky B., Baral J., Baranyai Z., Barbashinov N., Bargallo J., Barisic G., Barugola G., Batashki I., Battersby N., Belev N., Belli A., Beltran de Heredia J., Bemelman W., Benavides Buleje J., Benckert A., Bernal-Sprekelsen J., Bertocchi E., Beuran M., Bhan C., Bianco F., Bilali S., Bilali V., Bintintan V., Birindelli A., Birsan T., Blanco Antona F., Blas J., Blasco-Segura T., Blom R., Bocchetti T., Boerma E., Bogdan M., Boland M., Bomans B., Borda N., Bowen M., Bradulskis S., Branagan G., Brankovic B., Brenna M., Brewer H., Broadhurst J., Bronder C., Brouwer R., Buccianti P., Buchs N., Buchwald P., Bugatti A., Bui A., Burcos T., Buskens C., Bustamante C., Caceres N., Cagigas Fernandez C., Calero-Lillo A., Camps I., Canda A., Caravaca-Garcia I., Carballo F., Carcoforo P., Carlander J., Carlos S., Caro A., Carpelan A., Carrasco Prats M., Carrillo Lopez M., Carvello M., Casal E., Casoni Pattacini G., Castellvi Valls J., Castillo Diego J., Cavallesco G., Cavenaile V., Cayetano L., Ceccotti A., Cervera-Aldama J., Chabok A., Chafai N., Chandrasinghe P., Chandratreya N., Chaudhri S., Chaudhry Z., Cherdancev D., Chernov A., Chevallay M., Chirletti P., Chouillard E., Chouliaras C., Chowdri N., Cillo M., Cini C., Ciubotaru C., Ciuce C., Claeys D., Cocorullo G., Codina-Cazador A., Colak E., Coletta D., Colombo F., Copaescu C., Corte Real J., Corver M., Cosic J., Costa S., Costa Pereira J., Costa Pereira C., Costa-Navarro D., Cotte E., Cracco N., Cristian D., Cuadrado M., Cuk V., Cunha M., Cunha J., Curinga R., Curletti G., Curtis N., Dabic D., Dainius E., d'Alessandro A., Daniels I., Darvin V., Dauser B., David G., Davidova O., Davies E., de Andres Asenjo B., De franciscis S., de Graaf E., De la Portilla F., De Luca E., De Nisco C., De Toma G., Defoort B., Den Boer F., Di Candido F., Di Saverio S., Diaz Pavon J., Dieguez Fernandez B., Diez-Alonso M., Dimitrijevic I., Dindelegan G., Djuric M., Domingos H., Doornebosch P., Dos Santos M., Drami I., Dudarovaska H., Dusek T., Dzhumabaev H., Eden Y., Egenvall M., Eismiontas V., El Sorogy M., Elgeidie A., Elhemaly M., El-Hussuna A., Ellul S., Elmore U., ElNakeeb A., Elrefai M., Emile S., Enrriquez-Navascues J., Epstein J., Escartin J., Escola D., Escuder J., Espin E., Espina B., Estefania D., Etienne J., Fabbri S., Falato A., Fares R., Farina P., Farkasova M., Farres R., Fasolini F., Fatayer T., Febles G., Feliu F., Feo C., Feoktistov D., Fernandez F., Fernandez Isart M., Fernando J., Ferreira G., Ferrer R., Ferreras Garcia C., Ferri M., Figueiredo N., Finotti E., Fitzgerald J., Flateh Backe I., Flor-Lorente B., Forero-Torres A., Foschi D., Francart D., Francois Y., Frasson M., Freil-Lanter C., Frois Borges M., Fuzun M., Gala T., Galleano R., Galvez P., Galvez Saldana A., Gamundi Cuesta M., Garcia Cabrera A., Garcia Egea J., Garcia Olmo D., Garcia-Gonzalez J., Garcia-Granero A., Garcia-Granero E., Garcia-Septiem J., Gardea A., Garipov M., Gefen R., Geraghty A., Gerkis S., Germanos S., Ghaffari S., Ghilles E., Gianotti L., Gil Santos M., Gilsanz Martin C., Gingert C., Gklavas A., Glehen O., Golda T., Gomez N., Gomez R., Gomez Ruiz M., Gonzalez Santin V., Graham B., Grainger J., Grama F., Gregoir T., Gregori M., Grolich T., Grosek J., Guadalajara H., Guckenheimer S., Guevara J., Gulotta G., Gupta S., Gurevich N., Gurjar S., Haapaniemi S., Hahnloser D., Hamad Y., Hamid M., Hanly A., Harris G., Harsanyi L., Hartig N., Hawkin P., Henriques P., Herbst F., Hermann N., Hernandez Garcia M., Hoch J., Hrora A., Huhtinen H., Iarumov N., Ilkanich A., Insua C., Ioannidis P., Iqbal M., Iqbal A., Isik A., Ismaiel M., Ivlev D., Jadhav V., Jareno S., Jehaes C., Jimenez V., Jimenez-Toscano M., Jimenez-Miramon J., Jimenez-Rodriguez R., Jonsson T., Jotautas V., Julia D., Juloski J., Jung B., Kala Z., Kalayci M., Kara Y., Karachun A., Karagul S., Karvonen J., Katorkin S., Katsoulis I., Katsounis D., Kaubrys M., Kaul N., Kefalou E., Keijzers M., Kelly M., Kenic M., Kennelly R., Khan J., Khan M., Kho H., Kinas V., Knight J., Kocian P., Koeter T., Kokobelyan A., Konsten J., Koolen L., Kosir J., Kostic I., Krdzic I., Kreisler Moreno E., Krivokapic Z., Krstev P., Krsul D., Kumarasinghe N., La Torre F., Labarga F., Ladra M., Lage Laredo A., Lahodzich N., Lai C., Lakkis Z., Lal R., Lamas S., Lang T., Latkauskas T., Lawes D., Lazar G., Lebedev K., Lebedeva M., Lefevre J., Lekic Vitlov V., Lemma M., Leo C., Leon C., Leventoglu S., Levy B., Li L., Licari L., Lizdenis P., Loftas P., Longhi M., Longstaff L., Lopez Dominguez J., Lopez-Lara M., Lora P., Lorenzon L., Lorusso D., Lozev I., Lozoya Trujillo R., Lukic D., Lunins R., Luzan R., Luzzi A., Maderuelo V., Madsboll T., Mahotin D., Majbar M., Makhmudov A., Malik K., Maly O., Mamaloudis I., Mamedli Z., Manatakis D., Mandi D., Mangell P., Marharint T., Mariani N., Maric B., Marimuthu K., Marinello F., Marino F., Markiewicz S., Markovic V., Marom G., Maroni N., Maroulis I., Marsanic P., Marsman H., Martens M., Marti M., Martinek L., Martinez S., Martinez D., Martinez Manzano A., Martins R., Maslyankov S., McArdle K., McDermott F., Mege D., Mehraj A., Mehta A., Mendrila D., Menendez P., Mercantini P., Metwally I., Mikalauskas S., Millan M., Mingoli A., Mirshekar-Syahkal B., Moggia E., Mohan S., Moller P., Mompart Garcia S., Monami B., Moniz Pereira P., Montroni I., Morel P., Moshev B., Mostovoy E., Mothe S., Mukhtar H., Muller P., Munch S., Munoz Camarena J., Munoz-Collado S., Muratore A., Muscara F., Muysoms F., Myrelid P., N.Lah N., Nail S., Narayanan A., Nastos K., Negoi I., Nesbakken A., Nestler G., Nestorovic M., Nesytykh A., Newton K., Ng Y., Ngu J., Nguyen B., Nijs Y., Nikberg M., Nimmersgern T., Nogues E., Norcic G., Nutautiene V., Nygren J., O'Brien J., Ochogavia Segui A., O'Kelly J., Oliveira-Cunha M., Omar W., Omar G., Onishchenko S., Onody P., Opocher E., Orhalmi J., Oshowo A., Otero J., Ozgen U., Pace K., Padin H., Papaconstantinou I., Papadopoulos A., Papadopoulos G., Papandrea M., Paral J., Parc Y., Paredes J., Parmar M., Parra Banos P., Parray F., Pascual Damieta M., Pascual Miguelanez I., Passot G., Pastor C., Paszt A., Patel P., Paterson H., Patron Uriburu J., Paulos A., Pavlov V., Pcolkins A., Pecic V., Pena Ros E., Penkov R., Pera Roman M., Perunicic V., Pery R., Petrovic D., Pezzolla F., Photi E., Pikarsky A., Piramanayagam B., Pisani Ceretti A., Planellas P., Platt E., Pletinckx P., Podda M., Poskus T., Poskus E., Pozdnyakov A., Pravosudov I., Previsic A., Prieto D., Prochazka V., Prodan A., Proud D., Psaila J., Psaras G., Pulighe F., Pullig F., Qureshi M., Rachadell J., Radovanovic Z., Radovanovic D., Raguan B., Rahman M., Raiss M., Ramirez Faraco M., Ramos J., Ramos-Prada J., Rantala A., Rao M., Rasulov A., Ratnatunga K., Raymond T., Refky B., Reggiani L., Regusci L., Reyes Diaz M., Richardson J., Richiteanu G., Rios A., Ris F., Rodriguez Garcia P., Roffi N., Romairone E., Romano G., Romero I., Romero de Diego A., Romero-Simo M., Roque C., Rosati R., Rossi B., Rossi E., Rossini R., Ruano A., Rubbini M., Rubio-Perez I., Ruffo G., Ruiz H., Ruiz Carmona M., Ryska O., Sabia D., Sacchi M., Sacco R., Sakr A., Saladzinskas Z., Salamone G., Salomon M., Salvans Ruiz S., Sammarco G., Sampietro G., Samsonov D., Samsonyuk V., Sanchez J., Sanchez Romero A., Sanchez-Guillen L., Santak G., Santamaria-Olabarrieta M., Santos J., Saraceno F., Saralegui Y., Sarici I., Savino G., Scabini S., Schafli J., Schiltz B., Schofield A., Schon M., Scurtu R., Segalini E., Segelman J., Segura-Sampedro J., Seicean R., Sekulic A., Selniahina L., Seretis F., Serrano Paz P., Shaikh I., Shalaby M., Shams N., Sharma A., Sharma G., Shukla A., Shussman N., Shweejawee Z., Sielezneff I., Sigurdsson H., Sileri P., Silva M., Simcikas D., Simoes J., Simonka Z., Singh B., Sivins A., Skroubis G., Skull A., Slavchev M., Slavin M., Smart N., Smart C., Smart P., Smedh K., Smolarek S., Sokmen S., Sokolov M., Solana Bueno A., Solar L., Sorrentino L., Sotona O., Spacca D., Spinelli A., Stanojevic G., Stearns A., Stefan S., Stift A., Stijns J., Stoyanov V., Straarup D., Strupas K., Stubbs B., Subocius A., Sudlow A., Suero C., Sungurtekin U., Svagzdys S., Syk I., Tamelis A., Tamhane R., Tamini N., Tamosiunas A., Tanis P., Tarasov N., Tate S., Tennakoon A., Teo N., Terzi C., Tezas S., Thabet W., Tham J., Thavanesan N., Theodosopoulos T., Thomas W., Tiret E., Tiselius C., Todorov G., Tomazic A., Tomulescu V., Torkington J., Totis M., Trostchansky I., Truan N., Tulchinsky H., Tutino R., Tzivanakis A., Tzovaras G., Ugolini G., Unger L., Upanishad I., Urbani L., Uth Ovesen A., Vaizey C., Vallribera F., Valsdottir E., Valverde I., Valverde-Sintas J., Van Belle K., Van Cleven S., van Hagen P., van Loon Y., van Ruler O., Van Wijck K., Varabei A., Varcada M., Varpe P., Vartic M., Velchuru V., Vencius J., Venskutonis D., Vercher D., Vermaas M., Vertruyen M., Verza L., Vescio G., Vezakis A., Vieira P., Vignali A., Vigorita V., Vila Tura M., Vinson-Bonnet B., Viso Pons L., Voloshin S., Voronin Y., Vukusic L., Wang X., Wang J., Wani R., Warusavitarne J., Wasserberg N., Weerts J., Weiss D., Weizman A., Westerduin E., Wheat J., White I., Wik T., Wilson J., Winter D., Wolthuis A., Wong M., Yahia S., Yamamoto T., Yanishev A., Yao C., Yildiz A., Yuksel O., Zain Z., Zakaria A., Zakaria Z., Zampitis N., Zarand A., Zarco-Pleguezuelos A., Zattoni D., Zelic M., Zeromskas P., Zhuravlev A., Zimmerman D., Zuhdy M., Zukanovic G., Pinkney, T. D., Taylor, H., Tong, C., Schmitz, N. -D., Morton, D. G., Bhangu, A., Blackwell, S., Dardanov, D., Dulskas, A., Gallo, G., Glasbey, J., Keatley, J., Knowles, C., Li, Y. E., Mccourt, V., Minaya-Bravo, A., Neary, P., Nepogodiev, D., Pata, F., Pellino, G., Sivrikoz, E., van Ramshorst, G., Zmora, O., Perry, R., Magill, E. L., Abdalkoddus, M., Abelevich, A., Abraham, S., Abraham-Nordling, M., Adamina, M., Agalar, C., Agresta, F., Ahallat, M., Ahmad, N., Aiupov, R., Akca, O., Aleksic, A., Aleotti, F., Alias, D., Alonso, J., Alonso Goncalves, S., Alonso Martin, J., Alonso Poza, A., Alonso-Hernandez, N., Alos Company, R., Al-Saeedi, M., Alvarez-Laso, C., Alvarez-Gallego, M., Amanatidis, T., Americano, M., Amorim, E., Anandan, L., Anania, G., Ancans, G., Andreev, P., Andrejevic, P., Antonacci, N., Anwer, M., Aonzo, P., Arencibia, B., Argeny, S., Arieli, H., Arnold, S., Ashraf, M., Aslam, M., Atanasov, B., Atif, M., Atladottir, J., Avital, S., Awny, S., Aytac, B., Azahr, N., Aznar-Puig, S., Bailey, S., Balalis, D., Baldi, C., Baldonedo, R., Balducci, G., Balestra, F., Balestri, R., Balfour, A., Baloyiannis, I., Banky, B., Baral, J., Baranyai, Z., Barbashinov, N., Bargallo, J., Barisic, G., Barugola, G., Batashki, I., Battersby, N., Belev, N., Belli, A., Beltran de Heredia, J., Bemelman, W., Benavides Buleje, J., Benckert, A., Bernal-Sprekelsen, J., Bertocchi, E., Beuran, M., Bhan, C., Bianco, F., Bilali, S., Bilali, V., Bintintan, V., Birindelli, A., Birsan, T., Blanco Antona, F., Blas, J., Blasco-Segura, T., Blom, R., Bocchetti, T., Boerma, E., Bogdan, M., Boland, M., Bomans, B., Borda, N., Bowen, M., Bradulskis, S., Branagan, G., Brankovic, B., Brenna, M., Brewer, H., Broadhurst, J., Bronder, C., Brouwer, R., Buccianti, P., Buchs, N., Buchwald, P., Bugatti, A., Bui, A., Burcos, T., Buskens, C., Bustamante, C., Caceres, N., Cagigas Fernandez, C., Calero-Lillo, A., Camps, I., Canda, A., Caravaca-Garcia, I., Carballo, F., Carcoforo, P., Carlander, J., Carlos, S., Caro, A., Carpelan, A., Carrasco Prats, M., Carrillo Lopez, M., Carvello, M., Casal, E., Casoni Pattacini, G., Castellvi Valls, J., Castillo Diego, J., Cavallesco, G., Cavenaile, V., Cayetano, L., Ceccotti, A., Cervera-Aldama, J., Chabok, A., Chafai, N., Chandrasinghe, P., Chandratreya, N., Chaudhri, S., Chaudhry, Z., Cherdancev, D., Chernov, A., Chevallay, M., Chirletti, P., Chouillard, E., Chouliaras, C., Chowdri, N., Cillo, M., Cini, C., Ciubotaru, C., Ciuce, C., Claeys, D., Cocorullo, G., Codina-Cazador, A., Colak, E., Coletta, D., Colombo, F., Copaescu, C., Corte Real, J., Corver, M., Cosic, J., Costa, S., Costa Pereira, J., Costa Pereira, C., Costa-Navarro, D., Cotte, E., Cracco, N., Cristian, D., Cuadrado, M., Cuk, V., Cunha, M., Cunha, J., Curinga, R., Curletti, G., Curtis, N., Dabic, D., Dainius, E., D'Alessandro, A., Daniels, I., Darvin, V., Dauser, B., David, G., Davidova, O., Davies, E., de Andres Asenjo, B., De franciscis, S., de Graaf, E., De la Portilla, F., De Luca, E., De Nisco, C., De Toma, G., Defoort, B., Den Boer, F., Di Candido, F., Di Saverio, S., Diaz Pavon, J., Dieguez Fernandez, B., Diez-Alonso, M., Dimitrijevic, I., Dindelegan, G., Djuric, M., Domingos, H., Doornebosch, P., Dos Santos, M., Drami, I., Dudarovaska, H., Dusek, T., Dzhumabaev, H., Eden, Y., Egenvall, M., Eismiontas, V., El Sorogy, M., Elgeidie, A., Elhemaly, M., El-Hussuna, A., Ellul, S., Elmore, U., Elnakeeb, A., Elrefai, M., Emile, S., Enrriquez-Navascues, J., Epstein, J., Escartin, J., Escola, D., Escuder, J., Espin, E., Espina, B., Estefania, D., Etienne, J., Fabbri, S., Falato, A., Fares, R., Farina, P., Farkasova, M., Farres, R., Fasolini, F., Fatayer, T., Febles, G., Feliu, F., Feo, C., Feoktistov, D., Fernandez, F., Fernandez Isart, M., Fernando, J., Ferreira, G., Ferrer, R., Ferreras Garcia, C., Ferri, M., Figueiredo, N., Finotti, E., Fitzgerald, J., Flateh Backe, I., Flor-Lorente, B., Forero-Torres, A., Foschi, D., Francart, D., Francois, Y., Frasson, M., Freil-Lanter, C., Frois Borges, M., Fuzun, M., Gala, T., Galleano, R., Galvez, P., Galvez Saldana, A., Gamundi Cuesta, M., Garcia Cabrera, A., Garcia Egea, J., Garcia Olmo, D., Garcia-Gonzalez, J., Garcia-Granero, A., Garcia-Granero, E., Garcia-Septiem, J., Gardea, A., Garipov, M., Gefen, R., Geraghty, A., Gerkis, S., Germanos, S., Ghaffari, S., Ghilles, E., Gianotti, L., Gil Santos, M., Gilsanz Martin, C., Gingert, C., Gklavas, A., Glehen, O., Golda, T., Gomez, N., Gomez, R., Gomez Ruiz, M., Gonzalez Santin, V., Graham, B., Grainger, J., Grama, F., Gregoir, T., Gregori, M., Grolich, T., Grosek, J., Guadalajara, H., Guckenheimer, S., Guevara, J., Gulotta, G., Gupta, S., Gurevich, N., Gurjar, S., Haapaniemi, S., Hahnloser, D., Hamad, Y., Hamid, M., Hanly, A., Harris, G., Harsanyi, L., Hartig, N., Hawkin, P., Henriques, P., Herbst, F., Hermann, N., Hernandez Garcia, M., Hoch, J., Hrora, A., Huhtinen, H., Iarumov, N., Ilkanich, A., Insua, C., Ioannidis, P., Iqbal, M., Iqbal, A., Isik, A., Ismaiel, M., Ivlev, D., Jadhav, V., Jareno, S., Jehaes, C., Jimenez, V., Jimenez-Toscano, M., Jimenez-Miramon, J., Jimenez-Rodriguez, R., Jonsson, T., Jotautas, V., Julia, D., Juloski, J., Jung, B., Kala, Z., Kalayci, M., Kara, Y., Karachun, A., Karagul, S., Karvonen, J., Katorkin, S., Katsoulis, I., Katsounis, D., Kaubrys, M., Kaul, N., Kefalou, E., Keijzers, M., Kelly, M., Kenic, M., Kennelly, R., Khan, J., Khan, M., Kho, H., Kinas, V., Knight, J., Kocian, P., Koeter, T., Kokobelyan, A., Konsten, J., Koolen, L., Kosir, J., Kostic, I., Krdzic, I., Kreisler Moreno, E., Krivokapic, Z., Krstev, P., Krsul, D., Kumarasinghe, N., La Torre, F., Labarga, F., Ladra, M., Lage Laredo, A., Lahodzich, N., Lai, C., Lakkis, Z., Lal, R., Lamas, S., Lang, T., Latkauskas, T., Lawes, D., Lazar, G., Lebedev, K., Lebedeva, M., Lefevre, J., Lekic Vitlov, V., Lemma, M., Leo, C., Leon, C., Leventoglu, S., Levy, B., Li, L., Licari, L., Lizdenis, P., Loftas, P., Longhi, M., Longstaff, L., Lopez Dominguez, J., Lopez-Lara, M., Lora, P., Lorenzon, L., Lorusso, D., Lozev, I., Lozoya Trujillo, R., Lukic, D., Lunins, R., Luzan, R., Luzzi, A., Maderuelo, V., Madsboll, T., Mahotin, D., Majbar, M., Makhmudov, A., Malik, K., Maly, O., Mamaloudis, I., Mamedli, Z., Manatakis, D., Mandi, D., Mangell, P., Marharint, T., Mariani, N., Maric, B., Marimuthu, K., Marinello, F., Marino, F., Markiewicz, S., Markovic, V., Marom, G., Maroni, N., Maroulis, I., Marsanic, P., Marsman, H., Martens, M., Marti, M., Martinek, L., Martinez, S., Martinez, D., Martinez Manzano, A., Martins, R., Maslyankov, S., Mcardle, K., Mcdermott, F., Mege, D., Mehraj, A., Mehta, A., Mendrila, D., Menendez, P., Mercantini, P., Metwally, I., Mikalauskas, S., Millan, M., Mingoli, A., Mirshekar-Syahkal, B., Moggia, E., Mohan, S., Moller, P., Mompart Garcia, S., Monami, B., Moniz Pereira, P., Montroni, I., Morel, P., Moshev, B., Mostovoy, E., Mothe, S., Mukhtar, H., Muller, P., Munch, S., Munoz Camarena, J., Munoz-Collado, S., Muratore, A., Muscara, F., Muysoms, F., Myrelid, P., N. Lah, N., Nail, S., Narayanan, A., Nastos, K., Negoi, I., Nesbakken, A., Nestler, G., Nestorovic, M., Nesytykh, A., Newton, K., Ng, Y., Ngu, J., Nguyen, B., Nijs, Y., Nikberg, M., Nimmersgern, T., Nogues, E., Norcic, G., Nutautiene, V., Nygren, J., O'Brien, J., Ochogavia Segui, A., O'Kelly, J., Oliveira-Cunha, M., Omar, W., Omar, G., Onishchenko, S., Onody, P., Opocher, E., Orhalmi, J., Oshowo, A., Otero, J., Ozgen, U., Pace, K., Padin, H., Papaconstantinou, I., Papadopoulos, A., Papadopoulos, G., Papandrea, M., Paral, J., Parc, Y., Paredes, J., Parmar, M., Parra Banos, P., Parray, F., Pascual Damieta, M., Pascual Miguelanez, I., Passot, G., Pastor, C., Paszt, A., Patel, P., Paterson, H., Patron Uriburu, J., Paulos, A., Pavlov, V., Pcolkins, A., Pecic, V., Pena Ros, E., Penkov, R., Pera Roman, M., Perunicic, V., Pery, R., Petrovic, D., Pezzolla, F., Photi, E., Pikarsky, A., Piramanayagam, B., Pisani Ceretti, A., Planellas, P., Platt, E., Pletinckx, P., Podda, M., Poskus, T., Poskus, E., Pozdnyakov, A., Pravosudov, I., Previsic, A., Prieto, D., Prochazka, V., Prodan, A., Proud, D., Psaila, J., Psaras, G., Pulighe, F., Pullig, F., Qureshi, M., Rachadell, J., Radovanovic, Z., Radovanovic, D., Raguan, B., Rahman, M., Raiss, M., Ramirez Faraco, M., Ramos, J., Ramos-Prada, J., Rantala, A., Rao, M., Rasulov, A., Ratnatunga, K., Raymond, T., Refky, B., Reggiani, L., Regusci, L., Reyes Diaz, M., Richardson, J., Richiteanu, G., Rios, A., Ris, F., Rodriguez Garcia, P., Roffi, N., Romairone, E., Romano, G., Romero, I., Romero de Diego, A., Romero-Simo, M., Roque, C., Rosati, R., Rossi, B., Rossi, E., Rossini, R., Ruano, A., Rubbini, M., Rubio-Perez, I., Ruffo, G., Ruiz, H., Ruiz Carmona, M., Ryska, O., Sabia, D., Sacchi, M., Sacco, R., Sakr, A., Saladzinskas, Z., Salamone, G., Salomon, M., Salvans Ruiz, S., Sammarco, G., Sampietro, G., Samsonov, D., Samsonyuk, V., Sanchez, J., Sanchez Romero, A., Sanchez-Guillen, L., Santak, G., Santamaria-Olabarrieta, M., Santos, J., Saraceno, F., Saralegui, Y., Sarici, I., Savino, G., Scabini, S., Schafli, J., Schiltz, B., Schofield, A., Schon, M., Scurtu, R., Segalini, E., Segelman, J., Segura-Sampedro, J., Seicean, R., Sekulic, A., Selniahina, L., Seretis, F., Serrano Paz, P., Shaikh, I., Shalaby, M., Shams, N., Sharma, A., Sharma, G., Shukla, A., Shussman, N., Shweejawee, Z., Sielezneff, I., Sigurdsson, H., Sileri, P., Silva, M., Simcikas, D., Simoes, J., Simonka, Z., Singh, B., Sivins, A., Skroubis, G., Skull, A., Slavchev, M., Slavin, M., Smart, N., Smart, C., Smart, P., Smedh, K., Smolarek, S., Sokmen, S., Sokolov, M., Solana Bueno, A., Solar, L., Sorrentino, L., Sotona, O., Spacca, D., Spinelli, A., Stanojevic, G., Stearns, A., Stefan, S., Stift, A., Stijns, J., Stoyanov, V., Straarup, D., Strupas, K., Stubbs, B., Subocius, A., Sudlow, A., Suero, C., Sungurtekin, U., Svagzdys, S., Syk, I., Tamelis, A., Tamhane, R., Tamini, N., Tamosiunas, A., Tanis, P., Tarasov, N., Tate, S., Tennakoon, A., Teo, N., Terzi, C., Tezas, S., Thabet, W., Tham, J., Thavanesan, N., Theodosopoulos, T., Thomas, W., Tiret, E., Tiselius, C., Todorov, G., Tomazic, A., Tomulescu, V., Torkington, J., Totis, M., Trostchansky, I., Truan, N., Tulchinsky, H., Tutino, R., Tzivanakis, A., Tzovaras, G., Ugolini, G., Unger, L., Upanishad, I., Urbani, L., Uth Ovesen, A., Vaizey, C., Vallribera, F., Valsdottir, E., Valverde, I., Valverde-Sintas, J., Van Belle, K., Van Cleven, S., van Hagen, P., van Loon, Y., van Ruler, O., Van Wijck, K., Varabei, A., Varcada, M., Varpe, P., Vartic, M., Velchuru, V., Vencius, J., Venskutonis, D., Vercher, D., Vermaas, M., Vertruyen, M., Verza, L., Vescio, G., Vezakis, A., Vieira, P., Vignali, A., Vigorita, V., Vila Tura, M., Vinson-Bonnet, B., Viso Pons, L., Voloshin, S., Voronin, Y., Vukusic, L., Wang, X., Wang, J., Wani, R., Warusavitarne, J., Wasserberg, N., Weerts, J., Weiss, D., Weizman, A., Westerduin, E., Wheat, J., White, I., Wik, T., Wilson, J., Winter, D., Wolthuis, A., Wong, M., Yahia, S., Yamamoto, T., Yanishev, A., Yao, C., Yildiz, A., Yuksel, O., Zain, Z., Zakaria, A., Zakaria, Z., Zampitis, N., Zarand, A., Zarco-Pleguezuelos, A., Zattoni, D., Zelic, M., Zeromskas, P., Zhuravlev, A., Zimmerman, D., Zuhdy, M., and Zukanovic, G.
Subjects: medicine.medical_specialty, Prehabilitation, medicine.medical_treatment, MEDLINE, Colorectal Neoplasm, Perioperative Care, NO, medicine, Humans, 03.02. Klinikai orvostan, Perioperative Optimisation, Enhanced recovery after surgery, Digestive System Surgical Procedures, LS7_4, Enhanced Recovery After Surgery (ERAS), business.industry, Gastroenterology, Digestive System Surgical Procedure, Guideline, Colorectal surgery, Surgery, Family medicine, Perioperative care, Nasogastric intubation, Preoperative fasting, Colorectal Neoplasms, Enhanced Recovery After Surgery, business, Colorectal Surgery, Human
Abstract: Aim The Enhanced Recovery After Surgery (ERAS® ) Society guidelines aim to standardise perioperative care in colorectal surgery via 25 principles. We aimed to assess the variation in uptake of these principles across an international network of colorectal units. Method An online survey was circulated amongst European Society of Coloproctology members in 2019/20. For each ERAS® principle, respondents were asked to score how frequently the principle was implemented in their hospital, from 1 ('rarely') to 4 ('always'). Respondents were also asked to recall whether practice had changed since 2017. Subgroup analyses based on hospital characteristics were conducted. Results Of hospitals approached, 58% responded to the survey (195/335), with 296 individual responses (multiple responses were received from some hospitals). The majority were European (163/195 [83.6%]). Overall, respondents indicated they 'most often' or 'always' adhered to most individual ERAS® principles (18/25 [72%]). Variability in uptake of principles was reported, with universal uptake of some principles (e.g., prophylactic antibiotics; early mobilisation) and inconsistency from 'rarely' to 'always' in others (e.g., no nasogastric intubation; no preoperative fasting and carbohydrate drinks). In alignment with 2018 ERAS® guideline updates, adherence to principles for prehabilitation, managing anaemia, and postoperative nutrition appears to have increased since 2017. Conclusions Uptake of ERAS® principles varied across hospitals, and not all 25 principles were equally adhered to. Whilst some principles exhibited a high level of acceptance, others had a wide variability in uptake indicative of controversy or barriers to uptake. Further research into specific principles is required to improve ERAS® implementation.
Published: 2021

46. The frequency of rare and monogenic diseases in pediatric organ transplant recipients in Italy

Author: Vaisitti T., Peritore D., Magistroni P., Ricci A., Lombardini L., Gringeri E., Catalano S., Spada M., Sciveres M., Di Giorgio A., Limongelli G., Varrenti M., Gerosa G., Terzi A., Napoleone C. P., Amodeo A., Ragni L., Strologo L., Benetti E., Fontana I., Testa S., Peruzzi L., Mitrotti A., Abbate S., Comai G., Gotti E., Schiavon M., Boffini M., De Angelis D., Bertani A., Pinelli D., Torre M., Poggi C., Deaglio S., Cardillo M., Amoroso A., Serena A., Giorgia C., Vaisitti, T., Peritore, D., Magistroni, P., Ricci, A., Lombardini, L., Gringeri, E., Catalano, S., Spada, M., Sciveres, M., Di Giorgio, A., Limongelli, G., Varrenti, M., Gerosa, G., Terzi, A., Napoleone, C. P., Amodeo, A., Ragni, L., Strologo, L., Benetti, E., Fontana, I., Testa, S., Peruzzi, L., Mitrotti, A., Abbate, S., Comai, G., Gotti, E., Schiavon, M., Boffini, M., De Angelis, D., Bertani, A., Pinelli, D., Torre, M., Poggi, C., Deaglio, S., Cardillo, M., Amoroso, A., Serena, A., and Giorgia, C.
Subjects: Registrie, Pediatrics, medicine.medical_specialty, Transplant outcome, Transplant Recipient, Monogenic diseases, Organ transplantation, Rare diseases, Child, Humans, Italy, Quality of Life, Registries, Transplant Recipients, Kidney Transplantation, Organ Transplantation, Disease, Quality of life, medicine, Pharmacology (medical), Monogenic disease, Genetics (clinical), Lung, business.industry, Research, Liver and kidney, General Medicine, Transplantation, medicine.anatomical_structure, Cohort, Medicine, business, Rare disease, Human
Abstract: Background Rare diseases are chronic and life-threatening disorders affecting Results To the purpose of our analysis, we considered heart, lung, liver and kidney transplants included in the Transplant Registry (TR) of the Italian National Transplantation Center in the 2002–2019 timeframe. Overall, 49,404 recipients were enrolled in the cohort, 5.1% of whom in the pediatric age. For 40,909 (82.8%) transplant recipients, a disease diagnosis was available, of which 38,615 in the adult cohort, while 8,495 patients (17.2%) were undiagnosed. There were 128 disease categories, and of these, 117 were listed in the main rare disease databases. In the pediatric cohort, 2,294 (5.6%) patients had a disease diagnosis: of the 2,126 (92.7%) patients affected by a rare disease, 1,402 (61.1%) presented with a monogenic condition. As expected, the frequencies of pathologies leading to organ failure were different between the pediatric and the adult cohort. Moreover, the pediatric group was characterized, compared to the adult one, by an overall better survival of the graft at ten years after transplant, with the only exception of lung transplants. When comparing survival considering rare vs non-rare diseases or rare and monogenic vs rare non-monogenic conditions, no differences were highlighted for kidney and lung transplants, while rare diseases had a better survival in liver as opposed to heart transplants. Conclusions This work represents the first national survey analyzing the main genetic causes and frequencies of rare and/or monogenic diseases leading to organ failure and requiring transplantation both in adults and children.
Published: 2021

47. Right ventricular function as assessed by cardiac magnetic resonance imaging‐derived strain parameters compared to high‐fidelity micromanometer catheter measurements

Author: Paul M. Hassoun, Ryan J. Tedford, Todd M. Kolb, Rubina M. Khair, Tomoki Fujii, Ela Chamera, Steven Hsu, Stefan L. Zimmerman, David A. Kass, Catherine E. Simpson, Ichizo Tsujino, Rachel L. Damico, Stephen C. Mathai, Christopher J Mullin, Bharath Ambale-Venkatesh, Takahiro Sato, Joao A.C. Lima, Celia P. Corona-Villalobos, Valentina Mercurio, Sato, Takahiro, Ambale-Venkatesh, Bharath, Zimmerman, Stefan L, Tedford, Ryan J, Hsu, Steven, Chamera, Ela, Fujii, Tomoki, Mullin, Christopher J, Mercurio, Valentina, Khair, Rubina, Corona-Villalobos, Celia P, Simpson, Catherine E, Damico, Rachel L, Kolb, Todd M, Mathai, Stephen C, Lima, Joao A C, Kass, David A, Tsujino, Ichizo, and Hassoun, Paul M
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, Diseases of the respiratory system, Cardiac magnetic resonance imaging, pulmonary arterial hypertension, Internal medicine, medicine, Diseases of the circulatory (Cardiovascular) system, In patient, Original Research Article, tau, cardiovascular diseases, RC705-779, medicine.diagnostic_test, Strain (chemistry), Ventricular function, business.industry, strain and strain rate, right ventricular failure, pressure volume loop, Strain rate, medicine.disease, Pulmonary hypertension, Catheter, RC666-701, cardiovascular system, Cardiology, business, Cardiac magnetic resonance
Abstract: Right ventricular function has prognostic significance in patients with pulmonary hypertension. We evaluated whether cardiac magnetic resonance-derived strain and strain rate parameters could reliably reflect right ventricular systolic and diastolic function in precapillary pulmonary hypertension. End-systolic elastance and the time constant of right ventricular relaxation tau, both derived from invasive high-fidelity micromanometer catheter measurements, were used as gold standards for assessing systolic and diastolic right ventricular function, respectively. Nineteen consecutive precapillary pulmonary hypertension patients underwent cardiac magnetic resonance and right heart catheterization prospectively. Cardiac magnetic resonance data were compared with those of 19 control subjects. In pulmonary hypertension patients, associations between strain- and strain rate-related parameters and invasive hemodynamic parameters were evaluated. Longitudinal peak systolic strain, strain rate, and early diastolic strain rate were lower in PAH patients than in controls; peak atrial-diastolic strain rate was higher in pulmonary hypertension patients. Similarly, circumferential peak systolic strain rate was lower and peak atrial-diastolic strain rate was higher in pulmonary hypertension. In pulmonary hypertension, no correlations existed between cardiac magnetic resonance-derived and hemodynamically derived measures of systolic right ventricular function. Regarding diastolic parameters, tau was significantly correlated with peak longitudinal atrial-diastolic strain rate ( r = −0.61), deceleration time ( r = 0.75), longitudinal systolic to diastolic time ratio ( r = 0.59), early diastolic strain rate ( r = −0.5), circumferential peak atrial-diastolic strain rate ( r = −0.52), and deceleration time ( r = 0.62). Strain analysis of the right ventricular diastolic phase is a reliable non-invasive method for detecting right ventricular diastolic dysfunction in PAH.
Published: 2021

48. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial

Author: Joohyuk Sohn, Giovanni Scambia, Bradley J. Monk, Keiichi Fujiwara, Kan Yonemori, Leslie M Randall, Julia Perkins Smith, Xiaoxi Zhang, Snehalkumar M. Bhoola, Carlos Linn, Amit M. Oza, Jonathan A. Ledermann, Myong Cheol Lim, Nicoletta Colombo, Elena Poddubskaya, Ross A. Stewart, Yaroslav Shparyk, Michael J. Birrer, Monk, B, Colombo, N, Oza, A, Fujiwara, K, Birrer, M, Randall, L, Poddubskaya, E, Scambia, G, Shparyk, Y, Lim, M, Bhoola, S, Sohn, J, Yonemori, K, Stewart, R, Zhang, X, Perkins Smith, J, Linn, C, and Ledermann, J
Subjects: medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, Antineoplastic Agents, Carcinoma, Ovarian Epithelial, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Antibodies, Maintenance Chemotherapy, law.invention, chemistry.chemical_compound, Antineoplastic Agents, Immunological, Randomized controlled trial, law, Ovarian Epithelial, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Monoclonal, Clinical endpoint, Humans, Medicine, Progression-free survival, Immune Checkpoint Inhibitors, Humanized, Aged, Ovarian Neoplasms, Intention-to-treat analysis, business.industry, Carcinoma, Middle Aged, Debulking, Interim analysis, Progression-Free Survival, Carboplatin, Regimen, Immunological, Settore MED/40 - GINECOLOGIA E OSTETRICIA, Oncology, chemistry, Female, epithelial ovarian cancer respond to frontline platinum-based chemotherapy, business
Abstract: Background: Although most patients with epithelial ovarian cancer respond to frontline platinum-based chemotherapy, around 70% will relapse within 3 years. The phase 3 JAVELIN Ovarian 100 trial compared avelumab (anti-PD-L1 monoclonal antibody) in combination with chemotherapy followed by avelumab maintenance, or chemotherapy followed by avelumab maintenance, versus chemotherapy alone in patients with treatment-naive epithelial ovarian cancer. Methods: JAVELIN Ovarian 100 was a global, open-label, three-arm, parallel, randomised, phase 3 trial run at 159 hospitals and cancer treatment centres in 25 countries. Eligible women were aged 18 years and older with stage III–IV epithelial ovarian, fallopian tube, or peritoneal cancer (following debulking surgery, or candidates for neoadjuvant chemotherapy), and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (1:1:1) via interactive response technology to receive chemotherapy (six cycles; carboplatin dosed at an area under the serum-concentration-time curve of 5 or 6 intravenously every 3 weeks plus paclitaxel 175 mg/m2 every 3 weeks or 80 mg/m2 once a week [investigators' choice]) followed by avelumab maintenance (10 mg/kg intravenously every 2 weeks; avelumab maintenance group); chemotherapy plus avelumab (10 mg/kg intravenously every 3 weeks) followed by avelumab maintenance (avelumab combination group); or chemotherapy followed by observation (control group). Randomisation was in permuted blocks of size six and stratified by paclitaxel regimen and resection status. Patients and investigators were masked to assignment to the two chemotherapy groups without avelumab at the time of randomisation until completion of the chemotherapy phase. The primary endpoint was progression-free survival assessed by blinded independent central review in all randomly assigned patients (analysed by intention to treat). Safety was analysed in all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, NCT02718417. The trial was fully enrolled and terminated at interim analysis due to futility, and efficacy is no longer being assessed. Findings: Between May 19, 2016 and Jan 23, 2018, 998 patients were randomly assigned (avelumab maintenance n=332, avelumab combination n=331, and control n=335). At the planned interim analysis (data cutoff Sept 7, 2018), prespecified futility boundaries were crossed for the progression-free survival analysis, and the trial was stopped as recommended by the independent data monitoring committee and endorsed by the protocol steering committee. Median follow-up for progression-free survival for all patients was 10·8 months (IQR 7·1–14·9); 11·1 months (7·0–15·3) for the avelumab maintenance group, 11·0 months (7·4–14·5) for the avelumab combination group, and 10·2 months (6·7–14·0) for the control group. Median progression-free survival was 16·8 months (95% CI 13·5–not estimable [NE]) with avelumab maintenance, 18·1 months (14·8–NE) with avelumab combination treatment, and NE (18·2 months–NE) with control treatment. The stratified hazard ratio for progression-free survival was 1·43 (95% CI 1·05–1·95; one-sided p=0·99) with the avelumab maintenance regimen and 1·14 (0·83–1·56; one-sided p=0·79) with the avelumab combination regimen, versus control treatment. The most common grade 3–4 adverse events were anaemia (69 [21%] patients in the avelumab maintenance group, 63 [19%] in the avelumab combination group, and 53 [16%] in the control group), neutropenia (91 [28%], 99 [30%], and 88 [26%]), and neutrophil count decrease (49 [15%], 45 [14%], and 59 [18%]). Serious adverse events of any grade occurred in 92 (28%) patients in the avelumab maintenance group, 118 (36%) in the avelumab combination group, and 64 (19%) in the control group. Treatment-related deaths occurred in one (
Published: 2021

49. Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer

Author: Thomas P. A. Debray, Christopher Berridge, Thomas Van den Broeck, Cathy Yuhong Yuan, Silke Gillessen, Nicola Fossati, Fabio Zattoni, Malcolm David Mason, Thomas B. Lam, Giorgio Gandaglia, Ann Henry, Olivier Rouvière, Marcus G. Cumberbatch, Guillaume Ploussard, Shane O'Hanlon, Thomas Wiegel, Philip Cornford, Henk G. van der Poel, Andrea Farolfi, Lisa Moris, Jeremy Grummet, Matthew Liew, N. Grivas, Daniela E. Oprea-Lager, Michael Lardas, Ivo G. Schoots, Erik Briers, Maria De Santis, Nicolas Mottet, Theodorus H. van der Kwast, Derya Tilki, Peter-Paul M. Willemse, Roderick C.N. van den Bergh, Lardas, M., Grivas, N., Debray, T. P. A., Zattoni, F., Berridge, C., Cumberbatch, M., Van den Broeck, T., Briers, E., De Santis, M., Farolfi, A., Fossati, N., Gandaglia, G., Gillessen, S., O'Hanlon, S., Henry, A., Liew, M., Mason, M., Moris, L., Oprea-Lager, D., Ploussard, G., Rouviere, O., Schoots, I. G., van der Kwast, T., van der Poel, H., Wiegel, T., Willemse, P. -P., Yuan, C. Y., Grummet, J. P., Tilki, D., van den Bergh, R. C. N., Lam, T. B., Cornford, P., and Mottet, N.
Subjects: Male, medicine.medical_specialty, Evidence synthesis, Patient-related factors, Prognostic factors, Prostate cancer, Systematic review, Tumour-related factors, Urinary incontinence, Urology, medicine.medical_treatment, 030232 urology & nephrology, Context (language use), 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, medicine, Humans, Prospective Studies, Randomized Controlled Trials as Topic, Retrospective Studies, Prostatectomy, business.industry, Confounding, Prostate, Prostatic Neoplasms, Odds ratio, Prognosis, medicine.disease, Urinary Incontinence, Urethra, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Meta-analysis, medicine.symptom, business
Abstract: Context While urinary incontinence (UI) commonly occurs after radical prostatectomy (RP), it is unclear what factors increase the risk of UI development. Objective To perform a systematic review of patient- and tumour-related prognostic factors for post-RP UI. The primary outcome was UI within 3 mo after RP. Secondary outcomes included UI at 3–12 mo and ≥12 mo after RP. Evidence acquisition Databases including Medline, EMBASE, and CENTRAL were searched between January 1990 and May 2020. All studies reporting patient- and tumour-related prognostic factors in univariable or multivariable analyses were included. Surgical factors were excluded. Risk of bias (RoB) and confounding assessments were performed using the Quality In Prognosis Studies (QUIPS) tool. Random-effects meta-analyses were performed for all prognostic factor, where possible. Evidence synthesis A total of 119 studies (5 randomised controlled trials, 24 prospective, 88 retrospective, and 2 case-control studies) with 131 379 patients were included. RoB was high for study participation and confounding; moderate to high for statistical analysis, study attrition, and prognostic factor measurement; and low for outcome measurements. Significant prognostic factors for postoperative UI within 3 mo after RP were age (odds ratio [OR] per yearly increase 1.04, 95% confidence interval [CI] 1.03–1.05), membranous urethral length (MUL; OR per 1-mm increase 0.81, 95% CI 0.74–0.88), prostate volume (PV; OR per 1-ml increase 1.005, 95% CI 1.000–1.011), and Charlson comorbidity index (CCI; OR 1.28, 95% CI 1.09–1.50). Conclusions Increasing age, shorter MUL, greater PV, and higher CCI are independent prognostic factors for UI within 3 mo after RP, with all except CCI remaining prognostic at 3–12 mo. Patient summary We reviewed the literature to identify patient and disease factors associated with urinary incontinence after surgery for prostate cancer. We found increasing age, larger prostate volume, shorter length of a section of the urethra (membranous urethra), and lower fitness were associated with worse urinary incontinence for the first 3 mo after surgery, with all except lower fitness remaining predictive at 3–12 mo.
Published: 2022

50. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study

Author: Gabriella Fabbrocini, L Bonzano, Silvia Ferrucci, S Ribero, Simona Tavecchio, Giovanni Pellacani, Steven Paul Nisticò, C Detoraki, Franco Rongioletti, Cataldo Patruno, Paolo Romita, Eustachio Nettis, Viviana Piras, Michela Ortoncelli, M Carbonara, Giulia Calabrese, Danilo Di Bona, E. Di Leo, Luigi Macchia, Caterina Foti, G Argenziano, Maddalena Napolitano, Nettis, E, Ferrucci, S M, Ortoncelli, M, Pellacani, G, Foti, C, Di Leo, E, Patruno, C, Rongioletti, F, Argenziano, G, Macchia, L, Tavecchio, S, Napolitano, M, Ribero, S, Bonzano, L, Romita, P, Di Bona, D, Nisticò, S P, Piras, V, Calabrese, G, Detoraki, C, Carbonara, M, Fabbrocini, G, Nettis, E., Ferrucci, S. M., Ortoncelli, M., Pellacani, G., Foti, C., Di Leo, E., Patruno, C., Rongioletti, F., Argenziano, G., Macchia, L., Tavecchio, S., Napolitano, M., Ribero, S., Bonzano, L., Romita, P., Di Bona, D., Nistico, S. P., Piras, V., Calabrese, G., Detoraki, C., Carbonara, M., and Fabbrocini, G.
Subjects: Adult, medicine.medical_specialty, Immunology, Population, Dupilumab, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Dermatitis, Atopic, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Retrospective Studie, Interquartile range, Internal medicine, Humans, Immunology and Allergy, Medicine, Eosinophilia, Multicenter real-life study, education, Retrospective Studies, Atopic dermatitis, education.field_of_study, business.industry, Conjunctiviti, Retrospective cohort study, Dermatology Life Quality Index, Immunoglobulin E, Conjunctivitis, Atopic dermatiti, medicine.disease, Clinical trial, Treatment Outcome, 030228 respiratory system, Multicentric real-life study, medicine.symptom, business, Human
Abstract: BACKGROUND Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date. METHODS Adult patients with moderate-to-severe AD, defined as an Eczema Area Severity Index (EASI) score of 24 or higher, treated with dupilumab at ten Italian academic centers, were included in the study. Physician-reported outcome measures (EASI), patient-reported outcome measures (pruritus and sleep score, Dermatology Life Quality Index, DLQI) and serological markers [immunoglobulin (Ig) E and eosinophil count] after 16 weeks were analyzed. RESULTS We enrolled 543 patients with moderate-to-severe AD. Two patients (0.4%) discontinued treatment. The median ± interquartile percentage change from baseline to 16 weeks of treatment in the EASI score was -87.5±22.0 (p
Published: 2022

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

2,366,763 results on '"Was, M."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources